Medtronic

Cardiac Rhythm Heart Failure

Product Performance Report

Important Patient Management Information for Physicians

2015

First Edition – Issue 72

CRHF Product Performance Report

2015

First Edition

Issue 72

Cutoff date for this edition is 31 January 2015 for Lead Study data and 9 February for all other data.

This report is available online at www.medtronic.com/CRDMProductPerformance

Our Commitment to Quality

Medtronic was founded in 1949 and has grown to become a global leader in medical technology. Seeing what a difference medical technology could make in the lives of patients inspired our founder to develop the Medtronic Mission, which remains unchanged today.

The third tenet of the mission is all about quality:

"To strive without reserve for the greatest possible reliability and quality in our products, to be the unsurpassed standard of comparison, and to be recognized as a company of dedication, honesty, integrity, and service."

Regardless of function, all CRHF employees play a role in product quality. Whether designing new therapies, sourcing components, manufacturing products, hiring talented people, assigning financial resources to project teams, or serving in one of the hundreds of other roles, every employee has an influence on product quality.

Product performance information is received from many sources through various channels. Medtronic monitors information from many sources from Research and Development through Manufacturing and Field Performance Vigilance.

When a device is returned to Medtronic, laboratory technicians and engineers assess overall device function. Analysis of returned product is performed according to written procedures. These procedures determine the minimum analysis required. The analysis required varies depending on the type of device, age of the device, the associated information received with the device, actual experience with models of similar design, and other factors. Additional analysis is performed as necessary to investigate a performance concern from a customer, or to collect specific reliability data.

When a malfunction is identified, failure analysis is performed to provide the detailed information necessary to investigate possible causes and actions. Medtronic CRHF maintains in-house expertise and performs its failure analysis using facilities it owns and supports. This capability permits detailed failure analysis.

Analysis results are compared to original manufacturing records and design intent. Clinical observations are added to laboratory findings to help determine root cause. Each event is then compared to other events. If a pattern is detected, actions are taken to identify a common root cause, assess patient risk and an appropriate course of action.

Medtronic instituted the industry's first product performance reports in 1983 by publishing data on our chronic lead studies. Pacemakers and other devices followed as our performance reporting has constantly evolved based on customer needs and feedback. One thing has been a constant. It is our sincere commitment to communicate clearly, offering timely and appropriate product performance data and reliability information. This has always been and will continue to be our goal.

Tim Samsel
Vice President, Quality and Regulatory Medtronic
Cardiac Rhythm Heart Failure Medtronic, Inc.

Contact Information

We invite our customers to use these telephone numbers to call with suggestions, inquiries, or specific problems related to our products.

US Technical Services Department

Phone: 1 (800) 723-4636 (Tachy)
1 (800) 505-4636 (Brady)
Fax: 1 (800) 824-2362
www.medtronic.com/corporate/contact.jsp

For questions related to this CRHF Product Performance Report, please call US Technical Services at the number above, or write to:

Tim Smith
Medtronic, Inc.
8200 Coral Sea Street NE MVN61 Mounds View, MN 55112 USA
Email: tim.smith@medtronic.com

International Technical Centers

Europe (Heerlen NL) +31-45-566-8844
Japan (Tokyo) +81-3-6430-7026

For questions related to returning explanted product or returning product that shows signs of malfunction, please contact:

Outside the United States:
Your Medtronic representative or international technical center at the number above.

Within the United States:
Your Medtronic representative or
CRHF Returned Product Analysis Laboratory
Phone: 1 (800) 328-2518, ext. 44800
Email: crdm.returnedproduct@medtronic.com

Editorial Staff

Editor
Tim Samsel, Vice President, CRHF Quality and Regulatory

Trademarks of Medtronic, Inc.

Introduction

All product performance reports are not created equal. For 32 years, Medtronic has monitored performance via both returned product analysis and multicenter clinical studies.

This Product Performance Report (PPR) presents device survival estimates, advisory summaries, performance notes, and other information pertinent to assessing the performance of Medtronic implantable pulse generators (IPGs), implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, and implantable pacing and defibrillation leads.

This Product Performance Report has been prepared in accordance with International Standard ISO 5841- 2:2000(E).

The survival estimates provided in this report are considered to be representative of worldwide performance.

Survival Estimates

Medtronic, like other companies, monitors CRT, ICD, and IPG device performance using returned product analysis. We also monitor CRT, ICD, and IPG device performance using an active multicenter clinical study.

Returned product analysis is a passive approach to assessing product performance. This approach provides a suitable measure of product performance only when a significant number of explanted products are returned to the manufacturer. Returned product analysis provides a measure of hardware performance, but not necessarily the total clinical performance (e.g., the incidence of complications such as infection, erosion, muscle stimulation, etc. are not estimated).

The survival estimates provided in this report for CRT, ICD, and IPG devices are based on returned product analysis. This approach is suitable because a significant number of explanted generators are returned for analysis.

Lead performance is monitored differently. In contrast to CRT, ICD, and IPG devices, a very small percentage of leads are returned to the manufacturer due to the difficulty of explanting them. For leads, an active clinical study provides more accurate survival estimates compared to estimates based solely on returned product analysis.

Survival estimates for leads are based on clinical observations recorded via Medtronic's PAN Registry. This multicenter clinical study is designed to record clinical observations representative of the total clinical experience. Therefore, the lead survival estimates include both lead hardware failure and lead-related medical complications, and do not differentiate a lead hardware failure from other clinical events such as exit block, perforation, dislodgement, or concurrent pulse generator failure.

The actuarial life table method is applied to the data collected for CRT, ICD, and IPG devices and leads to provide the survival estimates included in this report. A general introduction to understanding this method of survival analysis is given later in this introduction.

ICD Charge Times

Since May 2000, Medtronic has provided important information on charge time performance of ICDs. The information provided in this report shows how ICD charge time can vary during the time a device is implanted. The information is presented in graphical format showing charge time as a function of implant time. The data for charge times are collected from devices enrolled in the PAN registry.

Introduction continued

Advisory Summaries

This Product Performance Report includes summaries of all advisories applicable to the performance of the products included in the report. An advisory is added to the report when any product affected by the advisory remains in service and at risk of experiencing the behavior described in the advisory. The advisory will remain in the report until Medtronic estimates no product affected by the advisory remains active, or the risk of experiencing the behavior described in the advisory has passed.

For most advisories, the products subject to the advisory retain essentially the same survival probability as the products of the same model(s) not affected by the advisory. For those advisories where the survival probabilities of the affected and non-affected populations do differ significantly, Medtronic will provide separate survival data for each population. The separate survival data will remain in the report until Medtronic estimates no affected product remains in active service.

Performance Notes

This report concludes with a number of Performance Notes developed by Medtronic to provide additional product performance information relevant to follow-up practice and patient management.

How You Can Help

Medtronic urges all physicians to return explanted products and to notify Medtronic when a product is no longer in use, regardless of the reason for explant or removal from use. The procedures for returning products vary by geographic location.

Mailer kits with prepaid US postage are available for use within the United States to send CRTs, ICDs, IPGs, ICMs, and leads to Medtronic's Cardiac Rhythm and Heart Failure (CRFH) Returned Product Analysis Lab. These mailers are sized to accommodate the devices and leads from a single patient or clinical event and are designed to meet US postal regulations for mailing biohazard materials.

If the product being returned is located outside the United States, please contact your local Medtronic representative for instructions.

Medtronic also requests the return of explanted products from non-clinical sources, such as funeral homes, and will assume responsibility for storage and disposal of the product once received.

Mailer kits can be obtained by contacting the Returned Product Lab. For information on how to contact the Lab, refer to the Contact Information page of this report.

We continually strive to improve this CRFH Product Performance Report. In keeping with this philosophy, we ask for your suggestions on the content and format of this report, as well as any information you have regarding the performance of Medtronic products. For information on how to comment on this report, see the Contact Information page.

Overview of Survival Analysis

Medtronic uses the Cutler-Ederer actuarial life table method for devices and Kaplan-Meier for leads to estimate the length of time over which they will perform within performance limits established by Medtronic. This probability to perform within performance limits over time is called the survival probability.

Devices and leads are followed until an event occurs where the device or lead ceases to operate within performance limits. The length of time from implant to the event is recorded for individual devices and leads in the population sample. The population sample for CRT, ICD, and IPG devices is made up of patients whose devices are registered as implanted in the United States. For leads, the population sample is the patients enrolled in our multicenter, international prospective Product Surveillance Registry.

Introduction continued

For CRTs, IPGs and ICDs, the events can be normal battery depletion or a device malfunction. For leads, the events are complications as defined in the study protocol.

The actuarial life table method allows Medtronic to account for devices and leads removed from service for reasons unrelated to performance and for device and leads still in service. Devices and leads removed for reasons unrelated to performance or are still in service are said to be suspended. Examples of devices and leads removed from service for reasons unrelated to performance include:

- Removed to upgrade the device or lead
- No longer in service due to the death of the patient for reasons unrelated to the device or leads
- Implanted in patients who are lost to follow-up

For each suspension, the device or lead has performed within performance limits for a period of time, after which its performance is unknown.

An Example

The following example describes the survival analysis method used to establish the survival probability estimates for Medtronic CRFH devices and leads. The example is intended to provide an overview of the analysis process. The definitions of malfunctions and complications, and other details specific to calculating device and lead survival estimates, are provided in the articles Method for Estimating CRT, ICD, and IPG Device Performance and Method for Estimating Lead Performance.

Figure 1 Implant times for devices of 16 patients. Gray bars with a yellow X indicate devices removed from service due to an event. Blue bars indicate suspended devices.



Figure 1 illustrates 16 patients who have implanted devices. The first patient's device (serial number BH004134) operated within performance limits for 32 months. At that time an event occurred. The fourth patient's device (serial number BH008926) did not have an event but is suspended, perhaps because it was still in service at the time of the analysis. This patient had 66 months of implant experience. In this example, Figure 1 shows that seven of the 16 devices suffered events, and nine are suspended.

The first step in the life table method is to divide the implant time into intervals of a specific length. This example will use 12-month intervals.

The number of devices entered, suspended, and removed due to an event are counted and summarized, as shown in Table 1. For the first two intervals, all 16 devices survived and none were removed. In the interval (24-36 months), device BH004134 was removed due to an event. Therefore the table entries show that 16 entered the interval, none were suspended, and one was removed due to an event.

For the interval from 36-48 months, only 15 devices entered the interval and one was removed for an event. The remaining intervals are examined and the data entered in columns A, B, and C in like manner. The rest of the columns are filled in using calculations on the data in columns A, B, and C.

Introduction continued

The Effective Sample Size (D) is the number of devices with full opportunity to experience a qualifying event in the interval. This is computed by subtracting one half the number suspended in the interval from the number that entered the interval. This calculation more accurately reflects the number of devices that could have experienced a qualifying event than simply using the number that entered the interval. Using the number of devices that enter an interval overestimates the sample size because the suspended devices do not complete the interval. Ignoring the suspended devices underestimates the sample size because suspended devices are not credited with their full service time. Using one half the number of suspended devices effectively splits the difference.

The next column in the table is the Proportion with Event (E). This is the proportion of devices that had an event in the interval. It is calculated by dividing the Number of Events (C) by the Effective Sample Size (D). The number can be interpreted as the estimated rate at which events occur in the time interval.

The Interval Survival Probability (F) is the estimate of probability of surviving to the end of the interval assuming the device was working at the beginning of the interval. It is calculated as 1 minus the Proportion with Event (E). This number can be interpreted as the estimated rate at which events do not occur in the time interval.

Table 1 Life Table for Figure 1

	A	B	C	D	E	F	G
Interval in Months	Number Entered	Number Suspended	Number of Events	Effective Sample Size	Proportion with Event	Interval Survival Probability	Cumulative Survival Probability
0	16	0	0	16	0.000	1.000	1.000
0-12	16	0	0	16	0.000	1.000	1.000
12-24	16	0	0	16	0.000	1.000	1.000
24-36	16	0	1	16	0.063	0.938	0.938
36-48	15	0	1	15	0.067	0.933	0.875
48-60	14	0	1	14	0.071	0.929	0.813
60-72	13	1	2	12.5	0.160	0.840	0.683
72-84	10	2	0	9	0.000	1.000	0.683
84-96	8	3	0	6.5	0.000	1.000	0.683
96-108	5	2	2	4	0.500	0.500	0.341
108-120	1	0	0	1	0.000	1.000	0.341
120-132	1	1	0	0.5	0.000	1.000	0.341

Definitions:

A
Number Entered

Number of devices active at the start of the interval

B
Number Suspended

Number of devices removed from service for reasons other than an event

C
Number of Events

Number of units removed from service due to an event

D
Effective Sample Size

Number of units with full opportunity to experience a qualifying event in the interval. Computed by subtracting one half the Number Suspended from the Number Entered.

E
Proportion with Event

Proportion of devices that had an event in the interval. Computed by dividing the Number of Events by the Effective Sample Size.

F
Interval Survival Probability

The probability of surviving to the end of the interval, assuming the device was working at the beginning of the interval. Computed as 1 minus the Proportion With Event.

G
Cumulative Survival Probability

The overall probability of surviving to the end of the interval. Computed by multiplying the Interval Survival Probability by the previous interval's Cumulative Survival Probability.

Introduction continued

Cumulative Survival Probability (G) is the estimate of the unconditional probability of surviving to the end of the interval. It is computed by multiplying the Interval Survival Probability (F) by the previous interval's Cumulative Survival Probability. The probability of surviving to 132 months in the example is estimated for the table to be 0.341, or 34.1%. The Cumulative Survival Probabilities (G) of the life table can be plotted versus time intervals in the first column to give a survival curve. Figure 2 shows the survival curve for the data in Table 1.

Figure 2 Survival Curve for Data Given in Table 1



%	0	12	24	36	48	60	72	84	96	108	120	132
#	100	100	100	93.8	87.5	81.3	68.3	68.3	68.3	34.1	34.1	34.1
	16	16	16	16	15	14	12.5	9	6.5	4	1	0.5
	Effective Sample Size											

Confidence Intervals

Since survival curves are based on a sample of the device and lead population, they are only estimates of survival. The larger the effective sample size, the more confident the estimate. A confidence interval can be calculated to assess the confidence in an estimate. In the Product Performance Report, Medtronic provides a 95% confidence interval. This can be interpreted as meaning that 95% of the time, the true survival of the device will fall somewhere in the interval.

Survival Curves in the Product Performance Report

Since the survival estimate can become very imprecise with small effective sample sizes, Medtronic truncates the survival curve when the effective sample size is less than 100 for CRTs, ICDs, and IPGs, and when the number entered is less than 50 for leads. The survival charts in the Product Performance Report show the effective sample size for each year interval where Medtronic has experience. When the effective sample size reaches 100 for CRTs, ICDs, and IPGs or when the number entered reaches 50 for leads, the next data point is added to the survival curve.

Although the report provides tabular data in one-year intervals, the device curves are actually computed and plotted using the Cutler-Ederer method and 1-month intervals (for CRT, ICD, and IPG devices) and leads curves are computed and plotted using Kaplan-Meier, which uses individual survival times.

A number of references are available for additional information on survival analysis using the Cutler-Ederer life table method[1] and for the Kaplan-Meier method.[2]

[1] Lee, Elisa T.(2003) Statistical Methods for Survival Data Analysis – 3rd Edition (Wiley Series in Probability and Statistics).

[2] Klein, John P., Moeschberger, Melvin L. Survival Analysis Techniques for Censored and Truncated Data, New York: Springer-Verlag New York, Inc., 1997.

Method for Estimating CRT, ICD, and IPG Device Performance

The performance of CRT, ICD, and IPG devices is expressed in terms of device survival estimates, where "survival" refers to the function of the device, not the survival of the patient. These survival estimates are intended to illustrate the probability that a device will survive for a given number of years without malfunction or battery depletion.

The survival estimates are determined from the analysis of Medtronic Cardiac Rhythm and Heart Failure (CRHF's) United States device registration data and US returned product analysis data. These data are presented graphically and numerically.

Because this analysis is based on returned product analysis, the performance data does not reflect any device-related medical complications such as erosion, infection, muscle stimulation, or muscle inhibition.

Categorization of Depleted and Malfunctioning Devices for Survival Analysis

For survival estimation, every device returned to Medtronic CRHF and analyzed in the CRHF Returned Product Analysis laboratory is assigned to one of three categories. The device 1) is functioning normally, 2) has reached normal battery depletion, or 3) has malfunctioned. This categorization is combined with data from our device registry for the total number of implants and the implant durations to create the survival curves presented on the following pages.

Definition of Malfunction

Medtronic CRHF considers a device as having malfunctioned whenever the analysis shows that any parameter was outside the performance limits established by Medtronic while implanted and in service. To be considered a malfunction or battery depletion, the device must have been returned to Medtronic and analyzed.

Devices damaged after explant, damaged due to failure to heed warnings or contraindications in the labeling, or damaged due to interaction with other implanted devices (including leads) are not considered device malfunctions.

A device subject to a safety advisory is not considered to have malfunctioned unless it has been returned to Medtronic CRHF and found, through analysis, to actually have performed outside the performance limits established by Medtronic.

Not all malfunctions expose the patient to a loss of therapy. Some malfunctions included in the following survival estimates may not have been detected at all by the physician or the patient. These malfunctions, however, are included in the survival estimates and provide important feedback to our product development organization.

To provide insight into the nature of malfunctions, each malfunction is categorized as Malfunction with Compromised Therapy Function or Malfunction without Compromised Therapy Function.

For this report, Normal Battery Depletion, Malfunction with Compromised Therapy Function, and Malfunction without Compromised Therapy Function are defined as follows:

Normal Battery Depletion – The condition when:

(a) a device is returned with no associated complaint and the device has reached its elective replacement indicator(s) with implant time that meets or exceeds the nominal (50 percentile) predicted longevity at default (labeled) settings, or
(b) a device is returned and the device has reached its elective replacement indicator(s) with implant time exceeding 80% of the expected longevity calculated using the available device setting information.

Medtronic CRHF establishes expected longevity by statistically characterizing the power consumed by the device and the power available from the device battery. This characterization is applied to a number of parameter configurations to derive a statistical mean longevity value and standard deviation for each parameter configuration. The statistical mean value minus three standard deviations is used as the expected longevity for determining if a battery depleted normally. The actual longevity achieved for any device while implanted will depend on the actual programmed parameters and patient factors, and may differ significantly from these estimates.

Malfunction with Compromised Therapy Function

The condition when a device is found to have malfunctioned in a manner that compromised pacing or defibrillation therapy (including complete loss or partial degradation), while implanted and in service, as confirmed by returned product analysis.

Examples: Sudden loss of battery voltage; accelerated current drain such that low battery was not detected before loss of therapy; sudden malfunction during defibrillation therapy resulting in aborted delivery of therapy, intermittent malfunction where therapy is compromised while in the malfunction state.

Malfunction without Compromised Therapy Function

The condition when a device is found to have malfunctioned in a manner that did not compromise pacing or defibrillation therapy, while implanted and in service, as confirmed by returned product analysis.

Examples: Error affecting diagnostic functions, telemetry function, data storage; malfunction of a component that causes battery to lose power quickly enough to cause premature battery depletion, but slowly enough that the condition is detected through normal follow-up before therapy is lost; mechanical problems with connector header that do not affect therapy.

Expanded Malfunction Detail

The malfunctions are further divided into categories that identify the subject area of the malfunction. The malfunctions are divided into the following subject areas:

Electrical Component – Findings linked to electrical components such as integrated circuits, resistors, capacitors, diodes, etc.

Electrical Interconnect – Findings linked to the connections between electrical components such as wires, solder joints, wire bonds, etc.

Battery – Findings linked to the battery and its components

Software/Firmware – Findings linked to software or firmware function

Possible Early Battery Depletion – Findings where the actual reported implant time is less than 80% of the expected longevity calculated using the available device setting information with no device malfunction observed. There may not be sufficient device setting information to determine conclusively if battery depletion was normal or premature in the absence of a specific root cause finding. However, returned devices meeting the above criteria are conservatively classified as Possible Early Battery Depletion malfunctions.

Other – Findings related to other components such as insulators, grommets, setscrews, and packaging, and findings where analysis is inconclusive.

Returned Product Analysis Process

Analysis of returned product is performed according to written procedures. These procedures determine the minimum analysis required. The analysis required varies depending on the type of device, age of the device, the associated information received with the device, actual experience with models of similar design, and other factors. Additional analysis is performed as necessary to investigate a performance concern from a customer, or to collect specific reliability data.

When a device is returned with a performance concern from a customer, the general analysis process includes a preliminary analysis of the device in its as-received condition, followed by an automated functional test using test equipment equivalent to the equipment used in manufacturing.

When a malfunction is identified, failure analysis is performed to provide the detailed information necessary to investigate possible causes and actions. Medtronic CRHF maintains in-house expertise and performs its failure analysis using facilities it owns and supports. This capability permits detailed failure analysis.

Statistical Methods for Survival Analysis

Of the several different statistical methods available for survival analysis, the Standard Actuarial Method, with suspensions assumed distributed evenly within the intervals (Cutler-Ederer Method), is used to determine survival estimates for CRT, IPG and ICD devices. Implant times are calculated from the implant date to the earlier of the explant date or the cutoff date of the report. From this data an estimate of the probability of device survival is calculated at each monthly interval.

On the following pages, each graph includes a survival curve where events include malfunctions and normal battery depletions. This survival curve is a good representation of the probability a device will survive a period of time without malfunction and without battery depletion. For example, if a device survival probability is 95% after 5 years of service, then the device has a 5% chance of being removed due to battery depletion or malfunction in the first 5 years following implant.

In addition, a second curve is included to show survival excluding normal battery depletion. This curve is a good representation of the probability for a device to survive without malfunction. This curve includes only malfunctions as events and excludes normal battery depletion.

Since the survival estimate can become very imprecise with small effective sample sizes, Medtronic truncates the survival curve when the effective sample size is less than 100 for CRT, ICD, and IPG devices. The survival charts in the Product Performance Report show the effective sample size for each year interval where we have experience. When the effective sample size reaches 100, the next data point is added to the survival curve.

Although the report provides tabular data in one-year intervals, the curves are actually computed and plotted using one-month intervals.

The data in the tables are rounded to the nearest tenth of one percent. Occasionally, a graph may show 100% survival, but have one or more malfunctions or battery depletions. This occurs because, even with the malfunctions or battery depletions, the data rounds to 100%.

Sample Size and How the Population and Population Samples Are Defined

The population sample from which the survival estimates are derived is comprised of the devices registered as implanted in the United States as of the report cutoff date. The number of registered implants, as well as an estimate of the number that remain in active service, is listed for each model. To be included in the population, the device must have been registered with Medtronic’s registration system and implanted for at least one day.

This sample based on US implants is considered to be representative of the worldwide population, and therefore the survival estimates shown in this report should be representative of the performance worldwide of these models.

A CRT, ICD, or IPG model or model family will be included in this report when it has accumulated at least 10,000 implant months and will remain in the report as long as at least 500 devices remain active.

Methods Used to Adjust for Underreporting of Malfunction and Battery Depletion

The tables on the following pages show the actual number of malfunctions and battery depletions recorded by the analysis lab for US registered devices. Since not all devices are returned to Medtronic CRHF for analysis, these numbers underestimate the true number of malfunctions and battery depletions. To more accurately estimate the all-cause device survival probabilities, the number of malfunctions and battery depletions used to plot each interval of the all-cause survival curves is adjusted (multiplied) by a factor that is based on an estimate of the magnitude of underreporting. The magnitude of underreporting is estimated by comparing data in Medtronic's Device And Registrant Tracking (DART) system with data from Returned Product Analysis.

The DART system is an important element of Medtronic's Quality System. The DART system is designed to meet or exceed the US FDA's device tracking requirements set forth by the Safe Medical Devices Act. In the United States, over 98% of Medtronic's CRT, ICD, and IPG implants become registered in the DART system.

Because pacemakers do not cure the patient's underlying health problem, when a pacemaker stops functioning (due to either normal battery replacement or malfunction) it is replaced with a new pacemaker. Therefore, the replacement recorded in the DART system is a good indication that the previous pacemaker experienced either battery depletion or malfunction. The fraction of replaced devices that are subsequently returned can be used to estimate the correction factor for the under reporting of the combination of battery depletion and malfunction.

Note that devices of patients who have expired do not factor into the calculation of the correction. It is possible some proportion of these devices experienced battery depletion or malfunction. Since these are not counted into the correction factor based on the return rate of replaced devices, a correction factor based only on the return rate of replaced devices may still underestimate the true rate of battery depletion and malfunction. However, devices that are replaced because the patient is receiving a system upgrade or are removed because the patient no longer needs it (e.g., due to heart transplant) do contribute to the calculation of the correction factor and therefore impart an opposite bias.

Also note that this method of calculating the correction factor cannot distinguish between devices that are removed due to malfunction and those due to normal battery depletion. It might seem intuitive that devices that unexpectedly malfunction should be much more likely to be returned to the manufacturer than a device with ordinary normal battery depletion. But this has not been conclusively demonstrated. Therefore, this method only provides a correction factor reflecting the combination of battery depletion and malfunction.

No adjustment for underreporting is applied to the malfunction-free survival curve because a method for estimating malfunction-only underreporting has not been developed.

Adjustments to Registered Implants to Compensate for Unreported Devices Removed from Service

Devices are at times removed from service for reasons other than device malfunction or battery depletion. Examples are devices removed from service due to non-device related patient mortality and devices removed due to changes in the patient's medical condition. Because an accurate estimate of device survival depends on an accurate estimate of the number of devices in service, it is important not to overstate the number of devices in service.

Medtronic addresses this under reporting to ensure the number of devices in service is not overstated . Regular updates obtained from the Social Security Administration about deceased persons are used to update Medtronic's DART data about patients who have died but whose deaths had not been reported to Medtronic. In addition, the patient mortality rate derived from our DART system is monitored and compared to published mortality rates for comparable patient populations. If, during calculation of the survival curves, the patient mortality indicated by the data in DART is significantly different from published rates, an adjustment is applied to correct the difference. The correction factor for under reporting devices is also applied to account for devices that were removed and not reported or returned.

Cardiac Resynchronization Therapy

7285 InSync III Protect

US Market Release Date	
CE Market Approval Date	04/07/2004
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-DDDR
Max Delivered Energy	30 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

7285, 7295, Survival Curve



Years

Excluding NBD

Including NBD

Effective Sample Size

Cardiac Resynchronization Therapy

7295 InSync II Protect

US Market Release Date	02/02/2004
CE Market Approval Date	
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-DDDR
Max Delivered Energy	30 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

7285, 7295, Survival Curve



Years

Excluding NBD

Including NBD

Effective Sample Size

Cardiac Resynchronization Therapy

7299 InSync Sentry

US Market Release Date	04/08/2005
CE Market Approval Date	
Registered US Implants	31,184
Estimated Active US Implants	1,974
Normal Battery Depletions (US)	9,906

NBG Code	VVE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	179
Therapy Not Compromised Malfunctions	169
Battery Malfunction	0
Electrical Component	19
Electrical Interconnect	0
Other Malfunction	1
Poss Early Battery Depltn	147
Software Malfunction	2
Therapy Compromised Malfunctions	10
Battery Malfunction	0
Electrical Component	10
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

7299, Survival Curve



Years	1	2	3	4	5	6	at 74 mo
Excluding NBD	100.0%	99.9%	99.7%	99.2%	99.0%	98.8%	98.8%
Including NBD	99.1%	97.3%	90.7%	71.4%	28.1%	3.0%	1.5%
Effective Sample Size	27077	23696	19200	12911	4472	318	146

Cardiac Resynchronization Therapy

7304 InSync Maximo

US Market Release Date	04/08/2005
CE Market Approval Date	01/14/2005
Registered US Implants	18,985
Estimated Active US Implants	1,454
Normal Battery Depletions (US)	5,565

NBG Code	VVE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	114
Therapy Not Compromised Malfunctions	109
Battery Malfunction	1
Electrical Component	15
Electrical Interconnect	0
Other Malfunction	1
Poss Early Battery Depltn	92
Software Malfunction	0
Therapy Compromised Malfunctions	5
Battery Malfunction	0
Electrical Component	4
Electrical Interconnect	0
Other Malfunction	1
Poss Early Battery Depltn	0
Software Malfunction	0

7304, Survival Curve



Years	1	2	3	4	5	at 69 mo
Excluding NBD	100.0%	99.9%	99.6%	99.1%	99.1%	99.1%
Including NBD	99.0%	97.2%	90.8%	71.5%	26.6%	2.5%
Effective Sample Size	16802	14690	11949	8034	2420	208

Cardiac Resynchronization Therapy

C154DWK Concerto CRT-D

US Market Release Date	05/12/2006
CE Market Approval Date	
Registered US Implants	81,309
Estimated Active US Implants	13,363
Normal Battery Depletions (US)	22,779

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	1,424
Therapy Not Compromised Malfunctions	1,377
Battery Malfunction	0
Electrical Component	717
Electrical Interconnect	2
Other Malfunction	3
Poss Early Battery Depltn	651
Software Malfunction	4
Therapy Compromised Malfunctions	47
Battery Malfunction	0
Electrical Component	45
Electrical Interconnect	2
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

C154DWK, C164AWK, C174AWK, Survival Curve



Years	1	2	3	4	5	6	at 82 mo
Excluding NBD	100.0%	99.8%	99.5%	98.4%	96.9%	96.9%	96.8%
Including NBD	99.6%	98.1%	93.5%	80.6%	51.4%	24.7%	8.5%
Effective Sample Size	72761	64326	54951	42868	24424	7191	317

Cardiac Resynchronization Therapy

C164AWK Concerto CRT-D

US Market Release Date	04/17/2007
CE Market Approval Date	
Registered US Implants	178
Estimated Active US Implants	5
Normal Battery Depletions (US)	72

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	4
Therapy Not Compromised Malfunctions	4
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	4
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

C154DWK, C164AWK, C174AWK, Survival Curve



Years	1	2	3	4	5	6	at 82 mo
Excluding NBD	100.0%	99.8%	99.5%	98.4%	96.9%	96.9%	96.8%
Including NBD	99.6%	98.1%	93.5%	80.6%	51.4%	24.7%	8.5%
Effective Sample Size	72761	64326	54951	42868	24424	7191	317

Cardiac Resynchronization Therapy

C174AWK Concerto CRT-D

US Market Release Date	
CE Market Approval Date	03/07/2006
Registered US Implants	5
Estimated Active US Implants	3
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

C154DWK, C164AWK, C174AWK, Survival Curve



Years	1	2	3	4	5	6	at 82 mo
Excluding NBD	100.0%	99.8%	99.5%	98.4%	96.9%	96.9%	96.8%
Including NBD	99.6%	98.1%	93.5%	80.6%	51.4%	24.7%	8.5%
Effective Sample Size	72761	64326	54951	42868	24424	7191	317

Cardiac Resynchronization Therapy

D204TRM Consulta CRT-D

US Market Release Date	01/09/2012
CE Market Approval Date	
Registered US Implants	2,080
Estimated Active US Implants	1,874
Normal Battery Depletions (US)	12

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

CONSULTA, CRT, Survival Curve



Years	1	2	3	4	5	at 70 mo
Excluding NBD	100.0%	99.7%	99.3%	98.8%	98.7%	98.6%
Including NBD	99.7%	98.5%	93.5%	82.3%	62.2%	32.5%
Effective Sample Size	62504	54612	43556	27821	7662	154

Cardiac Resynchronization Therapy

D214TRM Consulta CRT-D

US Market Release Date	
CE Market Approval Date	07/22/2010
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

CONSULTA, CRT, Survival Curve



Years	1	2	3	4	5	at 70 mo
Excluding NBD	100.0%	99.7%	99.3%	98.8%	98.7%	98.6%
Including NBD	99.7%	98.5%	93.5%	82.3%	62.2%	32.5%
Effective Sample Size	62504	54612	43556	27821	7662	154

Cardiac Resynchronization Therapy

D224TRK Consulta CRT-D

US Market Release Date	09/15/2008
CE Market Approval Date	
Registered US Implants	65,770
Estimated Active US Implants	33,720
Normal Battery Depletions (US)	8,368

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	567
Therapy Not Compromised Malfunctions	546
Battery Malfunction	2
Electrical Component	43
Electrical Interconnect	1
Other Malfunction	1
Poss Early Battery Depltn	493
Software Malfunction	6
Therapy Compromised Malfunctions	21
Battery Malfunction	1
Electrical Component	20
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

CONSULTA, CRT, Survival Curve



Years	1	2	3	4	5	at 70 mo
Excluding NBD	100.0%	99.7%	99.3%	98.8%	98.7%	98.6%
Including NBD	99.7%	98.5%	93.5%	82.3%	62.2%	32.5%
Effective Sample Size	62504	54612	43556	27821	7662	154

Cardiac Resynchronization Therapy

D234TRK Consulta CRT-D

US Market Release Date	
CE Market Approval Date	03/14/2008
Registered US Implants	1
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

CONSULTA, CRT, Survival Curve



Years	1	2	3	4	5	at 70 mo
Excluding NBD	100.0%	99.7%	99.3%	98.8%	98.7%	98.6%
Including NBD	99.7%	98.5%	93.5%	82.3%	62.2%	32.5%
Effective Sample Size	62504	54612	43556	27821	7662	154

Cardiac Resynchronization Therapy

D264TRM Maximo II CRT-D

US Market Release Date	01/09/2012
CE Market Approval Date	07/22/2010
Registered US Implants	15
Estimated Active US Implants	13
Normal Battery Depletions (US)	0

NBG Code	VVE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

MAXIMO, II, CRT, Survival Curve



Years	1	2	3	4	5	at 70 mo
Excluding NBD	100.0%	99.7%	99.4%	98.8%	98.6%	98.5%
Including NBD	99.8%	98.4%	93.6%	81.3%	58.3%	37.4%
Effective Sample Size	14141	12273	9752	6100	1971	145

Cardiac Resynchronization Therapy

D274TRK Concerto II CRT-D

US Market Release Date	08/15/2009
CE Market Approval Date	
Registered US Implants	30,166
Estimated Active US Implants	16,579
Normal Battery Depletions (US)	3,266

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	175
Therapy Not Compromised Malfunctions	170
Battery Malfunction	1
Electrical Component	16
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	152
Software Malfunction	1
Therapy Compromised Malfunctions	5
Battery Malfunction	1
Electrical Component	4
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

CONCERTO, II, Survival Curve



Years	1	2	3	4	5	at 62 mo
Excluding NBD	100.0%	99.9%	99.6%	99.2%	99.2%	99.2%
Including NBD	99.8%	98.7%	94.1%	83.5%	65.9%	62.6%
Effective Sample Size	27419	25273	22253	13404	1584	432

Cardiac Resynchronization Therapy

D284TRK Maximo II CRT-D

US Market Release Date	09/17/2008
CE Market Approval Date	03/14/2008
Registered US Implants	15,119
Estimated Active US Implants	7,489
Normal Battery Depletions (US)	2,136

NBG Code	VVE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	132
Therapy Not Compromised Malfunctions	127
Battery Malfunction	0
Electrical Component	5
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	122
Software Malfunction	0
Therapy Compromised Malfunctions	5
Battery Malfunction	0
Electrical Component	5
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

MAXIMO, II, CRT, Survival Curve



Years	1	2	3	4	5	at 70 mo
Excluding NBD	100.0%	99.7%	99.4%	98.8%	98.6%	98.5%
Including NBD	99.8%	98.4%	93.6%	81.3%	58.3%	37.4%
Effective Sample Size	14141	12273	9752	6100	1971	145

Cardiac Resynchronization Therapy

D294TRK Concerto II CRT-D

US Market Release Date	
CE Market Approval Date	08/20/2008
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

CONCERTO, II, Survival Curve



Years	1	2	3	4	5	at 62 mo
Excluding NBD	100.0%	99.9%	99.6%	99.2%	99.2%	99.2%
Including NBD	99.8%	98.7%	94.1%	83.5%	65.9%	62.6%
Effective Sample Size	27419	25273	22253	13404	1584	432

Cardiac Resynchronization Therapy

D314TRG Protecta XT CRT-D

US Market Release Date	03/25/2011
CE Market Approval Date	
Registered US Implants	41,680
Estimated Active US Implants	34,909
Normal Battery Depletions (US)	737

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	40
Therapy Not Compromised Malfunctions	38
Battery Malfunction	0
Electrical Component	10
Electrical Interconnect	0
Other Malfunction	1
Poss Early Battery Depltn	27
Software Malfunction	0
Therapy Compromised Malfunctions	2
Battery Malfunction	0
Electrical Component	2
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxTRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	99.9%	99.9%	99.9%
Including NBD	99.9%	99.1%	96.0%	92.1%
Effective Sample Size	57354	40614	12554	131

Cardiac Resynchronization Therapy

D314TRM Protecta XT CRT-D

US Market Release Date	11/09/2011
CE Market Approval Date	
Registered US Implants	12,182
Estimated Active US Implants	11,144
Normal Battery Depletions (US)	61

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	6
Therapy Not Compromised Malfunctions	5
Battery Malfunction	0
Electrical Component	4
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	1
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxTRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	99.9%	99.9%	99.9%
Including NBD	99.9%	99.1%	96.0%	92.1%
Effective Sample Size	57354	40614	12554	131

Cardiac Resynchronization Therapy

D334TRG Protecta CRT-D

US Market Release Date	03/25/2011
CE Market Approval Date	
Registered US Implants	7,820
Estimated Active US Implants	6,677
Normal Battery Depletions (US)	108

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	8
Therapy Not Compromised Malfunctions	7
Battery Malfunction	0
Electrical Component	3
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	4
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxTRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	99.9%	99.9%	99.9%
Including NBD	99.9%	99.1%	96.0%	92.1%
Effective Sample Size	57354	40614	12554	131

Cardiac Resynchronization Therapy

D334TRM Protecta CRT-D

US Market Release Date	11/09/2011
CE Market Approval Date	
Registered US Implants	1,729
Estimated Active US Implants	1,583
Normal Battery Depletions (US)	9

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	2
Therapy Not Compromised Malfunctions	2
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	1
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxTRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	99.9%	99.9%	99.9%
Including NBD	99.9%	99.1%	96.0%	92.1%
Effective Sample Size	57354	40614	12554	131

Cardiac Resynchronization Therapy

D354TRG Protecta XT CRT-D

US Market Release Date	
CE Market Approval Date	03/25/2010
Registered US Implants	1
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxTRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	99.9%	99.9%	99.9%
Including NBD	99.9%	99.1%	96.0%	92.1%
Effective Sample Size	57354	40614	12554	131

Cardiac Resynchronization Therapy

D354TRM Protecta XT CRT-D

US Market Release Date	
CE Market Approval Date	07/15/2010
Registered US Implants	1
Estimated Active US Implants	1
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxTRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	99.9%	99.9%	99.9%
Including NBD	99.9%	99.1%	96.0%	92.1%
Effective Sample Size	57354	40614	12554	131

Cardiac Resynchronization Therapy

D364TRG Protecta CRT-D

US Market Release Date	
CE Market Approval Date	03/25/2010
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxTRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	99.9%	99.9%	99.9%
Including NBD	99.9%	99.1%	96.0%	92.1%
Effective Sample Size	57354	40614	12554	131

Cardiac Resynchronization Therapy

D364TRM Protecta CRT-D

US Market Release Date	
CE Market Approval Date	07/15/2010
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxTRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	99.9%	99.9%	99.9%
Including NBD	99.9%	99.1%	96.0%	92.1%
Effective Sample Size	57354	40614	12554	131

Cardiac Resynchronization Therapy

D384TRG Cardia CRT-D

US Market Release Date	
CE Market Approval Date	01/12/2011
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxTRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	99.9%	99.9%	99.9%
Including NBD	99.9%	99.1%	96.0%	92.1%
Effective Sample Size	57354	40614	12554	131

Cardiac Resynchronization Therapy

D394TRG Egida CRT-D

US Market Release Date	
CE Market Approval Date	01/12/2011
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxTRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	99.9%	99.9%	99.9%
Including NBD	99.9%	99.1%	96.0%	92.1%
Effective Sample Size	57354	40614	12554	131

Cardiac Resynchronization Therapy

DTBA1D1 Viva XT

US Market Release Date	01/29/2013
CE Market Approval Date	
Registered US Implants	22,275
Estimated Active US Implants	21,273
Normal Battery Depletions (US)	1

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

DTBA1D4 Viva XT

US Market Release Date	01/29/2013
CE Market Approval Date	
Registered US Implants	12,125
Estimated Active US Implants	11,689
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	3
Therapy Not Compromised Malfunctions	2
Battery Malfunction	0
Electrical Component	2
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

DTBA1Q1 Viva Quad XT

US Market Release Date	
CE Market Approval Date	
Registered US Implants	1,768
Estimated Active US Implants	1,738
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

DTBA1QQ Viva Quad XT

US Market Release Date	
CE Market Approval Date	
Registered US Implants	4,949
Estimated Active US Implants	4,897
Normal Battery Depletions (US)	1

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

DTBA2D1 Viva XT

US Market Release Date	
CE Market Approval Date	08/10/2012
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

DTBA2D4 Viva XT

US Market Release Date	
CE Market Approval Date	08/10/2012
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

DTBA2Q1 Viva Quad XT

US Market Release Date	
CE Market Approval Date	09/13/2013
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

DTBA2QQ Viva Quad XT

US Market Release Date	
CE Market Approval Date	08/10/2012
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

DTBB1D1 Viva S

US Market Release Date	01/29/2013
CE Market Approval Date	
Registered US Implants	6,419
Estimated Active US Implants	6,077
Normal Battery Depletions (US)	1

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

DTBB1D4 Viva S

US Market Release Date	01/29/2013
CE Market Approval Date	
Registered US Implants	2,820
Estimated Active US Implants	2,718
Normal Battery Depletions (US)	1

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

DTBB1Q1 Viva Quad S

US Market Release Date	
CE Market Approval Date	
Registered US Implants	254
Estimated Active US Implants	248
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

DTBB1QQ Viva Quad S

US Market Release Date	
CE Market Approval Date	
Registered US Implants	634
Estimated Active US Implants	625
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

DTBB2D1 Viva S

US Market Release Date	
CE Market Approval Date	08/10/2012
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

DTBB2D4 Viva S

US Market Release Date	
CE Market Approval Date	08/10/2012
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

DTBB2QQ Viva Quad S

US Market Release Date	
CE Market Approval Date	08/10/2012
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

DTBC2D1 Brava

US Market Release Date	
CE Market Approval Date	08/10/2012
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

DTBC2D4 Brava

US Market Release Date	
CE Market Approval Date	08/10/2012
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

DTBC2Q1 Brava Quad

US Market Release Date	
CE Market Approval Date	09/13/2013
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

DTBC2QQ Brava Quad

US Market Release Date	
CE Market Approval Date	08/10/2012
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, CRT-D, Survival Curve



Years	1	at 23 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	99.9%
Effective Sample Size	17880	140

Cardiac Resynchronization Therapy

8040 InSync

US Market Release Date	08/28/2001
CE Market Approval Date	
Registered US Implants	15,332
Estimated Active US Implants	1,142
Normal Battery Depletions (US)	1,501

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	34
Therapy Not Compromised Malfunctions	24
Battery Malfunction	0
Electrical Component	4
Electrical Interconnect	16
Other Malfunction	1
Poss Early Battery Depltn	3
Software Malfunction	0
Therapy Compromised Malfunctions	10
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	10
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

8040, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	11	at 143 mo
Excluding NBD	100.0%	100.0%	99.9%	99.8%	99.7%	99.6%	99.6%	99.6%	99.5%	99.4%	99.3%	99.3%
Including NBD	99.5%	98.9%	96.3%	92.7%	86.5%	78.9%	67.6%	53.3%	40.2%	28.6%	16.5%	7.7%
Effective Sample Size	12231	10056	8027	6248	4848	3666	2619	1708	1082	644	305	101

Cardiac Resynchronization Therapy

8042 InSync III

US Market Release Date	02/25/2003
CE Market Approval Date	02/07/2001
Registered US Implants	39,428
Estimated Active US Implants	11,744
Normal Battery Depletions (US)	3,326
NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	29
Therapy Not Compromised Malfunctions	19
Battery Malfunction	5
Electrical Component	2
Electrical Interconnect	3
Other Malfunction	7
Poss Early Battery Depltn	2
Software Malfunction	0
Therapy Compromised Malfunctions	10
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	10
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

8042, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 122 mo
Excluding NBD	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.9%	99.8%	99.7%	99.7%
Including NBD	99.7%	99.5%	98.7%	96.9%	93.8%	87.9%	76.4%	58.6%	37.9%	20.7%	18.3%
Effective Sample Size	34468	30086	26389	23155	17013	11311	6964	3601	1355	231	125

Cardiac Resynchronization Therapy

C2TR01 Syncra CRT-P

US Market Release Date	03/22/2011
CE Market Approval Date	05/11/2010
Registered US Implants	8,281
Estimated Active US Implants	7,087
Normal Battery Depletions (US)	6
NBG Code	OOE-DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

C2TR01, C3TR01, C4TR01, Survival Curve



Years	1	2	3	at 47 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	99.9%	99.8%	99.5%
Effective Sample Size	18671	11417	5076	238

Cardiac Resynchronization Therapy

C3TR01 Consulta CRT-P

US Market Release Date	
CE Market Approval Date	05/11/2010
Registered US Implants	1
Estimated Active US Implants	1
Normal Battery Depletions (US)	0

NBG Code	OAE-DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

C2TR01, C3TR01, C4TR01, Survival Curve



Years	1	2	3	at 47 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	99.9%	99.8%	99.5%
Effective Sample Size	18671	11417	5076	238

Cardiac Resynchronization Therapy

C4TR01 Consulta CRT-P

US Market Release Date	03/22/2011
CE Market Approval Date	
Registered US Implants	16,845
Estimated Active US Implants	15,127
Normal Battery Depletions (US)	11

NBG Code	OAE-DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

C2TR01, C3TR01, C4TR01, Survival Curve



Years	1	2	3	at 47 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	99.9%	99.8%	99.5%
Effective Sample Size	18671	11417	5076	238

Implantable Cardioverter Defibrillator

7230B Marquis VR

US Market Release Date	12/17/2002
CE Market Approval Date	08/21/2002
Registered US Implants	237
Estimated Active US Implants	17
Normal Battery Depletions (US)	26
NBG Code	VVE-VVIR
Max Delivered Energy	30J

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	1
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

7230, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 130 mo
Excluding NBD	99.9%	99.9%	99.9%	99.8%	99.7%	99.6%	99.5%	99.4%	99.4%	99.4%	99.4%
Including NBD	99.5%	99.2%	98.9%	98.6%	97.9%	94.1%	85.9%	74.6%	45.4%	18.4%	14.7%
Effective Sample Size	17325	13571	11364	10210	9151	8035	6781	5477	3090	845	107

Implantable Cardioverter Defibrillator

7230Cx Marquis VR

US Market Release Date	12/17/2002
CE Market Approval Date	04/10/2002
Registered US Implants	18,565
Estimated Active US Implants	1,735
Normal Battery Depletions (US)	3,324
NBG Code	VVE-VVIR
Max Delivered Energy	30J

Total Malfunctions (US)	57
Therapy Not Compromised Malfunctions	31
Battery Malfunction	1
Electrical Component	14
Electrical Interconnect	0
Other Malfunction	1
Poss Early Battery Depltn	14
Software Malfunction	1
Therapy Compromised Malfunctions	26
Battery Malfunction	17
Electrical Component	9
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

7230, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 130 mo
Excluding NBD	99.9%	99.9%	99.9%	99.8%	99.7%	99.6%	99.5%	99.4%	99.4%	99.4%	99.4%
Including NBD	99.5%	99.2%	98.9%	98.6%	97.9%	94.1%	85.9%	74.6%	45.4%	18.4%	14.7%
Effective Sample Size	17325	13571	11364	10210	9151	8035	6781	5477	3090	845	107

Implantable Cardioverter Defibrillator

7230E Marquis VR

US Market Release Date	12/17/2002
CE Market Approval Date	08/21/2002
Registered US Implants	633
Estimated Active US Implants	62
Normal Battery Depletions (US)	77

NBG Code	VVE-VVIR
Max Delivered Energy	30J

Total Malfunctions (US)	3
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	2
Battery Malfunction	2
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

7230, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 130 mo
Excluding NBD	99.9%	99.9%	99.9%	99.8%	99.7%	99.6%	99.5%	99.4%	99.4%	99.4%	99.4%
Including NBD	99.5%	99.2%	98.9%	98.6%	97.9%	94.1%	85.9%	74.6%	45.4%	18.4%	14.7%
Effective Sample Size	17325	13571	11364	10210	9151	8035	6781	5477	3090	845	107

Implantable Cardioverter Defibrillator

7231Cx GEM III VR

US Market Release Date	12/12/2000
CE Market Approval Date	12/08/2000
Registered US Implants	17,494
Estimated Active US Implants	1,474
Normal Battery Depletions (US)	3,915

NBG Code	VVE-VVIR
Max Delivered Energy	30J

Total Malfunctions (US)	36
Therapy Not Compromised Malfunctions	26
Battery Malfunction	1
Electrical Component	21
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	4
Software Malfunction	0
Therapy Compromised Malfunctions	10
Battery Malfunction	1
Electrical Component	8
Electrical Interconnect	1
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

7231, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 120 mo
Excluding NBD	99.9%	99.9%	99.8%	99.8%	99.8%	99.7%	99.7%	99.7%	99.7%	99.7%
Including NBD	99.3%	98.8%	98.1%	97.3%	95.5%	86.3%	73.6%	49.9%	18.5%	4.7%
Effective Sample Size	15740	14055	12441	10949	9552	7901	6156	3750	1114	103

Implantable Cardioverter Defibrillator

7232B Maximo VR

US Market Release Date	10/06/2003
CE Market Approval Date	10/22/2004
Registered US Implants	170
Estimated Active US Implants	59
Normal Battery Depletions (US)	18

NBG Code	VVE-VVIR
Max Delivered Energy	35J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

7232, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 118 mo
Excluding NBD	100.0%	99.9%	99.9%	99.9%	99.8%	99.8%	99.8%	99.8%	99.8%	99.8%
Including NBD	99.6%	99.4%	99.1%	98.6%	97.2%	91.7%	83.8%	73.3%	51.4%	21.1%
Effective Sample Size	40686	36632	32881	29216	25876	22472	18411	13726	6636	331

Implantable Cardioverter Defibrillator

7232Cx Maximo VR

US Market Release Date	10/06/2003
CE Market Approval Date	10/28/2003
Registered US Implants	43,681
Estimated Active US Implants	11,144
Normal Battery Depletions (US)	7,268
NBG Code	VVE-VVIR
Max Delivered Energy	35J

Total Malfunctions (US)	76
Therapy Not Compromised Malfunctions	61
Battery Malfunction	0
Electrical Component	28
Electrical Interconnect	0
Other Malfunction	6
Poss Early Battery Depltn	25
Software Malfunction	2
Therapy Compromised Malfunctions	15
Battery Malfunction	0
Electrical Component	12
Electrical Interconnect	1
Other Malfunction	1
Poss Early Battery Depltn	1
Software Malfunction	0

7232, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 118 mo
Excluding NBD	100.0%	99.9%	99.9%	99.9%	99.8%	99.8%	99.8%	99.8%	99.8%	99.8%
Including NBD	99.6%	99.4%	99.1%	98.6%	97.2%	91.7%	83.8%	73.3%	51.4%	21.1%
Effective Sample Size	40686	36632	32881	29216	25876	22472	18411	13726	6636	331

Implantable Cardioverter Defibrillator

7232E Maximo VR

US Market Release Date	10/06/2003
CE Market Approval Date	10/22/2004
Registered US Implants	491
Estimated Active US Implants	149
Normal Battery Depletions (US)	41

NBG Code	VVE-VVIR
Max Delivered Energy	35J

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

7232, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 118 mo
Excluding NBD	100.0%	99.9%	99.9%	99.9%	99.8%	99.8%	99.8%	99.8%	99.8%	99.8%
Including NBD	99.6%	99.4%	99.1%	98.6%	97.2%	91.7%	83.8%	73.3%	51.4%	21.1%
Effective Sample Size	40686	36632	32881	29216	25876	22472	18411	13726	6636	331

Implantable Cardioverter Defibrillator

7274 Marquis DR

US Market Release Date	03/01/2002
CE Market Approval Date	02/25/2002
Registered US Implants	48,387
Estimated Active US Implants	2,616
Normal Battery Depletions (US)	9,077

NBG Code	VVE-DDDR
Max Delivered Energy	30J

Total Malfunctions (US)	196
Therapy Not Compromised Malfunctions	89
Battery Malfunction	6
Electrical Component	31
Electrical Interconnect	0
Other Malfunction	1
Poss Early Battery Depltn	51
Software Malfunction	0
Therapy Compromised Malfunctions	107
Battery Malfunction	80
Electrical Component	27
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

7274, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 117 mo
Excluding NBD	100.0%	99.9%	99.8%	99.6%	99.4%	99.3%	99.2%	99.1%	99.1%	99.1%
Including NBD	99.3%	99.0%	98.3%	97.1%	91.6%	71.4%	37.9%	8.4%	4.0%	2.9%
Effective Sample Size	42837	34501	26566	22609	18798	12963	6049	1015	298	104

Implantable Cardioverter Defibrillator

7278 Maximo DR

US Market Release Date	10/06/2003
CE Market Approval Date	10/28/2003
Registered US Implants	37,666
Estimated Active US Implants	4,094
Normal Battery Depletions (US)	10,483

NBG Code	VVE-DDDR
Max Delivered Energy	35J

Total Malfunctions (US)	72
Therapy Not Compromised Malfunctions	62
Battery Malfunction	0
Electrical Component	24
Electrical Interconnect	0
Other Malfunction	4
Poss Early Battery Depltn	34
Software Malfunction	0
Therapy Compromised Malfunctions	10
Battery Malfunction	0
Electrical Component	9
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	1
Software Malfunction	0

7278, Survival Curve



Years	1	2	3	4	5	6	7	8	at 102 mo
Excluding NBD	100.0%	99.9%	99.9%	99.8%	99.8%	99.7%	99.7%	99.7%	99.7%
Including NBD	99.4%	99.1%	98.5%	96.9%	88.8%	66.3%	35.6%	8.3%	3.3%
Effective Sample Size	33861	30308	27185	23955	19874	13308	6138	1053	207

Implantable Cardioverter Defibrillator

7288 Intrinsic

US Market Release Date	06/21/2004
CE Market Approval Date	05/04/2004
Registered US Implants	30,665
Estimated Active US Implants	2,870
Normal Battery Depletions (US)	10,029

NBG Code	VVE-DDDR
Max Delivered Energy	35J

Total Malfunctions (US)	71
Therapy Not Compromised Malfunctions	64
Battery Malfunction	2
Electrical Component	27
Electrical Interconnect	0
Other Malfunction	1
Poss Early Battery Depltn	33
Software Malfunction	1
Therapy Compromised Malfunctions	7
Battery Malfunction	0
Electrical Component	5
Electrical Interconnect	0
Other Malfunction	2
Poss Early Battery Depltn	0
Software Malfunction	0

7288, Survival Curve



Years	1	2	3	4	5	6	7	8	at 106 mo
Excluding NBD	100.0%	99.9%	99.9%	99.8%	99.8%	99.7%	99.7%	99.7%	99.7%
Including NBD	99.4%	99.0%	98.5%	97.5%	90.2%	71.4%	34.9%	8.1%	4.8%
Effective Sample Size	28595	26260	23691	20984	17800	12924	5869	954	140

Implantable Cardioverter Defibrillator

D144DRG Entrust Escudo

US Market Release Date	
CE Market Approval Date	06/05/2008
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D144DRG, D154ATG, D154DRG, Survival Curve



Years	1	2	3	4	5	6	7	8	at 104 mo
Excluding NBD	100.0%	99.9%	99.8%	99.7%	99.4%	99.4%	99.4%	99.4%	99.4%
Including NBD	99.6%	99.3%	98.7%	97.5%	90.7%	72.0%	41.8%	15.6%	6.4%
Effective Sample Size	26272	24061	21693	19252	16148	11945	6073	1727	107

Implantable Cardioverter Defibrillator

D144VRC Entrust Escudo

US Market Release Date	
CE Market Approval Date	06/05/2008
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D144VRC, D154VRC, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 110 mo
Excluding NBD	100.0%	99.9%	99.8%	99.7%	99.5%	99.2%	98.9%	98.8%	98.8%	98.8%
Including NBD	99.8%	99.5%	99.2%	98.7%	97.8%	92.8%	86.2%	78.5%	67.1%	62.9%
Effective Sample Size	13630	12418	11171	9950	8872	7862	6558	4915	777	270

Implantable Cardioverter Defibrillator

D154ATG Entrust AT

US Market Release Date	06/30/2005
CE Market Approval Date	02/04/2005
Registered US Implants	28,169
Estimated Active US Implants	3,680
Normal Battery Depletions (US)	8,572

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	124
Therapy Not Compromised Malfunctions	110
Battery Malfunction	0
Electrical Component	30
Electrical Interconnect	1
Other Malfunction	1
Poss Early Battery Depltn	75
Software Malfunction	3
Therapy Compromised Malfunctions	14
Battery Malfunction	0
Electrical Component	14
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D144DRG, D154ATG, D154DRG, Survival Curve



Years	1	2	3	4	5	6	7	8	at 104 mo
Excluding NBD	100.0%	99.9%	99.8%	99.7%	99.4%	99.4%	99.4%	99.4%	99.4%
Including NBD	99.6%	99.3%	98.7%	97.5%	90.7%	72.0%	41.8%	15.6%	6.4%
Effective Sample Size	26272	24061	21693	19252	16148	11945	6073	1727	107

Implantable Cardioverter Defibrillator

D154AWG Virtuoso DR

US Market Release Date	05/12/2006
CE Market Approval Date	
Registered US Implants	72,709
Estimated Active US Implants	25,470
Normal Battery Depletions (US)	13,847

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	1,455
Therapy Not Compromised Malfunctions	1,426
Battery Malfunction	6
Electrical Component	1,277
Electrical Interconnect	2
Other Malfunction	4
Poss Early Battery Depltn	133
Software Malfunction	4
Therapy Compromised Malfunctions	29
Battery Malfunction	0
Electrical Component	26
Electrical Interconnect	0
Other Malfunction	2
Poss Early Battery Depltn	1
Software Malfunction	0

D154AWG, D16AWG, Survival Curve



Years	1	2	3	4	5	6	7	at 93 mo
Excluding NBD	100.0%	99.9%	99.9%	99.4%	97.3%	97.1%	97.0%	97.0%
Including NBD	99.8%	99.6%	99.2%	97.8%	89.9%	71.3%	44.5%	18.4%
Effective Sample Size	67681	62397	57205	52252	44517	28257	9577	335

Implantable Cardioverter Defibrillator

D154DRG Entrust DR

US Market Release Date	06/14/2005
CE Market Approval Date	02/04/2005
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D144DRG, D154ATG, D154DRG, Survival Curve



Years	1	2	3	4	5	6	7	8	at 104 mo
Excluding NBD	100.0%	99.9%	99.8%	99.7%	99.4%	99.4%	99.4%	99.4%	99.4%
Including NBD	99.6%	99.3%	98.7%	97.5%	90.7%	72.0%	41.8%	15.6%	6.4%
Effective Sample Size	26272	24061	21693	19252	16148	11945	6073	1727	107

Implantable Cardioverter Defibrillator

D154VRC Entrust VR

US Market Release Date	06/30/2005
CE Market Approval Date	02/04/2005
Registered US Implants	14,468
Estimated Active US Implants	5,673
Normal Battery Depletions (US)	1,326

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	109
Therapy Not Compromised Malfunctions	88
Battery Malfunction	10
Electrical Component	44
Electrical Interconnect	0
Other Malfunction	10
Poss Early Battery Depltn	24
Software Malfunction	0
Therapy Compromised Malfunctions	21
Battery Malfunction	1
Electrical Component	19
Electrical Interconnect	0
Other Malfunction	1
Poss Early Battery Depltn	0
Software Malfunction	0

D144VRC, D154VRC, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 110 mo
Excluding NBD	100.0%	99.9%	99.8%	99.7%	99.5%	99.2%	98.9%	98.8%	98.8%	98.8%
Including NBD	99.8%	99.5%	99.2%	98.7%	97.8%	92.8%	86.2%	78.5%	67.1%	62.9%
Effective Sample Size	13630	12418	11171	9950	8872	7862	6558	4915	777	270

Implantable Cardioverter Defibrillator

D154VWC Virtuoso VR

US Market Release Date	05/12/2006
CE Market Approval Date	
Registered US Implants	33,137
Estimated Active US Implants	16,372
Normal Battery Depletions (US)	2,478

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	662
Therapy Not Compromised Malfunctions	646
Battery Malfunction	1
Electrical Component	625
Electrical Interconnect	1
Other Malfunction	4
Poss Early Battery Depltn	15
Software Malfunction	0
Therapy Compromised Malfunctions	16
Battery Malfunction	1
Electrical Component	15
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D154VWC,D164VWC, Survival Curve



Years	1	2	3	4	5	6	7	at 96 mo
Excluding NBD	100.0%	99.9%	99.9%	99.7%	98.2%	97.1%	97.0%	97.0%
Including NBD	99.8%	99.7%	99.5%	99.0%	96.2%	87.8%	77.5%	52.0%
Effective Sample Size	30825	28284	25951	23840	21343	15843	7839	190

Implantable Cardioverter Defibrillator

D164AWG Virtuoso DR

US Market Release Date	
CE Market Approval Date	03/07/2006
Registered US Implants	10
Estimated Active US Implants	6
Normal Battery Depletions (US)	1

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D154AWG, D16AWG, Survival Curve



Years	1	2	3	4	5	6	7	at 93 mo
Excluding NBD	100.0%	99.9%	99.9%	99.4%	97.3%	97.1%	97.0%	97.0%
Including NBD	99.8%	99.6%	99.2%	97.8%	89.9%	71.3%	44.5%	18.4%
Effective Sample Size	67681	62397	57205	52252	44517	28257	9577	335

Implantable Cardioverter Defibrillator

D164VWC Virtuoso VR

US Market Release Date	
CE Market Approval Date	03/07/2006
Registered US Implants	6
Estimated Active US Implants	4
Normal Battery Depletions (US)	0

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D154VWC,D164VWC, Survival Curve



Years	1	2	3	4	5	6	7	at 96 mo
Excluding NBD	100.0%	99.9%	99.9%	99.7%	98.2%	97.1%	97.0%	97.0%
Including NBD	99.8%	99.7%	99.5%	99.0%	96.2%	87.8%	77.5%	52.0%
Effective Sample Size	30825	28284	25951	23840	21343	15843	7839	190

Implantable Cardioverter Defibrillator

D204DRM Secura DR

US Market Release Date	01/09/2012
CE Market Approval Date	
Registered US Implants	1,874
Estimated Active US Implants	1,746
Normal Battery Depletions (US)	1

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	3
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	1
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	2
Battery Malfunction	0
Electrical Component	2
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SECURA, DR, Survival Curve



Years	1	2	3	4	5	6	at 75 mo
Excluding NBD	100.0%	99.9%	99.9%	99.8%	99.7%	99.7%	99.7%
Including NBD	99.8%	99.6%	99.3%	98.4%	95.6%	89.6%	87.5%
Effective Sample Size	49158	44354	38602	29019	12966	1990	436

Implantable Cardioverter Defibrillator

D204VRM Secura VR

US Market Release Date	05/02/2012
CE Market Approval Date	
Registered US Implants	1,172
Estimated Active US Implants	1,108
Normal Battery Depletions (US)	0

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SECURA, VR, Survival Curve



Years	1	2	3	4	5	6	at 76 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%	99.9%	99.8%	99.8%
Including NBD	99.9%	99.7%	99.5%	99.2%	98.9%	98.2%	97.3%
Effective Sample Size	20469	18017	15262	11344	5633	1104	156

Implantable Cardioverter Defibrillator

D214DRM Secura DR

US Market Release Date	
CE Market Approval Date	07/22/2010
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SECURA, DR, Survival Curve



Years	1	2	3	4	5	6	at 75 mo
Excluding NBD	100.0%	99.9%	99.9%	99.8%	99.7%	99.7%	99.7%
Including NBD	99.8%	99.6%	99.3%	98.4%	95.6%	89.6%	87.5%
Effective Sample Size	49158	44354	38602	29019	12966	1990	436

Implantable Cardioverter Defibrillator

D214VRM Secura VR

US Market Release Date	
CE Market Approval Date	12/17/2010
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SECURA, VR, Survival Curve



Years	1	2	3	4	5	6	at 76 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%	99.9%	99.8%	99.8%
Including NBD	99.9%	99.7%	99.5%	99.2%	98.9%	98.2%	97.3%
Effective Sample Size	20469	18017	15262	11344	5633	1104	156

Implantable Cardioverter Defibrillator

D224DRG Secura DR

US Market Release Date	09/15/2008
CE Market Approval Date	
Registered US Implants	49,845
Estimated Active US Implants	37,187
Normal Battery Depletions (US)	903

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	93
Therapy Not Compromised Malfunctions	78
Battery Malfunction	0
Electrical Component	22
Electrical Interconnect	0
Other Malfunction	1
Poss Early Battery Depltn	46
Software Malfunction	9
Therapy Compromised Malfunctions	15
Battery Malfunction	1
Electrical Component	12
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	1
Software Malfunction	1

SECURA, DR, Survival Curve



Years	1	2	3	4	5	6	at 75 mo
Excluding NBD	100.0%	99.9%	99.9%	99.8%	99.7%	99.7%	99.7%
Including NBD	99.8%	99.6%	99.3%	98.4%	95.6%	89.6%	87.5%
Effective Sample Size	49158	44354	38602	29019	12966	1990	436

Implantable Cardioverter Defibrillator

D224VRC Secura VR

US Market Release Date	09/15/2008
CE Market Approval Date	
Registered US Implants	19,942
Estimated Active US Implants	15,474
Normal Battery Depletions (US)	85

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	24
Therapy Not Compromised Malfunctions	18
Battery Malfunction	4
Electrical Component	5
Electrical Interconnect	0
Other Malfunction	1
Poss Early Battery Depltn	6
Software Malfunction	2
Therapy Compromised Malfunctions	6
Battery Malfunction	0
Electrical Component	5
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	1

SECURA, VR, Survival Curve



Years	1	2	3	4	5	6	at 76 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%	99.9%	99.8%	99.8%
Including NBD	99.9%	99.7%	99.5%	99.2%	98.9%	98.2%	97.3%
Effective Sample Size	20469	18017	15262	11344	5633	1104	156

Implantable Cardioverter Defibrillator

D234DRG Secura DR

US Market Release Date	
CE Market Approval Date	03/14/2008
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SECURA, DR, Survival Curve



Years	1	2	3	4	5	6	at 75 mo
Excluding NBD	100.0%	99.9%	99.9%	99.8%	99.7%	99.7%	99.7%
Including NBD	99.8%	99.6%	99.3%	98.4%	95.6%	89.6%	87.5%
Effective Sample Size	49158	44354	38602	29019	12966	1990	436

Implantable Cardioverter Defibrillator

D234VRC Secura VR

US Market Release Date	
CE Market Approval Date	03/14/2008
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SECURA, VR, Survival Curve



Years	1	2	3	4	5	6	at 76 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%	99.9%	99.8%	99.8%
Including NBD	99.9%	99.7%	99.5%	99.2%	98.9%	98.2%	97.3%
Effective Sample Size	20469	18017	15262	11344	5633	1104	156

Implantable Cardioverter Defibrillator

D264DRM Maximo II DR

US Market Release Date	01/09/2012
CE Market Approval Date	07/22/2010
Registered US Implants	6
Estimated Active US Implants	6
Normal Battery Depletions (US)	0

NBG Code	VVE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

MAXIMO, II, DR, Survival Curve



Years	1	2	3	4	5	6	at 76 mo
Excluding NBD	100.0%	100.0%	99.9%	99.8%	99.7%	99.7%	99.7%
Including NBD	99.9%	99.7%	99.4%	98.5%	96.0%	88.7%	86.0%
Effective Sample Size	19345	17344	14860	11089	5963	1199	104

Implantable Cardioverter Defibrillator

D264VRM Maximo II VR

US Market Release Date	05/02/2012
CE Market Approval Date	12/17/2010
Registered US Implants	1
Estimated Active US Implants	1
Normal Battery Depletions (US)	0

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

MAXIMO, II, VR, Survival Curve



Years	1	2	3	4	5	6	at 76 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.9%
Including NBD	99.8%	99.7%	99.5%	99.3%	98.9%	98.0%	97.4%
Effective Sample Size	13177	11853	9981	7319	3965	793	108

Implantable Cardioverter Defibrillator

D274DRG Virtuoso II DR

US Market Release Date	08/15/2009
CE Market Approval Date	
Registered US Implants	22,220
Estimated Active US Implants	17,206
Normal Battery Depletions (US)	202

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	16
Therapy Not Compromised Malfunctions	13
Battery Malfunction	3
Electrical Component	3
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	6
Software Malfunction	1
Therapy Compromised Malfunctions	3
Battery Malfunction	0
Electrical Component	2
Electrical Interconnect	0
Other Malfunction	1
Poss Early Battery Depltn	0
Software Malfunction	0

VIRTUOSO, II, DR, Survival Curve



Years	1	2	3	4	5	at 63 mo
Excluding NBD	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%
Including NBD	99.9%	99.8%	99.5%	98.9%	96.1%	94.3%
Effective Sample Size	20630	19226	17718	12087	2215	334

Implantable Cardioverter Defibrillator

D274VRC Virtuoso II VR

US Market Release Date	08/15/2009
CE Market Approval Date	
Registered US Implants	9,113
Estimated Active US Implants	7,312
Normal Battery Depletions (US)	23
NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	6
Therapy Not Compromised Malfunctions	6
Battery Malfunction	1
Electrical Component	2
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	2
Software Malfunction	1
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

VIRTUOSO, II, VR, Survival Curve



Years	1	2	3	4	5	at 62 mo
Excluding NBD	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%
Including NBD	99.8%	99.8%	99.6%	99.5%	99.1%	99.1%
Effective Sample Size	8581	8008	7330	4810	796	263

Implantable Cardioverter Defibrillator

D284DRG Maximo II DR

US Market Release Date	09/17/2008
CE Market Approval Date	03/14/2008
Registered US Implants	20,045
Estimated Active US Implants	14,936
Normal Battery Depletions (US)	415

NBG Code	VVE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	42
Therapy Not Compromised Malfunctions	36
Battery Malfunction	0
Electrical Component	9
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	27
Software Malfunction	0
Therapy Compromised Malfunctions	6
Battery Malfunction	0
Electrical Component	5
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	1
Software Malfunction	0

MAXIMO, II, DR, Survival Curve



Years	1	2	3	4	5	6	at 76 mo
Excluding NBD	100.0%	100.0%	99.9%	99.8%	99.7%	99.7%	99.7%
Including NBD	99.9%	99.7%	99.4%	98.5%	96.0%	88.7%	86.0%
Effective Sample Size	19345	17344	14860	11089	5963	1199	104

Implantable Cardioverter Defibrillator

D284VRC Maximo II VR

US Market Release Date	09/17/2008
CE Market Approval Date	03/14/2008
Registered US Implants	12,951
Estimated Active US Implants	10,210
Normal Battery Depletions (US)	61

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	15
Therapy Not Compromised Malfunctions	11
Battery Malfunction	1
Electrical Component	4
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	3
Software Malfunction	3
Therapy Compromised Malfunctions	4
Battery Malfunction	1
Electrical Component	2
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	1

MAXIMO, II, VR, Survival Curve



Years	1	2	3	4	5	6	at 76 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.9%
Including NBD	99.8%	99.7%	99.5%	99.3%	98.9%	98.0%	97.4%
Effective Sample Size	13177	11853	9981	7319	3965	793	108

Implantable Cardioverter Defibrillator

D294DRG Virtuoso II DR

US Market Release Date	
CE Market Approval Date	08/20/2008
Registered US Implants	1
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

VIRTUOSO, II, DR, Survival Curve



Years	1	2	3	4	5	at 63 mo
Excluding NBD	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%
Including NBD	99.9%	99.8%	99.5%	98.9%	96.1%	94.3%
Effective Sample Size	20630	19226	17718	12087	2215	334

Implantable Cardioverter Defibrillator

D294VRC Virtuoso II VR

US Market Release Date	
CE Market Approval Date	08/20/2008
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

VIRTUOSO, II, VR, Survival Curve



Years	1	2	3	4	5	at 62 mo
Excluding NBD	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%
Including NBD	99.8%	99.8%	99.6%	99.5%	99.1%	99.1%
Effective Sample Size	8581	8008	7330	4810	796	263

Implantable Cardioverter Defibrillator

D314DRG Protecta XT DR

US Market Release Date	03/25/2011
CE Market Approval Date	
Registered US Implants	34,312
Estimated Active US Implants	30,503
Normal Battery Depletions (US)	53

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	18
Therapy Not Compromised Malfunctions	13
Battery Malfunction	1
Electrical Component	11
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	1
Software Malfunction	0
Therapy Compromised Malfunctions	5
Battery Malfunction	0
Electrical Component	5
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxDRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.8%	99.6%	99.4%
Effective Sample Size	57472	40632	13475	337

Implantable Cardioverter Defibrillator

D314DRM Protecta XT DR

US Market Release Date	11/09/2011
CE Market Approval Date	
Registered US Implants	13,665
Estimated Active US Implants	12,669
Normal Battery Depletions (US)	9

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	4
Therapy Not Compromised Malfunctions	4
Battery Malfunction	0
Electrical Component	3
Electrical Interconnect	0
Other Malfunction	1
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxDRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.8%	99.6%	99.4%
Effective Sample Size	57472	40632	13475	337

Implantable Cardioverter Defibrillator

D314VRG Protecta XT VR

US Market Release Date	03/25/2011
CE Market Approval Date	
Registered US Implants	13,929
Estimated Active US Implants	12,514
Normal Battery Depletions (US)	15
NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	6
Therapy Not Compromised Malfunctions	5
Battery Malfunction	0
Electrical Component	4
Electrical Interconnect	0
Other Malfunction	1
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxVRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.9%	99.7%	99.5%
Effective Sample Size	27216	18397	5746	167

Implantable Cardioverter Defibrillator

D314VRM Protecta XT VR

US Market Release Date	05/02/2012
CE Market Approval Date	
Registered US Implants	7,226
Estimated Active US Implants	6,721
Normal Battery Depletions (US)	2

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxVRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.9%	99.7%	99.5%
Effective Sample Size	27216	18397	5746	167

Implantable Cardioverter Defibrillator

D334DRG Protecta DR

US Market Release Date	03/25/2011
CE Market Approval Date	
Registered US Implants	10,415
Estimated Active US Implants	9,348
Normal Battery Depletions (US)	20

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	8
Therapy Not Compromised Malfunctions	6
Battery Malfunction	0
Electrical Component	5
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	1
Software Malfunction	0
Therapy Compromised Malfunctions	2
Battery Malfunction	0
Electrical Component	2
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxDRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.8%	99.6%	99.4%
Effective Sample Size	57472	40632	13475	337

Implantable Cardioverter Defibrillator

D334DRM Protecta DR

US Market Release Date	11/09/2011
CE Market Approval Date	
Registered US Implants	2,881
Estimated Active US Implants	2,698
Normal Battery Depletions (US)	4

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxDRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.8%	99.6%	99.4%
Effective Sample Size	57472	40632	13475	337

Implantable Cardioverter Defibrillator

D334VRG Protecta VR

US Market Release Date	03/25/2011
CE Market Approval Date	
Registered US Implants	6,190
Estimated Active US Implants	5,584
Normal Battery Depletions (US)	5

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	3
Therapy Not Compromised Malfunctions	2
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	1
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxVRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.9%	99.7%	99.5%
Effective Sample Size	27216	18397	5746	167

Implantable Cardioverter Defibrillator

D334VRM Protecta VR

US Market Release Date	05/02/2012
CE Market Approval Date	
Registered US Implants	2,123
Estimated Active US Implants	1,990
Normal Battery Depletions (US)	0

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxVRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.9%	99.7%	99.5%
Effective Sample Size	27216	18397	5746	167

Implantable Cardioverter Defibrillator

D354DRG Protecta XT DR

US Market Release Date	
CE Market Approval Date	03/25/2010
Registered US Implants	2
Estimated Active US Implants	1
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxDRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.8%	99.6%	99.4%
Effective Sample Size	57472	40632	13475	337

Implantable Cardioverter Defibrillator

D354DRM Protecta XT DR

US Market Release Date	
CE Market Approval Date	07/15/2010
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxDRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.8%	99.6%	99.4%
Effective Sample Size	57472	40632	13475	337

Implantable Cardioverter Defibrillator

D354VRG Protecta XT VR

US Market Release Date	
CE Market Approval Date	03/25/2010
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxVRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.9%	99.7%	99.5%
Effective Sample Size	27216	18397	5746	167

Implantable Cardioverter Defibrillator

D354VRM Protecta XT VR

US Market Release Date	
CE Market Approval Date	12/17/2010
Registered US Implants	1
Estimated Active US Implants	1
Normal Battery Depletions (US)	0

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxVRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.9%	99.7%	99.5%
Effective Sample Size	27216	18397	5746	167

Implantable Cardioverter Defibrillator

D364DRG Protecta DR

US Market Release Date	
CE Market Approval Date	03/25/2010
Registered US Implants	1
Estimated Active US Implants	1
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxDRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.8%	99.6%	99.4%
Effective Sample Size	57472	40632	13475	337

Implantable Cardioverter Defibrillator

D364DRM Protecta DR

US Market Release Date	
CE Market Approval Date	07/15/2010
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxDRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.8%	99.6%	99.4%
Effective Sample Size	57472	40632	13475	337

Implantable Cardioverter Defibrillator

D364VRG Protecta VR

US Market Release Date	
CE Market Approval Date	03/25/2010
Registered US Implants	1
Estimated Active US Implants	1
Normal Battery Depletions (US)	0

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxVRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.9%	99.7%	99.5%
Effective Sample Size	27216	18397	5746	167

Implantable Cardioverter Defibrillator

D364VRM Protecta VR

US Market Release Date	
CE Market Approval Date	12/17/2010
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxVRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.9%	99.7%	99.5%
Effective Sample Size	27216	18397	5746	167

Implantable Cardioverter Defibrillator

D384DRG Cardia DR

US Market Release Date	
CE Market Approval Date	01/12/2011
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxDRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.8%	99.6%	99.4%
Effective Sample Size	57472	40632	13475	337

Implantable Cardioverter Defibrillator

D384VRG Cardia VR

US Market Release Date	
CE Market Approval Date	01/12/2011
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxVRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.9%	99.7%	99.5%
Effective Sample Size	27216	18397	5746	167

Implantable Cardioverter Defibrillator

D394DRG Egida DR

US Market Release Date	
CE Market Approval Date	01/12/2011
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-DDDR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxDRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.8%	99.6%	99.4%
Effective Sample Size	57472	40632	13475	337

Implantable Cardioverter Defibrillator

D394VRG Egida VR

US Market Release Date	
CE Market Approval Date	01/12/2011
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-VVIR
Max Delivered Energy	35 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

D3xxVRx, Survival Curve



Years	1	2	3	at 46 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%
Including NBD	99.9%	99.9%	99.7%	99.5%
Effective Sample Size	27216	18397	5746	167

Implantable Cardioverter Defibrillator

DDBB1D1 Evera XT

US Market Release Date	04/03/2013
CE Market Approval Date	
Registered US Implants	15,520
Estimated Active US Implants	14,994
Normal Battery Depletions (US)	1

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, DR, Survival Curve



Years	1	at 20 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	100.0%
Effective Sample Size	13934	335

Implantable Cardioverter Defibrillator

DDBB1D4 Evera XT

US Market Release Date	04/03/2013
CE Market Approval Date	
Registered US Implants	16,056
Estimated Active US Implants	15,650
Normal Battery Depletions (US)	1

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	2
Therapy Not Compromised Malfunctions	2
Battery Malfunction	0
Electrical Component	2
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, DR, Survival Curve



Years	1	at 20 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	100.0%
Effective Sample Size	13934	335

Implantable Cardioverter Defibrillator

DDBB2D1 Evera XT

US Market Release Date	
CE Market Approval Date	12/17/2012
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, DR, Survival Curve



Years	1	at 20 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	100.0%
Effective Sample Size	13934	335

Implantable Cardioverter Defibrillator

DDBB2D4 Evera XT

US Market Release Date	
CE Market Approval Date	12/17/2012
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, DR, Survival Curve



Years	1	at 20 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	100.0%
Effective Sample Size	13934	335

Implantable Cardioverter Defibrillator

DDBC3D1 Evera S

US Market Release Date	04/03/2013
CE Market Approval Date	12/17/2012
Registered US Implants	3,455
Estimated Active US Implants	3,328
Normal Battery Depletions (US)	0

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, DR, Survival Curve



Years	1	at 20 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	100.0%
Effective Sample Size	13934	335

Implantable Cardioverter Defibrillator

DDBC3D4 Evera S

US Market Release Date	04/03/2013
CE Market Approval Date	12/17/2013
Registered US Implants	3,050
Estimated Active US Implants	2,967
Normal Battery Depletions (US)	1

NBG Code	DDE-DDDR
Max Delivered Energy	36 J

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, DR, Survival Curve



Years	1	at 20 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	100.0%
Effective Sample Size	13934	335

Implantable Cardioverter Defibrillator

DVBB1D1 Evera XT

US Market Release Date	04/03/2013
CE Market Approval Date	
Registered US Implants	7,128
Estimated Active US Implants	6,903
Normal Battery Depletions (US)	0
NBG Code	VVE-VVIR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, VR, Survival Curve



Years	1	at 20 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	100.0%
Effective Sample Size	7955	223

Implantable Cardioverter Defibrillator

DVBB1D4 Evera XT

US Market Release Date	04/03/2013
CE Market Approval Date	
Registered US Implants	12,404
Estimated Active US Implants	12,086
Normal Battery Depletions (US)	1

NBG Code	VVE-VVIR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, VR, Survival Curve



Years	1	at 20 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	100.0%
Effective Sample Size	7955	223

Implantable Cardioverter Defibrillator

DVBB2D1 Evera XT

US Market Release Date	
CE Market Approval Date	12/17/2012
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-VVIR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, VR, Survival Curve



Years	1	at 20 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	100.0%
Effective Sample Size	7955	223

Implantable Cardioverter Defibrillator

DVBB2D4 Evera XT

US Market Release Date	
CE Market Approval Date	12/17/2012
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VVE-VVIR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, VR, Survival Curve



Years	1	at 20 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	100.0%
Effective Sample Size	7955	223

Implantable Cardioverter Defibrillator

DVBC3D1 Evera S

US Market Release Date	04/03/2013
CE Market Approval Date	12/17/2012
Registered US Implants	1,803
Estimated Active US Implants	1,746
Normal Battery Depletions (US)	0

NBG Code	VVE-VVIR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, VR, Survival Curve



Years	1	at 20 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	100.0%
Effective Sample Size	7955	223

Implantable Cardioverter Defibrillator

DVBC3D4 Evera S

US Market Release Date	04/03/2013
CE Market Approval Date	12/17/2012
Registered US Implants	2,758
Estimated Active US Implants	2,686
Normal Battery Depletions (US)	0

NBG Code	VVE-VVIR
Max Delivered Energy	36 J

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

BLACKWELL, VR, Survival Curve



Years	1	at 20 mo
Excluding NBD	100.0%	100.0%
Including NBD	100.0%	100.0%
Effective Sample Size	7955	223

Implantable Pulse Generator

A2DR01 Advisa DR MRI

US Market Release Date	01/15/2013
CE Market Approval Date	
Registered US Implants	70,202
Estimated Active US Implants	68,669
Normal Battery Depletions (US)	1

NBG Code	OAE-DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	4
Therapy Not Compromised Malfunctions	3
Battery Malfunction	0
Electrical Component	2
Electrical Interconnect	1
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

A2DR01, A3DR01, A5DR01, EN1DR01, Survival Curve



Years	1	2	3	4	at 58 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	100.0%	99.9%	99.9%
Effective Sample Size	40851	12039	6804	2770	161

Implantable Pulse Generator

A3DR01 Advisa DR MRI

US Market Release Date	
CE Market Approval Date	06/02/2009
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	OAE-DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

A2DR01, A3DR01, A5DR01, EN1DR01, Survival Curve



Years	1	2	3	4	at 58 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	100.0%	99.9%	99.9%
Effective Sample Size	40851	12039	6804	2770	161

Implantable Pulse Generator

A4DR01 Advisa DR

US Market Release Date	04/04/2011
CE Market Approval Date	
Registered US Implants	1,536
Estimated Active US Implants	1,433
Normal Battery Depletions (US)	0

NBG Code	OAE-DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

A2DR01, A3DR01, A5DR01, EN1DR01, Survival Curve



Years	1	2	3	4	at 58 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	100.0%	99.9%	99.9%
Effective Sample Size	40851	12039	6804	2770	161

Implantable Pulse Generator

A5DR01 Advisa DR

US Market Release Date	
CE Market Approval Date	06/02/2009
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	OAE-DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

A2DR01, A3DR01, A5DR01, EN1DR01, Survival Curve



Years	1	2	3	4	at 58 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	100.0%	99.9%	99.9%
Effective Sample Size	40851	12039	6804	2770	161

Implantable Pulse Generator

ADD01 Adapta D

US Market Release Date	07/17/2006
CE Market Approval Date	09/20/2005
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDD
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

ADDR01, ADDR03, ADDR06, ADD01, Survival Curve



Years	1	2	3	4	5	6	7	8	at 100 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	99.9%	99.9%	99.8%	99.5%	98.9%	97.0%	86.6%	77.1%
Effective Sample Size	368649	312517	254679	199788	143527	91801	46278	8301	494

Implantable Pulse Generator

ADDR01 Adapta DR

US Market Release Date	07/17/2006
CE Market Approval Date	09/20/2005
Registered US Implants	404,873
Estimated Active US Implants	320,831
Normal Battery Depletions (US)	2,704

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	68
Therapy Not Compromised Malfunctions	45
Battery Malfunction	0
Electrical Component	43
Electrical Interconnect	1
Other Malfunction	1
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	23
Battery Malfunction	0
Electrical Component	19
Electrical Interconnect	2
Other Malfunction	2
Poss Early Battery Depltn	0
Software Malfunction	0

ADDR01, ADDR03, ADDR06, ADD01, Survival Curve



Years	1	2	3	4	5	6	7	8	at 100 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	99.9%	99.9%	99.8%	99.5%	98.9%	97.0%	86.6%	77.1%
Effective Sample Size	368649	312517	254679	199788	143527	91801	46278	8301	494

Implantable Pulse Generator

ADDR03 Adapta DR

US Market Release Date	07/17/2006
CE Market Approval Date	09/20/2005
Registered US Implants	3,737
Estimated Active US Implants	2,761
Normal Battery Depletions (US)	59

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	2
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

ADDR01, ADDR03, ADDR06, ADD01, Survival Curve



Years	1	2	3	4	5	6	7	8	at 100 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	99.9%	99.9%	99.8%	99.5%	98.9%	97.0%	86.6%	77.1%
Effective Sample Size	368649	312517	254679	199788	143527	91801	46278	8301	494

Implantable Pulse Generator

ADDR06 Adapta DR

US Market Release Date	07/17/2006
CE Market Approval Date	09/20/2005
Registered US Implants	2,911
Estimated Active US Implants	1,842
Normal Battery Depletions (US)	94

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

ADDR01, ADDR03, ADDR06, ADD01, Survival Curve



Years	1	2	3	4	5	6	7	8	at 100 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	99.9%	99.9%	99.8%	99.5%	98.9%	97.0%	86.6%	77.1%
Effective Sample Size	368649	312517	254679	199788	143527	91801	46278	8301	494

Implantable Pulse Generator

ADDRL1 Adapta DR

US Market Release Date	07/17/2006
CE Market Approval Date	09/20/2005
Registered US Implants	106,991
Estimated Active US Implants	94,428
Normal Battery Depletions (US)	113

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	11
Therapy Not Compromised Malfunctions	7
Battery Malfunction	0
Electrical Component	6
Electrical Interconnect	1
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	4
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	1
Other Malfunction	2
Poss Early Battery Depltn	0
Software Malfunction	0

ADDRL1, Survival Curve



Years	1	2	3	4	5	6	7	8	at 99 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	99.9%	99.8%	99.7%	99.3%	98.9%	97.7%	97.7%
Effective Sample Size	91147	71048	51522	35237	21396	10944	4307	607	180

Implantable Pulse Generator

ADDRS1 Adapta DR

US Market Release Date	07/17/2006
CE Market Approval Date	09/20/2005
Registered US Implants	41,421
Estimated Active US Implants	28,715
Normal Battery Depletions (US)	1,705

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	10
Therapy Not Compromised Malfunctions	6
Battery Malfunction	0
Electrical Component	5
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	1
Software Malfunction	0
Therapy Compromised Malfunctions	4
Battery Malfunction	0
Electrical Component	2
Electrical Interconnect	0
Other Malfunction	2
Poss Early Battery Depltn	0
Software Malfunction	0

ADDRS1, Survival Curve



Years	1	2	3	4	5	6	7	at 90 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.9%	99.7%	99.5%	98.8%	96.5%	83.2%	50.6%	19.1%
Effective Sample Size	35370	28688	22416	16720	11179	5692	1224	107

Implantable Pulse Generator

ADSR01 Adapta SR

US Market Release Date	07/17/2006
CE Market Approval Date	09/20/2005
Registered US Implants	78,252
Estimated Active US Implants	54,282
Normal Battery Depletions (US)	707

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	11
Therapy Not Compromised Malfunctions	6
Battery Malfunction	0
Electrical Component	4
Electrical Interconnect	1
Other Malfunction	0
Poss Early Battery Depltn	1
Software Malfunction	0
Therapy Compromised Malfunctions	5
Battery Malfunction	0
Electrical Component	4
Electrical Interconnect	1
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

ADSR01, ADSR03, ADSR06, Survival Curve



Years	1	2	3	4	5	6	7	8	at 98 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%
Including NBD	100.0%	99.9%	99.8%	99.4%	98.8%	97.4%	92.8%	78.2%	67.7%
Effective Sample Size	71746	56696	43313	31904	22407	14042	6673	859	251

Implantable Pulse Generator

ADSR03 Adapta SR

US Market Release Date	07/17/2006
CE Market Approval Date	09/20/2005
Registered US Implants	1,808
Estimated Active US Implants	1,149
Normal Battery Depletions (US)	17

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

ADSR01, ADSR03, ADSR06, Survival Curve



Years	1	2	3	4	5	6	7	8	at 98 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%
Including NBD	100.0%	99.9%	99.8%	99.4%	98.8%	97.4%	92.8%	78.2%	67.7%
Effective Sample Size	71746	56696	43313	31904	22407	14042	6673	859	251

Implantable Pulse Generator

ADSR06 Adapta SR

US Market Release Date	07/17/2006
CE Market Approval Date	09/20/2005
Registered US Implants	2,469
Estimated Active US Implants	1,416
Normal Battery Depletions (US)	69

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	2
Therapy Not Compromised Malfunctions	2
Battery Malfunction	0
Electrical Component	2
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

ADSR01, ADSR03, ADSR06, Survival Curve



Years	1	2	3	4	5	6	7	8	at 98 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%
Including NBD	100.0%	99.9%	99.8%	99.4%	98.8%	97.4%	92.8%	78.2%	67.7%
Effective Sample Size	71746	56696	43313	31904	22407	14042	6673	859	251

Implantable Pulse Generator

ADVDD01 Adapta VDD

US Market Release Date	07/17/2006
CE Market Approval Date	09/20/2005
Registered US Implants	1,014
Estimated Active US Implants	657
Normal Battery Depletions (US)	31

NBG Code	VDD
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

ADVDD01, Survival Curve



Years	1	2	3	4	5	6	at 84 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	100.0%	100.0%	100.0%	96.9%	76.8%
Effective Sample Size	1403	1172	951	776	598	383	110

Implantable Pulse Generator

E1DR01 EnPulse DR

US Market Release Date	12/18/2003
CE Market Approval Date	
Registered US Implants	6,846
Estimated Active US Implants	739
Normal Battery Depletions (US)	1,688

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

E1DR01, E1DR03, E1DR06, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 124 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.7%	99.6%	99.2%	98.4%	97.4%	96.1%	87.5%	65.1%	34.2%	10.8%	6.3%
Effective Sample Size	6213	5761	5313	4845	4415	3985	3316	2224	1025	251	120

Implantable Pulse Generator

E1DR03 EnPulse DR

US Market Release Date	12/18/2003
CE Market Approval Date	
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

E1DR01, E1DR03, E1DR06, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 124 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.7%	99.6%	99.2%	98.4%	97.4%	96.1%	87.5%	65.1%	34.2%	10.8%	6.3%
Effective Sample Size	6213	5761	5313	4845	4415	3985	3316	2224	1025	251	120

Implantable Pulse Generator

E1DR06 EnPulse DR

US Market Release Date	12/18/2003
CE Market Approval Date	
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0
NBG Code	DDDR
Max Delivered Energy	

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

E1DR01, E1DR03, E1DR06, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 124 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.7%	99.6%	99.2%	98.4%	97.4%	96.1%	87.5%	65.1%	34.2%	10.8%	6.3%
Effective Sample Size	6213	5761	5313	4845	4415	3985	3316	2224	1025	251	120

Implantable Pulse Generator

E1DR21 EnPulse DR

US Market Release Date	12/18/2003
CE Market Approval Date	
Registered US Implants	1,856
Estimated Active US Implants	140
Normal Battery Depletions (US)	378

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

E1DR21, Survival Curve



Years	1	2	3	4	5	6	at 80 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.2%	98.8%	97.5%	95.3%	87.5%	52.1%	16.9%
Effective Sample Size	1628	1476	1317	1155	945	449	117

Implantable Pulse Generator

E2D01 EnPulse 2

US Market Release Date	02/20/2004
CE Market Approval Date	09/08/2003
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0
NBG Code	DDD
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

E2D01, E2D03, E2DR01, E2DR03, E2DR06, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 117 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.8%	99.7%	99.5%	99.1%	98.2%	96.7%	91.2%	73.6%	45.2%	15.9%
Effective Sample Size	94840	87664	80636	74009	67511	61334	54190	40500	14274	873

Implantable Pulse Generator

E2D03 EnPulse 2

US Market Release Date	02/20/2004
CE Market Approval Date	09/08/2003
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0
NBG Code	DDD
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

E2D01, E2D03, E2DR01, E2DR03, E2DR06, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 117 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.8%	99.7%	99.5%	99.1%	98.2%	96.7%	91.2%	73.6%	45.2%	15.9%
Effective Sample Size	94840	87664	80636	74009	67511	61334	54190	40500	14274	873

Implantable Pulse Generator

E2DR01 EnPulse 2 DR

US Market Release Date	02/20/2004
CE Market Approval Date	09/08/2003
Registered US Implants	97,093
Estimated Active US Implants	22,819
Normal Battery Depletions (US)	17,162

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	27
Therapy Not Compromised Malfunctions	20
Battery Malfunction	0
Electrical Component	18
Electrical Interconnect	0
Other Malfunction	1
Poss Early Battery Depltn	1
Software Malfunction	0
Therapy Compromised Malfunctions	7
Battery Malfunction	1
Electrical Component	3
Electrical Interconnect	3
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

E2D01, E2D03, E2DR01, E2DR03, E2DR06, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 117 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.8%	99.7%	99.5%	99.1%	98.2%	96.7%	91.2%	73.6%	45.2%	15.9%
Effective Sample Size	94840	87664	80636	74009	67511	61334	54190	40500	14274	873

Implantable Pulse Generator

E2DR03 EnPulse 2 DR

US Market Release Date	02/20/2004
CE Market Approval Date	09/08/2003
Registered US Implants	2,050
Estimated Active US Implants	500
Normal Battery Depletions (US)	359

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

E2D01, E2D03, E2DR01, E2DR03, E2DR06, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 117 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.8%	99.7%	99.5%	99.1%	98.2%	96.7%	91.2%	73.6%	45.2%	15.9%
Effective Sample Size	94840	87664	80636	74009	67511	61334	54190	40500	14274	873

Implantable Pulse Generator

E2DR06 EnPulse 2 DR

US Market Release Date	02/20/2004
CE Market Approval Date	09/08/2003
Registered US Implants	1,626
Estimated Active US Implants	292
Normal Battery Depletions (US)	267

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	2
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	1
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	1
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

E2D01, E2D03, E2DR01, E2DR03, E2DR06, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 117 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.8%	99.7%	99.5%	99.1%	98.2%	96.7%	91.2%	73.6%	45.2%	15.9%
Effective Sample Size	94840	87664	80636	74009	67511	61334	54190	40500	14274	873

Implantable Pulse Generator

E2DR21 EnPulse 2 DR

US Market Release Date	02/20/2004
CE Market Approval Date	09/08/2003
Registered US Implants	12,199
Estimated Active US Implants	1,544
Normal Battery Depletions (US)	2,288

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

E2DR21, Survival Curve



Years	1	2	3	4	5	6	7	at 95 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.4%	98.8%	97.9%	95.4%	88.3%	62.9%	25.3%	4.2%
Effective Sample Size	10835	9715	8725	7611	6295	3860	1187	111

Implantable Pulse Generator

E2DR31 EnPulse 2 DR

US Market Release Date	02/20/2004
CE Market Approval Date	09/08/2003
Registered US Implants	587
Estimated Active US Implants	343
Normal Battery Depletions (US)	31

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

E2DR31, E2DR33, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 115 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	100.0%	100.0%	100.0%	99.6%	98.7%	97.4%	95.7%	89.3%
Effective Sample Size	1354	1276	1203	1129	1059	994	897	816	416	119

Implantable Pulse Generator

E2DR33 EnPulse 2 DR

US Market Release Date	02/20/2004
CE Market Approval Date	09/08/2003
Registered US Implants	5
Estimated Active US Implants	5
Normal Battery Depletions (US)	1

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

E2DR31, E2DR33, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 115 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	100.0%	100.0%	100.0%	99.6%	98.7%	97.4%	95.7%	89.3%
Effective Sample Size	1354	1276	1203	1129	1059	994	897	816	416	119

Implantable Pulse Generator

E2SR01 EnPulse 2 SR

US Market Release Date	12/18/2003
CE Market Approval Date	09/08/2003
Registered US Implants	22,528
Estimated Active US Implants	3,557
Normal Battery Depletions (US)	2,638

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	4
Therapy Not Compromised Malfunctions	3
Battery Malfunction	0
Electrical Component	2
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	1
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	1
Poss Early Battery Depltn	0
Software Malfunction	0

E2SR01, E2SR03, E2SR06, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 113 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.7%	99.5%	99.0%	98.1%	96.5%	93.0%	82.8%	60.1%	37.9%	26.4%
Effective Sample Size	22600	19616	17124	14986	12871	11059	8978	5680	1332	200

Implantable Pulse Generator

E2SR03 EnPulse 2 SR

US Market Release Date	12/18/2003
CE Market Approval Date	09/08/2003
Registered US Implants	1,098
Estimated Active US Implants	185
Normal Battery Depletions (US)	130

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

E2SR01, E2SR03, E2SR06, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 113 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.7%	99.5%	99.0%	98.1%	96.5%	93.0%	82.8%	60.1%	37.9%	26.4%
Effective Sample Size	22600	19616	17124	14986	12871	11059	8978	5680	1332	200

Implantable Pulse Generator

E2SR06 EnPulse 2 SR

US Market Release Date	12/18/2003
CE Market Approval Date	09/08/2003
Registered US Implants	1,749
Estimated Active US Implants	263
Normal Battery Depletions (US)	187

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

E2SR01, E2SR03, E2SR06, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 113 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.7%	99.5%	99.0%	98.1%	96.5%	93.0%	82.8%	60.1%	37.9%	26.4%
Effective Sample Size	22600	19616	17124	14986	12871	11059	8978	5680	1332	200

Implantable Pulse Generator

E2VDD01 EnPulse 2 VDD

US Market Release Date	12/18/2003
CE Market Approval Date	09/08/2003
Registered US Implants	555
Estimated Active US Implants	89
Normal Battery Depletions (US)	93

NBG Code	VDD
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

E2VDD01, Survival Curve



Years	1	2	3	4	5	6	7	at 90 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.5%	99.5%	99.5%	99.3%	98.3%	86.5%	52.9%	35.9%
Effective Sample Size	705	649	595	543	489	406	189	113

Implantable Pulse Generator

EMDR01 EnRhythm MRI

US Market Release Date	
CE Market Approval Date	09/30/2008
Registered US Implants	111
Estimated Active US Implants	57
Normal Battery Depletions (US)	3

NBG Code	DDDRP
Max Delivered Energy	N/A

Total Malfunctions (US)	17
Therapy Not Compromised Malfunctions	17
Battery Malfunction	17
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

EMDR01, EMDR02, Survival Curve



Years	1	2	3	4	at 49 mo
Excluding NBD	100.0%	100.0%	100.0%	98.6%	97.9%
Including NBD	100.0%	100.0%	100.0%	96.4%	95.5%
Effective Sample Size	146	133	119	103	102

Implantable Pulse Generator

EN1DR01 Ensura MRI

US Market Release Date	
CE Market Approval Date	06/23/2010
Registered US Implants	4
Estimated Active US Implants	4
Normal Battery Depletions (US)	0

NBG Code	OOE-DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

A2DR01, A3DR01, A5DR01, EN1DR01, Survival Curve



Years	1	2	3	4	at 58 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	100.0%	99.9%	99.9%
Effective Sample Size	40851	12039	6804	2770	161

Implantable Pulse Generator

KD700 Kappa 700 DR

US Market Release Date	
CE Market Approval Date	
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDD
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KD700, KDR700, KDR701, KDR703, KDR706, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 117 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.7%	99.6%	99.4%	99.4%
Including NBD	99.5%	99.4%	99.0%	98.2%	96.6%	93.0%	82.0%	55.8%	24.3%	2.7%
Effective Sample Size	180087	165060	150467	135831	121507	105911	83632	48446	14852	1091

Implantable Pulse Generator

KD701 Kappa 700 DR

US Market Release Date	01/29/1999
CE Market Approval Date	03/20/1998
Registered US Implants	242
Estimated Active US Implants	47
Normal Battery Depletions (US)	21
NBG Code	DDD
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KD701, KD703, KD706, Survival Curve



Years	1	2	3	4	5	6	7	at 95 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	100.0%	99.0%	98.0%	96.2%	94.9%	89.6%
Effective Sample Size	289	260	229	206	186	162	137	100

Implantable Pulse Generator

KD703 Kappa 700 DR

US Market Release Date	01/29/1999
CE Market Approval Date	03/20/1998
Registered US Implants	1
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDD
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KD701, KD703, KD706, Survival Curve



Years	1	2	3	4	5	6	7	at 95 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	100.0%	99.0%	98.0%	96.2%	94.9%	89.6%
Effective Sample Size	289	260	229	206	186	162	137	100

Implantable Pulse Generator

KD706 Kappa 700 DR

US Market Release Date	01/29/1999
CE Market Approval Date	03/20/1998
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDD
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KD701, KD703, KD706, Survival Curve



Years	1	2	3	4	5	6	7	at 95 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	100.0%	99.0%	98.0%	96.2%	94.9%	89.6%
Effective Sample Size	289	260	229	206	186	162	137	100

Implantable Pulse Generator

KD901 Kappa 900 D

US Market Release Date	01/09/2002
CE Market Approval Date	09/28/2001
Registered US Implants	1
Estimated Active US Implants	0
Normal Battery Depletions (US)	0
NBG Code	DDD
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KD901, KD903, KD906, KDR901, KDR903, KDR906, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 126 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.9%
Including NBD	99.6%	99.5%	99.2%	98.7%	97.7%	95.5%	87.2%	63.7%	34.2%	13.1%	0.9%
Effective Sample Size	117160	107791	98688	89956	81409	72845	61181	40024	15870	3015	175

Implantable Pulse Generator

KD903 Kappa 900 D

US Market Release Date	01/09/2002
CE Market Approval Date	
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0
NBG Code	DDD
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KD901, KD903, KD906, KDR901, KDR903, KDR906, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 126 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.9%
Including NBD	99.6%	99.5%	99.2%	98.7%	97.7%	95.5%	87.2%	63.7%	34.2%	13.1%	0.9%
Effective Sample Size	117160	107791	98688	89956	81409	72845	61181	40024	15870	3015	175

Implantable Pulse Generator

KD906 Kappa 900 D

US Market Release Date	01/09/2002
CE Market Approval Date	09/28/2001
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0
NBG Code	DDD
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KD901, KD903, KD906, KDR901, KDR903, KDR906, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 126 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.9%
Including NBD	99.6%	99.5%	99.2%	98.7%	97.7%	95.5%	87.2%	63.7%	34.2%	13.1%	0.9%
Effective Sample Size	117160	107791	98688	89956	81409	72845	61181	40024	15870	3015	175

Implantable Pulse Generator

KDR401 Kappa 400 DR

US Market Release Date	01/30/1998
CE Market Approval Date	11/12/1996
Registered US Implants	39,406
Estimated Active US Implants	2,787
Normal Battery Depletions (US)	7,178

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	22
Therapy Not Compromised Malfunctions	13
Battery Malfunction	0
Electrical Component	9
Electrical Interconnect	1
Other Malfunction	2
Poss Early Battery Depltn	1
Software Malfunction	0
Therapy Compromised Malfunctions	9
Battery Malfunction	0
Electrical Component	6
Electrical Interconnect	3
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KDR401, KDR403, Survival Curve



Years	1	2	3	4	5	6	7	8	at 105 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.9%
Including NBD	99.7%	99.6%	99.3%	98.9%	97.7%	94.3%	80.0%	42.5%	5.5%
Effective Sample Size	44187	41058	37881	34829	31405	27423	20490	8453	888

Implantable Pulse Generator

KDR403 Kappa 400 DR

US Market Release Date	01/30/1998
CE Market Approval Date	11/12/1996
Registered US Implants	7,311
Estimated Active US Implants	827
Normal Battery Depletions (US)	1,114

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	6
Therapy Not Compromised Malfunctions	2
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	1
Software Malfunction	0
Therapy Compromised Malfunctions	4
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	3
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KDR401, KDR403, Survival Curve



Years	1	2	3	4	5	6	7	8	at 105 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.9%
Including NBD	99.7%	99.6%	99.3%	98.9%	97.7%	94.3%	80.0%	42.5%	5.5%
Effective Sample Size	44187	41058	37881	34829	31405	27423	20490	8453	888

Implantable Pulse Generator

KDR700 Kappa 700 DR

US Market Release Date	
CE Market Approval Date	
Registered US Implants	15
Estimated Active US Implants	1
Normal Battery Depletions (US)	4

NBG Code	DDD/RO
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KD700, KDR700, KDR701, KDR703, KDR706, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 117 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.7%	99.6%	99.4%	99.4%
Including NBD	99.5%	99.4%	99.0%	98.2%	96.6%	93.0%	82.0%	55.8%	24.3%	2.7%
Effective Sample Size	180087	165060	150467	135831	121507	105911	83632	48446	14852	1091

Implantable Pulse Generator

KDR701 Kappa 700 DR

US Market Release Date	01/29/1999
CE Market Approval Date	03/20/1998
Registered US Implants	194,144
Estimated Active US Implants	17,293
Normal Battery Depletions (US)	36,299

NBG Code	DDD/RO
Max Delivered Energy	N/A

Total Malfunctions (US)	702
Therapy Not Compromised Malfunctions	48
Battery Malfunction	1
Electrical Component	23
Electrical Interconnect	18
Other Malfunction	3
Poss Early Battery Depltn	3
Software Malfunction	0
Therapy Compromised Malfunctions	654
Battery Malfunction	0
Electrical Component	16
Electrical Interconnect	637
Other Malfunction	0
Poss Early Battery Depltn	1
Software Malfunction	0

KD700, KDR700, KDR701, KDR703, KDR706, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 117 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.7%	99.6%	99.4%	99.4%
Including NBD	99.5%	99.4%	99.0%	98.2%	96.6%	93.0%	82.0%	55.8%	24.3%	2.7%
Effective Sample Size	180087	165060	150467	135831	121507	105911	83632	48446	14852	1091

Implantable Pulse Generator

KDR703 Kappa 700 DR

US Market Release Date	02/05/1999
CE Market Approval Date	03/20/1998
Registered US Implants	9,226
Estimated Active US Implants	774
Normal Battery Depletions (US)	1,531

NBG Code	DDD/RO
Max Delivered Energy	N/A

Total Malfunctions (US)	34
Therapy Not Compromised Malfunctions	4
Battery Malfunction	0
Electrical Component	3
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	1
Software Malfunction	0
Therapy Compromised Malfunctions	30
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	29
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KD700, KDR700, KDR701, KDR703, KDR706, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 117 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.7%	99.6%	99.4%	99.4%
Including NBD	99.5%	99.4%	99.0%	98.2%	96.6%	93.0%	82.0%	55.8%	24.3%	2.7%
Effective Sample Size	180087	165060	150467	135831	121507	105911	83632	48446	14852	1091

Implantable Pulse Generator

KDR706 Kappa 700 DR

US Market Release Date	02/09/1999
CE Market Approval Date	03/20/1998
Registered US Implants	2,633
Estimated Active US Implants	176
Normal Battery Depletions (US)	402

NBG Code	DDD/RO
Max Delivered Energy	N/A

Total Malfunctions (US)	10
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	1
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	9
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	9
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KD700, KDR700, KDR701, KDR703, KDR706, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 117 mo
Excluding NBD	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.7%	99.6%	99.4%	99.4%
Including NBD	99.5%	99.4%	99.0%	98.2%	96.6%	93.0%	82.0%	55.8%	24.3%	2.7%
Effective Sample Size	180087	165060	150467	135831	121507	105911	83632	48446	14852	1091

Implantable Pulse Generator

KDR721 Kappa 700 DR

US Market Release Date	02/11/1999
CE Market Approval Date	03/20/1998
Registered US Implants	9,838
Estimated Active US Implants	721
Normal Battery Depletions (US)	1,361

NBG Code	DDD/RO
Max Delivered Energy	N/A

Total Malfunctions (US)	5
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	4
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	4
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KDR721, Survival Curve



Years	1	2	3	4	5	6	at 81 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%
Including NBD	99.8%	99.4%	98.1%	94.7%	84.4%	48.7%	4.8%
Effective Sample Size	8623	7613	6639	5600	4305	1785	171

Implantable Pulse Generator

KDR901 Kappa 900 DR

US Market Release Date	01/09/2002
CE Market Approval Date	09/28/2001
Registered US Implants	120,696
Estimated Active US Implants	15,339
Normal Battery Depletions (US)	25,607

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	70
Therapy Not Compromised Malfunctions	21
Battery Malfunction	0
Electrical Component	16
Electrical Interconnect	4
Other Malfunction	1
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	49
Battery Malfunction	0
Electrical Component	10
Electrical Interconnect	39
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KD901, KD903, KD906, KDR901, KDR903, KDR906, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 126 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.9%
Including NBD	99.6%	99.5%	99.2%	98.7%	97.7%	95.5%	87.2%	63.7%	34.2%	13.1%	0.9%
Effective Sample Size	117160	107791	98688	89956	81409	72845	61181	40024	15870	3015	175

Implantable Pulse Generator

KDR903 Kappa 900 DR

US Market Release Date	01/09/2002
CE Market Approval Date	09/28/2001
Registered US Implants	3,169
Estimated Active US Implants	326
Normal Battery Depletions (US)	612

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	3
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	3
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	3
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KD901, KD903, KD906, KDR901, KDR903, KDR906, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 126 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.9%
Including NBD	99.6%	99.5%	99.2%	98.7%	97.7%	95.5%	87.2%	63.7%	34.2%	13.1%	0.9%
Effective Sample Size	117160	107791	98688	89956	81409	72845	61181	40024	15870	3015	175

Implantable Pulse Generator

KDR906 Kappa 900 DR

US Market Release Date	01/09/2002
CE Market Approval Date	09/28/2001
Registered US Implants	1,509
Estimated Active US Implants	116
Normal Battery Depletions (US)	298

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	2
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	2
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	2
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KD901, KD903, KD906, KDR901, KDR903, KDR906, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 126 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.9%
Including NBD	99.6%	99.5%	99.2%	98.7%	97.7%	95.5%	87.2%	63.7%	34.2%	13.1%	0.9%
Effective Sample Size	117160	107791	98688	89956	81409	72845	61181	40024	15870	3015	175

Implantable Pulse Generator

KDR921 Kappa 900 DR

US Market Release Date	01/09/2002
CE Market Approval Date	09/28/2001
Registered US Implants	16,329
Estimated Active US Implants	1,319
Normal Battery Depletions (US)	2,886

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	4
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	3
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	3
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KDR921, Survival Curve



Years	1	2	3	4	5	6	at 84 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.3%	98.6%	97.7%	94.7%	85.8%	51.0%	4.3%
Effective Sample Size	14184	12614	11138	9597	7629	3534	235

Implantable Pulse Generator

KSR401 Kappa 400 SR

US Market Release Date	02/18/1998
CE Market Approval Date	11/12/1996
Registered US Implants	11,788
Estimated Active US Implants	866
Normal Battery Depletions (US)	1,278

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	4
Therapy Not Compromised Malfunctions	4
Battery Malfunction	0
Electrical Component	3
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	1
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KSR401, KSR403, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 111 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.6%	99.3%	98.9%	98.0%	97.1%	94.0%	83.2%	52.4%	14.9%	6.9%
Effective Sample Size	13589	11932	10430	9156	7902	6630	5025	2448	393	147

Implantable Pulse Generator

KSR403 Kappa 400 SR

US Market Release Date	02/24/1998
CE Market Approval Date	11/12/1996
Registered US Implants	3,620
Estimated Active US Implants	407
Normal Battery Depletions (US)	376

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	1
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KSR401, KSR403, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 111 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.6%	99.3%	98.9%	98.0%	97.1%	94.0%	83.2%	52.4%	14.9%	6.9%
Effective Sample Size	13589	11932	10430	9156	7902	6630	5025	2448	393	147

Implantable Pulse Generator

KSR700 Kappa 700 SR

US Market Release Date	
CE Market Approval Date	
Registered US Implants	1
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KSR700, KSR701, KSR703, KSR706, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	11	at 134 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.8%	99.8%	99.8%	99.8%
Including NBD	99.6%	99.2%	98.6%	97.2%	94.6%	89.9%	78.6%	54.9%	28.8%	18.3%	15.1%	13.9%
Effective Sample Size	48205	41529	35578	30377	25558	21008	15803	9014	3097	1041	245	135

Implantable Pulse Generator

KSR701 Kappa 700 SR

US Market Release Date	01/29/1999
CE Market Approval Date	03/20/1998
Registered US Implants	48,466
Estimated Active US Implants	4,309
Normal Battery Depletions (US)	5,041

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	22
Therapy Not Compromised Malfunctions	3
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	1
Other Malfunction	0
Poss Early Battery Depltn	1
Software Malfunction	0
Therapy Compromised Malfunctions	19
Battery Malfunction	0
Electrical Component	2
Electrical Interconnect	17
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KSR700, KSR701, KSR703, KSR706, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	11	at 134 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.8%	99.8%	99.8%	99.8%
Including NBD	99.6%	99.2%	98.6%	97.2%	94.6%	89.9%	78.6%	54.9%	28.8%	18.3%	15.1%	13.9%
Effective Sample Size	48205	41529	35578	30377	25558	21008	15803	9014	3097	1041	245	135

Implantable Pulse Generator

KSR703 Kappa 700 SR

US Market Release Date	02/08/1999
CE Market Approval Date	03/20/1998
Registered US Implants	3,607
Estimated Active US Implants	284
Normal Battery Depletions (US)	395

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	4
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	4
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	3
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KSR700, KSR701, KSR703, KSR706, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	11	at 134 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.8%	99.8%	99.8%	99.8%
Including NBD	99.6%	99.2%	98.6%	97.2%	94.6%	89.9%	78.6%	54.9%	28.8%	18.3%	15.1%	13.9%
Effective Sample Size	48205	41529	35578	30377	25558	21008	15803	9014	3097	1041	245	135

Implantable Pulse Generator

KSR706 Kappa 700 SR

US Market Release Date	02/09/1999
CE Market Approval Date	03/20/1998
Registered US Implants	2,920
Estimated Active US Implants	234
Normal Battery Depletions (US)	299

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	2
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KSR700, KSR701, KSR703, KSR706, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	11	at 134 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.8%	99.8%	99.8%	99.8%
Including NBD	99.6%	99.2%	98.6%	97.2%	94.6%	89.9%	78.6%	54.9%	28.8%	18.3%	15.1%	13.9%
Effective Sample Size	48205	41529	35578	30377	25558	21008	15803	9014	3097	1041	245	135

Implantable Pulse Generator

KSR901 Kappa 900 SR

US Market Release Date	01/09/2002
CE Market Approval Date	09/28/2001
Registered US Implants	34,134
Estimated Active US Implants	3,984
Normal Battery Depletions (US)	3,988

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	15
Therapy Not Compromised Malfunctions	7
Battery Malfunction	0
Electrical Component	6
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	1
Software Malfunction	0
Therapy Compromised Malfunctions	8
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	8
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KSR901, KSR903, KSR906, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 129 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.9%	99.9%
Including NBD	99.5%	99.1%	98.8%	97.7%	96.2%	93.1%	83.3%	59.6%	36.6%	26.9%	23.9%
Effective Sample Size	31945	27507	23902	20586	17669	14997	11832	7300	2856	890	203

Implantable Pulse Generator

KSR903 Kappa 900 SR

US Market Release Date	01/09/2002
CE Market Approval Date	09/28/2001
Registered US Implants	1,372
Estimated Active US Implants	128
Normal Battery Depletions (US)	164

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KSR901, KSR903, KSR906, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 129 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.9%	99.9%
Including NBD	99.5%	99.1%	98.8%	97.7%	96.2%	93.1%	83.3%	59.6%	36.6%	26.9%	23.9%
Effective Sample Size	31945	27507	23902	20586	17669	14997	11832	7300	2856	890	203

Implantable Pulse Generator

KSR906 Kappa 900 SR

US Market Release Date	01/09/2002
CE Market Approval Date	09/28/2001
Registered US Implants	1,322
Estimated Active US Implants	125
Normal Battery Depletions (US)	179

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	1
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KSR901, KSR903, KSR906, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 129 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%	99.9%	99.9%	99.9%
Including NBD	99.5%	99.1%	98.8%	97.7%	96.2%	93.1%	83.3%	59.6%	36.6%	26.9%	23.9%
Effective Sample Size	31945	27507	23902	20586	17669	14997	11832	7300	2856	890	203

Implantable Pulse Generator

KVDD901 Kappa 900 VDD

US Market Release Date	01/09/2002
CE Market Approval Date	09/28/2001
Registered US Implants	566
Estimated Active US Implants	56
Normal Battery Depletions (US)	81

NBG Code	VDD
Max Delivered Energy	N/A

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	1
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

KVDD901, Survival Curve



Years	1	2	3	4	5	6	7	at 86 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	99.8%	99.8%	99.8%
Including NBD	100.0%	100.0%	100.0%	99.7%	98.8%	89.2%	41.8%	31.5%
Effective Sample Size	765	707	651	594	544	435	153	130

Implantable Pulse Generator

P1501DR EnRhythm DR

US Market Release Date	05/05/2005
CE Market Approval Date	08/13/2004
Registered US Implants	110,145
Estimated Active US Implants	48,385
Normal Battery Depletions (US)	5,088

NBG Code	DDDRP
Max Delivered Energy	N/A

Total Malfunctions (US)	12,000
Therapy Not Compromised Malfunctions	11,947
Battery Malfunction	11,833
Electrical Component	52
Electrical Interconnect	2
Other Malfunction	2
Poss Early Battery Depltn	58
Software Malfunction	0
Therapy Compromised Malfunctions	53
Battery Malfunction	5
Electrical Component	37
Electrical Interconnect	4
Other Malfunction	5
Poss Early Battery Depltn	2
Software Malfunction	0

P1501DR, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 111 mo
Excluding NBD	100.0%	99.9%	99.7%	98.3%	94.6%	88.1%	82.5%	78.5%	76.6%	76.5%
Including NBD	99.9%	99.8%	99.3%	97.4%	92.0%	81.7%	69.1%	55.6%	42.3%	34.5%
Effective Sample Size	104143	97728	91347	81128	63885	45134	29495	16173	3178	506

Implantable Pulse Generator

RED01 Relia D

US Market Release Date	
CE Market Approval Date	05/07/2008
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDD
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

REDR01, RED01, Survival Curve



Years	1	2	3	4	at 49 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	100.0%	100.0%	100.0%
Effective Sample Size	280	244	191	110	105

Implantable Pulse Generator

REDR01 Relia DR

US Market Release Date	
CE Market Approval Date	05/07/2008
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

REDR01, RED01, Survival Curve



Years	1	2	3	4	at 49 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	100.0%	100.0%	100.0%
Effective Sample Size	280	244	191	110	105

Implantable Pulse Generator

RES01 Relia S

US Market Release Date	
CE Market Approval Date	05/07/2008
Registered US Implants	2
Estimated Active US Implants	1
Normal Battery Depletions (US)	0

NBG Code	AAI/VVI
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

RESR01, RES01, Survival Curve



Years	1	2	3	at 48 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	100.0%	100.0%
Effective Sample Size	299	249	182	102

Implantable Pulse Generator

RESR01 Relia SR

US Market Release Date	
CE Market Approval Date	05/07/2008
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	AAIR/VVIR, AAI/VVI
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

RESR01, RES01, Survival Curve



Years	1	2	3	at 48 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	100.0%	100.0%
Effective Sample Size	299	249	182	102

Implantable Pulse Generator

REVDD01 Relia VDD

US Market Release Date	
CE Market Approval Date	05/07/2008
Registered US Implants	0
Estimated Active US Implants	0
Normal Battery Depletions (US)	0

NBG Code	VDD
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

REVDD01, Survival Curve



Years

Excluding NBD

Including NBD

Effective Sample Size

Implantable Pulse Generator

RVDR01 Revo MRI SureScan

US Market Release Date	02/08/2011
CE Market Approval Date	
Registered US Implants	64,411
Estimated Active US Implants	60,005
Normal Battery Depletions (US)	7

NBG Code	DDDRP
Max Delivered Energy	N/A

Total Malfunctions (US)	22
Therapy Not Compromised Malfunctions	19
Battery Malfunction	1
Electrical Component	13
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	4
Software Malfunction	1
Therapy Compromised Malfunctions	3
Battery Malfunction	0
Electrical Component	3
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

RVDR01, Survival Curve



Years	1	2	3	at 48 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	99.9%	99.9%
Effective Sample Size	59866	48475	22095	368

Implantable Pulse Generator

SD203 Sigma 200 D

US Market Release Date	08/31/1999
CE Market Approval Date	12/17/1998
Registered US Implants	225
Estimated Active US Implants	27
Normal Battery Depletions (US)	18
NBG Code	DDD
Max Delivered Energy	N/A

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	1
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SDR203, SD203, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	11	12	13	at 167 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.8%	99.6%	99.5%	99.5%	99.5%	99.3%	99.2%	99.2%
Including NBD	99.8%	99.7%	99.5%	99.3%	98.8%	98.0%	96.1%	93.2%	88.6%	81.3%	69.9%	56.0%	44.1%	34.4%
Effective Sample Size	14194	12721	11314	10128	8991	7953	6916	5993	5144	4175	2980	1730	821	102

Implantable Pulse Generator

SD303 Sigma 300 D

US Market Release Date	08/26/1999
CE Market Approval Date	12/17/1998
Registered US Implants	122
Estimated Active US Implants	30
Normal Battery Depletions (US)	6
NBG Code	DDD
Max Delivered Energy	N/A

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	1
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SDR303, SDR306, SD303, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	11	12	13	at 167 mo
Excluding NBD	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%	99.7%	99.6%	99.5%	99.4%	99.4%	99.3%	99.3%	99.3%
Including NBD	99.8%	99.8%	99.6%	99.3%	99.0%	98.3%	97.3%	95.0%	91.1%	84.6%	74.3%	60.3%	47.1%	29.1%
Effective Sample Size	96572	86490	77398	69020	61448	54755	48332	41257	33481	24956	16447	8493	3378	150

Implantable Pulse Generator

SDR203 Sigma 200 DR

US Market Release Date	08/31/1999
CE Market Approval Date	12/17/1998
Registered US Implants	15,644
Estimated Active US Implants	2,430
Normal Battery Depletions (US)	1,214

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	40
Therapy Not Compromised Malfunctions	10
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	9
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	30
Battery Malfunction	0
Electrical Component	2
Electrical Interconnect	27
Other Malfunction	1
Poss Early Battery Depltn	0
Software Malfunction	0

SDR203, SD203, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	11	12	13	at 167 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.8%	99.6%	99.5%	99.5%	99.5%	99.3%	99.2%	99.2%
Including NBD	99.8%	99.7%	99.5%	99.3%	98.8%	98.0%	96.1%	93.2%	88.6%	81.3%	69.9%	56.0%	44.1%	34.4%
Effective Sample Size	14194	12721	11314	10128	8991	7953	6916	5993	5144	4175	2980	1730	821	102

Implantable Pulse Generator

SDR303 Sigma 300 DR

US Market Release Date	08/26/1999
CE Market Approval Date	12/17/1998
Registered US Implants	105,574
Estimated Active US Implants	23,077
Normal Battery Depletions (US)	6,791

NBG Code	DDD/RO
Max Delivered Energy	N/A

Total Malfunctions (US)	277
Therapy Not Compromised Malfunctions	60
Battery Malfunction	0
Electrical Component	9
Electrical Interconnect	49
Other Malfunction	1
Poss Early Battery Depltn	1
Software Malfunction	0
Therapy Compromised Malfunctions	217
Battery Malfunction	0
Electrical Component	7
Electrical Interconnect	209
Other Malfunction	1
Poss Early Battery Depltn	0
Software Malfunction	0

SDR303, SDR306, SD303, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	11	12	13	at 167 mo
Excluding NBD	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%	99.7%	99.6%	99.5%	99.4%	99.4%	99.3%	99.3%	99.3%
Including NBD	99.8%	99.8%	99.6%	99.3%	99.0%	98.3%	97.3%	95.0%	91.1%	84.6%	74.3%	60.3%	47.1%	29.1%
Effective Sample Size	96572	86490	77398	69020	61448	54755	48332	41257	33481	24956	16447	8493	3378	150

Implantable Pulse Generator

SDR306 Sigma 300 DR

US Market Release Date	08/30/1999
CE Market Approval Date	12/17/1998
Registered US Implants	1,209
Estimated Active US Implants	149
Normal Battery Depletions (US)	144

NBG Code	DDD/RO
Max Delivered Energy	N/A

Total Malfunctions (US)	5
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	5
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	5
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SDR303, SDR306, SD303, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	11	12	13	at 167 mo
Excluding NBD	100.0%	100.0%	100.0%	99.9%	99.9%	99.9%	99.7%	99.6%	99.5%	99.4%	99.4%	99.3%	99.3%	99.3%
Including NBD	99.8%	99.8%	99.6%	99.3%	99.0%	98.3%	97.3%	95.0%	91.1%	84.6%	74.3%	60.3%	47.1%	29.1%
Effective Sample Size	96572	86490	77398	69020	61448	54755	48332	41257	33481	24956	16447	8493	3378	150

Implantable Pulse Generator

SED01 Sensia D

US Market Release Date	07/17/2006
CE Market Approval Date	09/20/2005
Registered US Implants	4
Estimated Active US Implants	3
Normal Battery Depletions (US)	0
NBG Code	DDD
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SEDR01, SED01, Survival Curve



Years	1	2	3	4	5	6	7	8	at 99 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	99.9%	99.9%	99.7%	99.4%	98.6%	96.0%	83.6%	76.8%
Effective Sample Size	122225	102461	82943	63783	45604	28024	12770	1828	280

Implantable Pulse Generator

SEDR01 Sensia DR

US Market Release Date	07/17/2006
CE Market Approval Date	09/20/2005
Registered US Implants	139,942
Estimated Active US Implants	100,149
Normal Battery Depletions (US)	1,151

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	26
Therapy Not Compromised Malfunctions	15
Battery Malfunction	0
Electrical Component	12
Electrical Interconnect	2
Other Malfunction	1
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	11
Battery Malfunction	0
Electrical Component	4
Electrical Interconnect	2
Other Malfunction	5
Poss Early Battery Depltn	0
Software Malfunction	0

SEDR01, SED01, Survival Curve



Years	1	2	3	4	5	6	7	8	at 99 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	99.9%	99.9%	99.7%	99.4%	98.6%	96.0%	83.6%	76.8%
Effective Sample Size	122225	102461	82943	63783	45604	28024	12770	1828	280

Implantable Pulse Generator

SEDRL1 Sensia DR

US Market Release Date	07/17/2006
CE Market Approval Date	09/20/2005
Registered US Implants	1
Estimated Active US Implants	1
Normal Battery Depletions (US)	0

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SEDRL1, Survival Curve



Years	1	2	3	4	5	6	7	at 89 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	99.8%	99.8%	99.8%	99.8%	99.8%	99.8%	99.8%
Effective Sample Size	3775	3208	2591	2007	1330	713	305	124

Implantable Pulse Generator

SES01 Sensia S

US Market Release Date	07/17/2006
CE Market Approval Date	09/20/2005
Registered US Implants	4
Estimated Active US Implants	0
Normal Battery Depletions (US)	0
NBG Code	SSI
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SESR01, SES01, Survival Curve



Years	1	2	3	4	5	6	7	8	at 98 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.9%	99.9%	99.8%	99.6%	99.2%	98.3%	95.2%	81.1%	75.2%
Effective Sample Size	86855	69252	52668	38157	25923	15053	6387	717	188

Implantable Pulse Generator

SESR01 Sensia SR

US Market Release Date	07/17/2006
CE Market Approval Date	09/20/2005
Registered US Implants	102,785
Estimated Active US Implants	69,355
Normal Battery Depletions (US)	710

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	10
Therapy Not Compromised Malfunctions	7
Battery Malfunction	0
Electrical Component	6
Electrical Interconnect	0
Other Malfunction	1
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	3
Battery Malfunction	0
Electrical Component	2
Electrical Interconnect	1
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SESR01, SES01, Survival Curve



Years	1	2	3	4	5	6	7	8	at 98 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	99.9%	99.9%	99.8%	99.6%	99.2%	98.3%	95.2%	81.1%	75.2%
Effective Sample Size	86855	69252	52668	38157	25923	15053	6387	717	188

Implantable Pulse Generator

SS103 Sigma 100 S

US Market Release Date	08/30/1999
CE Market Approval Date	12/17/1998
Registered US Implants	767
Estimated Active US Implants	92
Normal Battery Depletions (US)	27
NBG Code	SSI
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SS103, SS106, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 124 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	99.8%	99.8%	99.1%	99.1%	98.2%	96.7%	91.7%	82.3%	82.3%
Effective Sample Size	634	507	406	331	263	234	201	171	138	109	101

Implantable Pulse Generator

SS106 Sigma 100 S

US Market Release Date	08/30/1999
CE Market Approval Date	12/17/1998
Registered US Implants	68
Estimated Active US Implants	4
Normal Battery Depletions (US)	7

NBG Code	SSI
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SS103, SS106, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 124 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	100.0%	99.8%	99.8%	99.1%	99.1%	98.2%	96.7%	91.7%	82.3%	82.3%
Effective Sample Size	634	507	406	331	263	234	201	171	138	109	101

Implantable Pulse Generator

SS203 Sigma 200 S

US Market Release Date	08/30/1999
CE Market Approval Date	
Registered US Implants	4
Estimated Active US Implants	1
Normal Battery Depletions (US)	0

NBG Code	SSI
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SSR203, SS203, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	11	12	13	14	at 171 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.8%	99.7%	99.6%	99.6%	99.6%	99.6%	99.6%	99.6%	99.6%
Including NBD	99.7%	99.5%	99.3%	99.1%	98.5%	97.5%	96.1%	93.8%	88.9%	81.6%	70.6%	61.6%	55.7%	52.2%	51.5%
Effective Sample Size	10339	8716	7406	6354	5454	4722	4045	3562	3052	2493	1852	1252	788	267	133

Implantable Pulse Generator

SS303 Sigma 300 S

US Market Release Date	09/15/1999
CE Market Approval Date	12/17/1998
Registered US Implants	221
Estimated Active US Implants	50
Normal Battery Depletions (US)	0

NBG Code	SSI
Max Delivered Energy	N/A

Total Malfunctions (US)	0
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SSR303, SSR306, SS303, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	11	12	13	14	at 171 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.8%	99.7%	99.7%	99.7%	99.6%	99.6%	99.6%	99.6%	99.6%
Including NBD	99.9%	99.7%	99.5%	99.2%	98.8%	98.2%	97.0%	95.0%	91.7%	86.0%	77.6%	68.2%	62.3%	56.9%	54.4%
Effective Sample Size	47121	39977	34124	29348	25390	22076	19201	16101	13053	9933	6763	3868	2056	500	119

Implantable Pulse Generator

SSR203 Sigma 200 SR

US Market Release Date	09/02/1999
CE Market Approval Date	
Registered US Implants	12,124
Estimated Active US Implants	1,483
Normal Battery Depletions (US)	584

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	14
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	14
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	14
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SSR203, SS203, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	11	12	13	14	at 171 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	99.8%	99.7%	99.6%	99.6%	99.6%	99.6%	99.6%	99.6%	99.6%
Including NBD	99.7%	99.5%	99.3%	99.1%	98.5%	97.5%	96.1%	93.8%	88.9%	81.6%	70.6%	61.6%	55.7%	52.2%	51.5%
Effective Sample Size	10339	8716	7406	6354	5454	4722	4045	3562	3052	2493	1852	1252	788	267	133

Implantable Pulse Generator

SSR303 Sigma 300 SR

US Market Release Date	08/30/1999
CE Market Approval Date	12/17/1998
Registered US Implants	51,699
Estimated Active US Implants	8,455
Normal Battery Depletions (US)	1,999

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	57
Therapy Not Compromised Malfunctions	14
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	12
Other Malfunction	2
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	43
Battery Malfunction	0
Electrical Component	3
Electrical Interconnect	40
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SSR303, SSR306, SS303, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	11	12	13	14	at 171 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.8%	99.7%	99.7%	99.7%	99.6%	99.6%	99.6%	99.6%	99.6%
Including NBD	99.9%	99.7%	99.5%	99.2%	98.8%	98.2%	97.0%	95.0%	91.7%	86.0%	77.6%	68.2%	62.3%	56.9%	54.4%
Effective Sample Size	47121	39977	34124	29348	25390	22076	19201	16101	13053	9933	6763	3868	2056	500	119

Implantable Pulse Generator

SSR306 Sigma 300 SR

US Market Release Date	09/07/1999
CE Market Approval Date	12/17/1998
Registered US Implants	2,218
Estimated Active US Implants	276
Normal Battery Depletions (US)	136

NBG Code	SSIR
Max Delivered Energy	N/A

Total Malfunctions (US)	2
Therapy Not Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	1
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	1
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SSR303, SSR306, SS303, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	11	12	13	14	at 171 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.8%	99.7%	99.7%	99.7%	99.6%	99.6%	99.6%	99.6%	99.6%
Including NBD	99.9%	99.7%	99.5%	99.2%	98.8%	98.2%	97.0%	95.0%	91.7%	86.0%	77.6%	68.2%	62.3%	56.9%	54.4%
Effective Sample Size	47121	39977	34124	29348	25390	22076	19201	16101	13053	9933	6763	3868	2056	500	119

Implantable Pulse Generator

SVDD303 Sigma 300 VDD

US Market Release Date	09/15/1999
CE Market Approval Date	12/17/1998
Registered US Implants	650
Estimated Active US Implants	70
Normal Battery Depletions (US)	80

NBG Code	VDD
Max Delivered Energy	N/A

Total Malfunctions (US)	1
Therapy Not Compromised Malfunctions	0
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	0
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	1
Battery Malfunction	0
Electrical Component	0
Electrical Interconnect	1
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0

SVDD303, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	at 131 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.8%	99.3%	99.3%	98.9%	98.9%
Including NBD	100.0%	100.0%	100.0%	100.0%	99.7%	99.2%	96.9%	92.4%	79.2%	55.6%	47.9%
Effective Sample Size	892	819	766	709	647	590	526	456	342	195	108

Implantable Pulse Generator

VEDR01 Versa DR

US Market Release Date	07/17/2006
CE Market Approval Date	09/20/2005
Registered US Implants	106,938
Estimated Active US Implants	76,935
Normal Battery Depletions (US)	1,208

NBG Code	DDDR
Max Delivered Energy	N/A

Total Malfunctions (US)	17
Therapy Not Compromised Malfunctions	9
Battery Malfunction	0
Electrical Component	7
Electrical Interconnect	2
Other Malfunction	0
Poss Early Battery Depltn	0
Software Malfunction	0
Therapy Compromised Malfunctions	8
Battery Malfunction	0
Electrical Component	4
Electrical Interconnect	0
Other Malfunction	4
Poss Early Battery Depltn	0
Software Malfunction	0

VEDR01, Survival Curve



Years	1	2	3	4	5	6	7	8	at 99 mo
Excluding NBD	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Including NBD	100.0%	99.9%	99.9%	99.7%	99.4%	98.5%	95.9%	84.2%	76.3%
Effective Sample Size	97622	84249	69837	55425	40902	27087	13905	2455	450

Method for Estimating Lead Performance

Medtronic Cardiac Rhythm and Heart Failure (CRHF) has tracked lead survival for over 32 years with its multicenter, global chronic lead studies.

Leads Performance Analysis

Implanted leads operate in the challenging biochemical environment of the human body and the body's response to foreign objects. Implanted leads are also subject to mechanical stresses associated with heart motion, body motion, and patient anatomy.

In this environment, pacemaker and defibrillation leads cannot be expected to last forever. While IPGs and ICDs have a battery that will deplete after a predictable length of time, a lead's longevity cannot be predicted easily based on mechanical measurements, nor are there simple indicators that a lead is approaching the end of its service life. Therefore, regular monitoring while implanted, and evaluation of lead integrity upon IPG or ICD replacement, is necessary to determine if a lead may be approaching the end of its service life.

Shortfalls Of Using Returned Product And Complaints To Estimate Lead Performance

Leads and lead segments returned to Medtronic are analyzed to determine whether or not they meet performance limits established by Medtronic. Although returned product analyses are valuable for gaining insight into lead failure mechanisms, this data cannot be used by itself for determining the survival probability of leads because only a small fraction of leads are explanted and returned for analysis. Some leads are modified due to adverse device effect, however may not be explanted. Additionally, those leads that are returned cannot be assumed to be statistically representative of the performance of the total population for a given lead model. Partial or total lead extraction can result in significant damage to a lead, making a definitive analysis of a suspected failure, and its cause, impossible.

To account for the under reporting inherent with lead survival analysis based solely on returned product, some manufacturers add reported complaints where adverse product performance is evident but the product itself has not been returned. The improvement to the accuracy of survival estimates depends on the degree to which all complaints are actually communicated to the manufacturer. Since not all complaints are communicated to the manufacturer, adding complaints to the survival analysis does not completely solve the under reporting problem.

Lead survival probabilities are more appropriately determined through a prospective clinical surveillance study that includes active follow up with the patients. Although Medtronic monitors returned product analysis and complaints, these are not used to determine lead survival estimates.

Medtronic consolidated all cardiac rhythm surveillance registries into the PAN Registry. The PAN Registry is a patient centric surveillance platform which follows patients implanted with Medtronic cardiac rhythm product(s). The Product Performance Report (PPR) tracks PAN Registry enrolled patients to monitor lead performance status in vivo. The PAN Registry is designed to record clinical observations representative of the total clinical experience. Lead survival estimates include both lead hardware failure and lead-related clinical events that are classified as product performance events, and do not differentiate a lead hardware failure from other clinical events such as Failure to capture, perforation, dislodgement, or concurrent pulse generator failure.

PAN Registry

Medtronic has been monitoring the performance of its cardiac therapy products with a multicenter study since 1983 and has evaluated the performance of more than 95,000 leads, with data reported from countries around the world. Throughout this time period, Medtronic has continually worked to adapt systems and processes to more effectively monitor product performance following market release. The following summarizes current registry requirements.

Method for Estimating Lead Performance continued

Medtronic's product surveillance registry is a world-wide study that has a prospective, non-randomized, observational design. A key purpose of the registry is to provide continuing evaluation and periodic reporting of the long-term reliability and performance of Medtronic market-released cardiac rhythm therapy products. Product-related adverse events, indicating the status of the product, are collected to measure product survival probabilities. The data gathered may also be used to support the design and development of new cardiac therapy products. The registry is designed to continue indefinitely, encompassing new products as they become commercially available.

To ensure a sufficiently large and representative source of data, participating clinical sites must meet pre-specified selection criteria. Patients are enrolled upon implantation of a Medtronic Cardiac rhythm product. Every effort is made to ensure participants are representative of the range of clinical environments in which Medtronic cardiac rhythm products are used. Eligible products for enrollment include Medtronic market-released cardiac rhythm therapy products for which additional information to further characterize product performance following market release is desired. Number of enrollments is reviewed regularly to ensure adequate sample size is obtained for each individual product. Enrollment may be capped and follow-up discontinued when sufficient duration and precision is achieved to effectively characterize product survivability.

Enrolled patients are followed in accordance with the standard care practices of their care provider from their implant date until they can no longer be followed (e.g., death, lost to follow-up, etc.). However, to ensure regular patient status assessments are completed, follow-up windows consistent with typical care practices have been established with a minimum annual follow-up requirement. Product-related adverse events, system modifications and changes in patient status (e.g. death and withdrawal from the study) are required to be reported upon occurrence. This active surveillance model ensures a robust dataset for effectively monitoring product performance.

Patients are eligible for enrollment if:

- Patient is intended to be implanted or is within 30 days post-implant of a Medtronic market-released cardiac lead connected to a market-released CRT, ICD, or IPG device, and the lead is used for a pacing, sensing, or defibrillation application, or
- Patient participated in a qualifying investigational study of a Medtronic cardiac rhythm product that is now market-released; complete implant and follow-up data are available; and the data can be appropriately and legally released

Each site is require to inform Medtronic whenever a lead event has occurred, a lead is modified, or when a patient is no longer participating. Timely, accurate, and complete reporting and analysis of safety information for surveillance is crucial for the protection of patients, clinicians, and the sponsor Medtronic continually evaluates the quality and integrity of the data through a combination of on-site and centralized monitoring activities.

Lead Complications

Chronic lead performance is characterized by estimating lead related complication free survival probabilities. For analysis purposes, the complication criteria, which align with the AdvaMed 'Industry Guidance for Uniform Reporting of Clinical Performance of Cardiac Rhythm Management Pulse Generators and Leads', are defined below. These criteria do not, however, enable a lead integrity or "hardware" failure to be conclusively differentiated from other clinical events such as an undetected lead dislodgement, perforation, or concurrent pulse generator failure manifested as a sensing or capture problem.

Method for Estimating Lead Performance continued

All reported lead-related adverse events are classified by the reporting investigator and are adjudicated by an independent event adjudication committee[1]. A lead-related event with at least one of the following classifications that is adjudicated by the committee as a complication and occurs more than 30 days after implant is considered a product performance event and will contribute to the survival analysis endpoint. Events with an onset date of 30 days or less after the implant are considered procedure related and therefore are not included as product performance events.

- Product performance events includes, but not limited to: Failure to capture
- Failure to sense/undersensing
- Oversensing
- Elevated pacing thresholds
- Abnormal pacing impedance (based on lead model, but normal range is typically 200 - 2,000 ohms)
- Abnormal defibrillation impedance (based on lead model, but normal range is typically 20 - 200 ohms)
- Lead Insulation breach
- Lead Conductor fracture, confirmed electrically, visually or radiographically
- Extracardiac stimulation
- Cardiac perforation
- Lead dislodgement
- Structural Lead Failure

Data Analysis Methods

The performance of leads is expressed in terms of lead survival estimates, where "survival" refers to the function of the lead, not the survival of the patient.. These survival estimates are intended to illustrate the probability that a lead will survive for a given number of years without a chronic lead-related complication.

Active surveillance normally begins at the time of implant and continues until a product performance or censoring event occurs. In some cases in the PAN Registry, active surveillance of a device starts after the device was implanted. The survival probability of such device is conditional on survival to the time when the device enters the Registry. This phenomenon is called Left-truncation[2]. PPR lead survival analysis is estimated using the Kaplan-Meier method, a statistical method to incorporate data from these retrospectively enrolled devices, left-truncated data, was applied. The statistical technique uses data from existing devices while appropriately adjusting the device survival curves for the time the device was not actively followed in the registry. Thus, in some cases sample sizes may fluctuate from one time interval to the next interval.

On the following pages, each graph includes a survival curve for each lead model. The survival estimates is the probability that a lead is free of a product performance event at a given time point. For example, if a survival probability is 95% after 5 years of service, then the lead has a 5% chance of experiencing a lead-related complication in the first 5 years following implant.

The data in the tables is rounded to the nearest tenth of one percent. Occasionally, a graph may show 100% survival, but have one or more complications. This occurs because even with the complications, the data rounds to 100%.

The survival curves are statistical estimates. As sample size increases and performance experience accumulates, the estimation improves. Confidence intervals are provided as a way to indicate the degree of certainty of the estimates. Greenwood’s formula is used to calculate the standard errors, and the log-log method is used to produce the 2-sided 95% confidence bounds.

Since the survival estimate can become very imprecise with small effective sample sizes, Medtronic truncates the survival curve when the number of leads entering an interval is less than 50 leads. When the number of leads entering an interval reaches 50, the next data point is added to the survival

curve. For those lead models that do not have sufficient sample size, a survival curve will not be presented.

Definition of Analysis Dataset

The survival estimates are derived from all device components successfully enrolled as of the data received cut-off date (e.g. date of data entry at a study site). The number of enrollments is listed for each lead model.

This sample is considered to be representative of the worldwide population, and therefore the survival estimates shown should be representative of the performance worldwide of these models.

Criteria for Model Inclusion

Performance information for a model or model family will be published when more than 100 leads have been enrolled and no fewer than 50 leads followed for at least 6 months. Medtronic, at its discretion, may stop providing updated performance information on lead models that received original US market-release approval 20 or more years ago.

Returned Product Analysis Results

Although the returned product analysis data is not used to generate the survival estimates, the data provides valuable insight into the causes of lead malfunction.

For reporting returned product analysis results, Medtronic CRHF considers a lead as having malfunctioned whenever the analysis shows that any parameter was outside the performance limits established by Medtronic while implanted and in service. To be considered a malfunction for returned product analysis reporting, the lead must have been returned to Medtronic and analyzed.

The results of the analysis is presented in four categories. The lead reporting categories are:

> **Conductor Fracture**: Conductor malfunction with complete or intermittent loss of continuity that could interrupt current flow (e.g., fractured conductors), including those associated with clavicle flex fatigue or crush damage.
>
> **Insulation Breach**: A malfunction of the insulation allowing inappropriate entry of body fluids or inappropriate current flow between the conductors, or between the conductor and the body. Examples include cuts, tears, depressions, abrasions, and material degradation.
>
> **Crimps/Welds/Bonds**: Any malfunction in a conductor or lead body associated with a point of connection.
>
> **Other:** Malfunctions of specific lead mechanical attributes, such as sensors, connectors, seal rings, or malfunction modes not included in the three categories above.

A lead subject to a safety advisory is not considered to have malfunctioned unless it has been returned to Medtronic CRHF and found, through analysis, to actually have performed outside the performance limits established by Medtronic.

For leads designed for either ventricular or atrial use, the numbers listed in the Returned Product Analysis tables include both.

The numbers of malfunctions listed in the Returned Product Analysis tables are the actual numbers confirmed in the returned product analysis. The numbers of complications listed in the complications tables are the actual numbers observed in the PSR centers around the world.

Method for Estimating Lead Performance continued

US Reports of Acute Lead Observations (Occurring within First Month of Service)

In the first weeks following lead implantation, physiologic responses and lead performance can vary until long-term lead stability is attained. Acute (defined as the first month after implant) lead performance may be subject to a number of factors, including patient-specific anatomy, clinical conditions and/or varying implant conditions/techniques. After a period of time, the implant and the lead performance stabilizes. It is for this reason that the Product Surveillance Registry results, which are intended to measure long-term performance, do not include complications that occur within the first 30 days after implant.

Information about the clinical experience in the first month of service is included in our reporting. The source for this information is Medtronic's complaint handling system database. The information is summarized in tables titled "US Reports of Acute Lead Observations."

Each Event Report received by Medtronic's complaint handling system is assigned one or more Reason for Report codes based on the information received. The Reason for Report codes have been grouped into Acute Lead Observation categories. The categories used for this product performance reporting are drawn from the "FDA Guidance for Submission of Research and Marketing Applications for Permanent Pacemaker Leads and for Pacemaker Lead Adapter 510(k) Submissions." The categories are:

1. Cardiac Perforation
2. Conductor Fracture
3. Lead Dislodgement
4. Failure to Capture
5. Oversensing
6. Failure to Sense
7. Insulation Breach
8. Impedance Abnormal
9. Extracardiac Stimulation
10. Unspecified

Although multiple observations are possible for any given lead, only one observation is reported per lead. The observation reported is the observation highest on the list. For example, if an Event Report includes observations for both Lead Dislodgement and Failure to Sense, Lead Dislodgement is reported.

The lead event reported to Medtronic may or may not have involved clinical action or product returned to Medtronic. The lead may have remained implanted and in service.

Estimated Number of Implanted and Active Leads in the United States

In addition to providing the number of leads enrolled in the PSR, we also provide the number of leads registered as implanted and the number remaining active in the United States based on the status recorded in the Medtronic Device and Registrant Tracking system.

Footnotes:

1: During the evolution of SLS, event adjudication was transitioned from a Medtronic technical review committee to an independent event adjudication committee in 2011. Data analyses include adjudication using both methods.

2: Klein, John P., Moeschberger, Melvin L. Survival Analysis Techniques for Censored and Truncated Data, New York: Springer-Verlag New York, Inc., 1997.

LEFT HEART PACING LEAD 2187

Distribution Data	
US Market Release	8/28/2001
CE Approval Date	
Registered US Implants	11,982
Estimated Active US	2,454
Product Characteristics	
Fixation Type	Distal Continous Curve
Lead Function	Pacing/Sensing
Steroid Indicator	None
Lead Placement	Transvenous
Lead Tip Location	Left Ventricular Cardiac Vein
Pace/Sense Polarity	Unipolar
Product Surveilance Registry Results	
Number of Leads Enrolled in Study	138
Cumulative Months of Follow-Up	6,379
Number of Leads Active in Study	7

Product Surveilance Registry Qualifying Complications	2
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	2
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	0
Extracardiac Stimulation	1
Failure To Capture	3
Failure To Sense	1
Impedance Abnormal	0
Insulation Breach	0
Lead Dislodgement	9
Oversensing	0
Unspecified	0
USA Returned Product Analysis	
Conductor Fracture	1
Crimp Weld Bond	0
Insulation Breach	0
Other	4



Years	1	2	3	at 48 mo
%	99.0%	99.0%	99.0%	99.0%
#	100	84	64	52

LEFT HEART PACING LEAD 4193

Distribution Data	
US Market Release	5/3/2002
CE Approval Date	12/22/2000
Registered US Implants	100,774
Estimated Active US	30,997
Product Characteristics	
Fixation Type	Distal Double Curve
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Left Ventricular Cardiac Vein
Pace/Sense Polarity	Unipolar
Product Surveillance Registry Results	
Number of Leads Enrolled in Study	739
Cumulative Months of Follow-Up	32,224
Number of Leads Active in Study	106

Product Surveillance Registry Qualifying Complications	41
Cardiac Perforation	0
Conductor Fracture	1
Electrical Abandonment	0
Extracardiac Stimulation	9
Failure To Capture	13
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	14
Medical Judgment	0
Other Complication	1
Oversensing	0
Unspecified	3

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	0
Extracardiac Stimulation	17
Failure To Capture	11
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach	0
Lead Dislodgement	45
Oversensing	1
Unspecified	2
USA Returned Product Analysis	
Conductor Fracture	59
Crimp Weld Bond	0
Insulation Breach	13
Other	48

4193, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	at 114 mo
%	95.8%	94.8%	94.1%	93.8%	93.4%	92.5%	92.5%	91.7%	91.7%	90.5%
#	561	417	345	271	209	173	139	106	69	53

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

LEFT HEART PACING LEAD 4194

Distribution Data	
US Market Release	8/24/2004
CE Approval Date	7/14/2003
Registered US Implants	113,369
Estimated Active US	63,630
Product Characteristics	
Fixation Type	Distal Double Curve
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Left Ventricular Cardiac Vein
Pace/Sense Polarity	Bipolar
Product Surveillance Registry Results	
Number of Leads Enrolled in Study	1,468
Cumulative Months of Follow-Up	52,175
Number of Leads Active in Study	686

Product Surveillance Registry Qualifying Complications	43
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	8
Failure To Capture	11
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach (ESC)	1
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	2
Lead Dislodgement	21
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	2
Conductor Fracture	2
Extracardiac Stimulation	41
Failure To Capture	39
Failure To Sense	0
Impedance Abnormal	6
Insulation Breach	0
Lead Dislodgement	144
Oversensing	2
Unspecified	5
USA Returned Product Analysis	
Conductor Fracture	18
Crimp Weld Bond	0
Insulation Breach	68
Other	9

4194, Survival Curve



Years	1	2	3	4	5	6	7	at 90 mo
%	98.8%	97.6%	96.9%	96.5%	96.0%	94.4%	94.4%	94.4%
#	1,138	866	657	405	262	164	98	73

LEFT HEART PACING LEAD 4195

Distribution Data	
US Market Release	8/15/2008
CE Approval Date	5/13/2005
Registered US Implants	16,761
Estimated Active US	12,662
Product Characteristics	
Fixation Type	Deployable Lobe Fixation
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Left Ventricular Cardiac Vein
Pace/Sense Polarity	Unipolar
Product Surveillance Registry Results	
Number of Leads Enrolled in Study	1,441
Cumulative Months of Follow-Up	43,390
Number of Leads Active in Study	827

Product Surveillance Registry Qualifying Complications	17
Cardiac Perforation	0
Conductor Fracture	1
Electrical Abandonment	0
Extracardiac Stimulation	7
Failure To Capture	3
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	1
Lead Dislodgement	4
Medical Judgment	0
Other Complication	1
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	0
Extracardiac Stimulation	28
Failure To Capture	19
Failure To Sense	0
Impedance Abnormal	3
Insulation Breach	0
Lead Dislodgement	29
Oversensing	0
Unspecified	1
USA Returned Product Analysis	
Conductor Fracture	5
Crimp Weld Bond	0
Insulation Breach	1
Other	4

4195, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	at 66 mo
%	99.3%	98.7%	98.6%	98.6%	98.1%	98.1%
#	1,136	825	527	279	89	55

LEFT HEART PACING LEAD 4196

Distribution Data	
US Market Release	5/15/2009
CE Approval Date	7/24/2007
Registered US Implants	61,607
Estimated Active US	49,366
Product Characteristics	
Fixation Type	Double Curve
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Left Ventricular Cardiac Vein
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	2,086
Cumulative Months of Follow-Up	58,184
Number of Leads Active in Study	939

Product Surveillance Registry Qualifying Complications	54
Cardiac Perforation	0
Conductor Fracture	1
Electrical Abandonment	0
Extracardiac Stimulation	12
Failure To Capture	18
Failure To Sense	0
Impedance Abnormal	1
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	20
Medical Judgment	0
Other Complication	2
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	1
Conductor Fracture	2
Extracardiac Stimulation	78
Failure To Capture	50
Failure To Sense	1
Impedance Abnormal	7
Insulation Breach	1
Lead Dislodgement	168
Oversensing	1
Unspecified	3
USA Returned Product Analysis	
Conductor Fracture	13
Crimp Weld Bond	0
Insulation Breach	0
Other	10

4196, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	at 54 mo
%	98.0%	97.3%	96.9%	96.5%	95.9%
#	1,603	1,184	783	244	89

LEFT HEART PACING LEAD 4296

Distribution Data	
US Market Release	4/1/2011
CE Approval Date	12/18/2009
Registered US Implants	28,068
Estimated Active US	25,563
Product Characteristics	
Fixation Type	Distal Double Curve
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Left Ventricular Cardiac Vein
Pace/Sense Polarity	Dual Electrodes
Product Surveillance Registry Results	
Number of Leads Enrolled in Study	1,347
Cumulative Months of Follow-Up	18,385
Number of Leads Active in Study	971

Product Surveillance Registry Qualifying Complications	10
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	3
Failure To Capture	2
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	5
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	2
Conductor Fracture	0
Extracardiac Stimulation	42
Failure To Capture	18
Failure To Sense	0
Impedance Abnormal	8
Insulation Breach	4
Lead Dislodgement	93
Oversensing	0
Unspecified	0
USA Returned Product Analysis	
Conductor Fracture	2
Crimp Weld Bond	2
Insulation Breach	0
Other	3

4296, Survival Curve



Years	1	2	at 30 mo
%	99.4%	98.4%	98.4%
#	709	232	88

LEFT HEART PACING LEAD 4298

Distribution Data	
US Market Release	
CE Approval Date	1/1/2013
Registered US Implants	7,796
Estimated Active US	7,664
Product Characteristics	
Fixation Type	Distal Double Curve
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Left Ventricular Cardiac Vein
Pace/Sense Polarity	Bipolar
Product Surveillance Registry Results	
Number of Leads Enrolled in Study	0
Cumulative Months of Follow-Up	0
Number of Leads Active in Study	0

Product Surveillance Registry Qualifying Complications	0
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	0
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	1
Conductor Fracture	0
Extracardiac Stimulation	14
Failure To Capture	10
Failure To Sense	0
Impedance Abnormal	3
Insulation Breach	0
Lead Dislodgement	8
Oversensing	0
Unspecified	0
USA Returned Product Analysis	
Conductor Fracture	0
Crimp Weld Bond	0
Insulation Breach	0
Other	4

4298, Survival Curve



Years	
%	
#	

LEFT HEART PACING LEAD 4396

Distribution Data	
US Market Release	3/31/2011
CE Approval Date	12/18/2009
Registered US Implants	5,890
Estimated Active US	5,300
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Left Ventricular Cardiac Vein
Pace/Sense Polarity	Dual Electrodes

Product Surveilance Registry Results	
Number of Leads Enrolled in Study	361
Cumulative Months of Follow-Up	5,775
Number of Leads Active in Study	260

Product Surveilance Registry Qualifying Complications	1
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	0
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	1
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	1
Conductor Fracture	1
Extracardiac Stimulation	10
Failure To Capture	5
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach	0
Lead Dislodgement	27
Oversensing	0
Unspecified	0
USA Returned Product Analysis	
Conductor Fracture	1
Crimp Weld Bond	0
Insulation Breach	0
Other	1

4396, Survival Curve



Years	1	2	at 30 mo
%	99.7%	99.7%	99.7%
#	194	76	52

LEFT HEART PACING LEAD 4398

Distribution Data	
US Market Release	
CE Approval Date	1/1/2013
Registered US Implants	395
Estimated Active US	379
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Left Ventricular Cardiac Vein
Pace/Sense Polarity	Bipolar

Product Surveilance Registry Results	
Number of Leads Enrolled in Study	0
Cumulative Months of Follow-Up	0
Number of Leads Active in Study	0

Product Surveilance Registry Qualifying Complications	0
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	0
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	2
Conductor Fracture	0
Extracardiac Stimulation	8
Failure To Capture	1
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach	0
Lead Dislodgement	1
Oversensing	0
Unspecified	0
USA Returned Product Analysis	
Conductor Fracture	0
Crimp Weld Bond	0
Insulation Breach	0
Other	1

4398, Survival Curve



Years
%
#

DEFIBRILLATION LEAD 6721

Distribution Data	
US Market Release	3/31/1994
CE Approval Date	1/1/1993
Registered US Implants	2,973
Estimated Active US	1,125
Product Characteristics	
Fixation Type	Suture
Lead Function	Defibrillation
Steroid Indicator	None
Lead Placement	Epi Patch
Lead Tip Location	Epicardial
Pace/Sense Polarity	n/a

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	410
Cumulative Months of Follow-Up	23,499
Number of Leads Active in Study	3

Product Surveillance Registry Qualifying Complications	47
Cardiac Perforation	0
Conductor Fracture	21
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	8
Failure To Sense	0
Impedance Abnormal	4
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	2
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	12
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	1
Conductor Fracture	2
Extracardiac Stimulation	0
Failure To Capture	0
Failure To Sense	1
Impedance Abnormal	3
Insulation Breach	0
Lead Dislodgement	0
Oversensing	1
Unspecified	0
USA Returned Product Analysis	
Conductor Fracture	13
Crimp Weld Bond	0
Insulation Breach	1
Other	0

6721, 6921, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	at 108 mo
%	96.6%	94.5%	91.9%	90.8%	89.0%	84.3%	82.9%	82.9%	82.9%
#	342	312	267	215	182	131	98	63	55

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

DEFIBRILLATION LEAD 6930

Distribution Data	
US Market Release	9/2/2004
CE Approval Date	
Registered US Implants	354
Estimated Active US	147
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	True Bipolar/One Coil

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	4
Cumulative Months of Follow-Up	211
Number of Leads Active in Study	2

Product Surveillance Registry Qualifying Complications	0
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	0
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	0
Extracardiac Stimulation	0
Failure To Capture	0
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach	0
Lead Dislodgement	0
Oversensing	0
Unspecified	1

USA Returned Product Analysis	
Conductor Fracture	5
Crimp Weld Bond	0
Insulation Breach	0
Other	0

6930, Survival Curve



Years
%
#

DEFIBRILLATION LEAD 6931

Distribution Data	
US Market Release	9/2/2004
CE Approval Date	
Registered US Implants	8,080
Estimated Active US	2,951
Product Characteristics	
Fixation Type	Active Screw In
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	True Bipolar/One Coil

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	301
Cumulative Months of Follow-Up	15,661
Number of Leads Active in Study	50

Product Surveillance Registry Qualifying Complications	55
Cardiac Perforation	0
Conductor Fracture	33
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	3
Failure To Sense	1
Impedance Abnormal	9
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	2
Medical Judgment	0
Other Complication	0
Oversensing	7
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	1
Conductor Fracture	2
Extracardiac Stimulation	0
Failure To Capture	1
Failure To Sense	1
Impedance Abnormal	0
Insulation Breach	0
Lead Dislodgement	1
Oversensing	3
Unspecified	1
USA Returned Product Analysis	
Conductor Fracture	586
Crimp Weld Bond	0
Insulation Breach	1
Other	5

6931, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	at 78 mo
%	98.2%	96.2%	93.1%	88.3%	81.9%	73.8%	73.8%
#	267	236	204	162	132	97	76

DEFIBRILLATION LEAD 6932

Distribution Data	
US Market Release	8/6/1996
CE Approval Date	
Registered US Implants	14,899
Estimated Active US	4,000
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	True Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	418
Cumulative Months of Follow-Up	25,621
Number of Leads Active in Study	34

Product Surveillance Registry Qualifying Complications	11
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	1
Failure To Capture	2
Failure To Sense	2
Impedance Abnormal	2
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	4
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	0
Extracardiac Stimulation	0
Failure To Capture	2
Failure To Sense	2
Impedance Abnormal	1
Insulation Breach	0
Lead Dislodgement	4
Oversensing	0
Unspecified	2
USA Returned Product Analysis	
Conductor Fracture	23
Crimp Weld Bond	0
Insulation Breach	26
Other	2

6932, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	11	at 138 mo
%	99.2%	98.3%	98.3%	98.3%	97.7%	97.7%	97.7%	96.7%	96.7%	95.5%	92.4%	92.4%
#	361	303	242	203	157	125	105	91	81	68	55	53

DEFIBRILLATION LEAD 6933

Distribution Data	
US Market Release	4/20/1994
CE Approval Date	
Registered US Implants	7,978
Estimated Active US	753
Product Characteristics	
Fixation Type	Passive
Lead Function	Defibrillation
Steroid Indicator	None
Lead Placement	Transvenous
Lead Tip Location	SVC/CS
Pace/Sense Polarity	One Coil

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	968
Cumulative Months of Follow-Up	54,252
Number of Leads Active in Study	7

Product Surveillance Registry Qualifying Complications	47
Cardiac Perforation	0
Conductor Fracture	16
Electrical Abandonment	0
Extracardiac Stimulation	4
Failure To Capture	6
Failure To Sense	1
Impedance Abnormal	3
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	2
Lead Dislodgement	1
Medical Judgment	0
Other Complication	0
Oversensing	10
Unspecified	4

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	0
Extracardiac Stimulation	0
Failure To Capture	0
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach	0
Lead Dislodgement	0
Oversensing	0
Unspecified	3
USA Returned Product Analysis	
Conductor Fracture	105
Crimp Weld Bond	0
Insulation Breach	16
Other	0

6933, 6937, 6937A, 6963, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	at 126 mo
%	98.4%	97.5%	97.2%	96.7%	95.4%	94.9%	93.9%	93.4%	92.2%	91.1%	91.1%
#	822	691	576	484	388	312	219	170	111	72	57

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

DEFIBRILLATION LEAD 6935

Distribution Data	
US Market Release	11/1/2008
CE Approval Date	3/31/2008
Registered US Implants	49,968
Estimated Active US	43,965
Product Characteristics	
Fixation Type	Active Screw In
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	True Bipolar/One Coil

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	2,350
Cumulative Months of Follow-Up	61,342
Number of Leads Active in Study	1,438

Product Surveillance Registry Qualifying Complications	23
Cardiac Perforation	0
Conductor Fracture	7
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	2
Failure To Sense	1
Impedance Abnormal	1
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	7
Medical Judgment	0
Other Complication	1
Oversensing	4
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	14
Conductor Fracture	0
Extracardiac Stimulation	0
Failure To Capture	19
Failure To Sense	5
Impedance Abnormal	14
Insulation Breach	1
Lead Dislodgement	33
Oversensing	37
Unspecified	5
USA Returned Product Analysis	
Conductor Fracture	133
Crimp Weld Bond	0
Insulation Breach	4
Other	37

6935, Survival Curve



Years	1	2	3	4	at 54 mo
%	99.4%	99.2%	98.9%	98.2%	98.2%
#	1,872	1,203	636	249	104

DEFIBRILLATION LEAD 6935M

Distribution Data	
US Market Release	8/2/2012
CE Approval Date	7/12/2012
Registered US Implants	45,858
Estimated Active US	44,333
Product Characteristics	
Fixation Type	Active Screw in
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	True Bipolar/One Coil

Product Surveilance Registry Results	
Number of Leads Enrolled in Study	1,709
Cumulative Months of Follow-Up	10,011
Number of Leads Active in Study	1,553

Product Surveilance Registry Qualifying Complications	5
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	0
Failure To Sense	0
Impedance Abnormal	1
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	2
Medical Judgment	0
Other Complication	1
Oversensing	1
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	12
Conductor Fracture	1
Extracardiac Stimulation	4
Failure To Capture	38
Failure To Sense	6
Impedance Abnormal	7
Insulation Breach	1
Lead Dislodgement	57
Oversensing	33
Unspecified	0
USA Returned Product Analysis	
Conductor Fracture	10
Crimp Weld Bond	0
Insulation Breach	1
Other	4

6935M, Survival Curve



Years	1	at 18 mo
%	99.4%	99.4%
#	329	116

DEFIBRILLATION LEAD 6937

Distribution Data	
US Market Release	3/22/1996
CE Approval Date	4/19/1994
Registered US Implants	2,056
Estimated Active US	380
Product Characteristics	
Fixation Type	Passive
Lead Function	Defibrillation
Steroid Indicator	None
Lead Placement	Transvenous
Lead Tip Location	SVC/CS
Pace/Sense Polarity	One Coil

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	968
Cumulative Months of Follow-Up	54,252
Number of Leads Active in Study	7

Product Surveillance Registry Qualifying Complications	47
Cardiac Perforation	0
Conductor Fracture	16
Electrical Abandonment	0
Extracardiac Stimulation	4
Failure To Capture	6
Failure To Sense	1
Impedance Abnormal	3
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	2
Lead Dislodgement	1
Medical Judgment	0
Other Complication	0
Oversensing	10
Unspecified	4

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	0
Extracardiac Stimulation	0
Failure To Capture	1
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach	0
Lead Dislodgement	1
Oversensing	0
Unspecified	0
USA Returned Product Analysis	
Conductor Fracture	18
Crimp Weld Bond	0
Insulation Breach	2
Other	1

6933, 6937, 6937A, 6963, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	at 126 mo
%	98.4%	97.5%	97.2%	96.7%	95.4%	94.9%	93.9%	93.4%	92.2%	91.1%	91.1%
#	822	691	576	484	388	312	219	170	111	72	57

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

DEFIBRILLATION LEAD 6937A

Distribution Data	
US Market Release	4/6/2001
CE Approval Date	
Registered US Implants	2,072
Estimated Active US	1,315
Product Characteristics	
Fixation Type	Passive
Lead Function	Defibrillation
Steroid Indicator	None
Lead Placement	Transvenous
Lead Tip Location	SVC/CS
Pace/Sense Polarity	One Coil

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	968
Cumulative Months of Follow-Up	54,252
Number of Leads Active in Study	7

Product Surveillance Registry Qualifying Complications	47
Cardiac Perforation	0
Conductor Fracture	16
Electrical Abandonment	0
Extracardiac Stimulation	4
Failure To Capture	6
Failure To Sense	1
Impedance Abnormal	3
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	2
Lead Dislodgement	1
Medical Judgment	0
Other Complication	0
Oversensing	10
Unspecified	4

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	3
Extracardiac Stimulation	0
Failure To Capture	0
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach	0
Lead Dislodgement	0
Oversensing	0
Unspecified	2
USA Returned Product Analysis	
Conductor Fracture	4
Crimp Weld Bond	0
Insulation Breach	0
Other	0

6933, 6937, 6937A, 6963, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	at 126 mo
%	98.4%	97.5%	97.2%	96.7%	95.4%	94.9%	93.9%	93.4%	92.2%	91.1%	91.1%
#	822	691	576	484	388	312	219	170	111	72	57

DEFIBRILLATION LEAD 6942

Distribution Data	
US Market Release	7/18/1997
CE Approval Date	
Registered US Implants	17,685
Estimated Active US	4,935
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	Integrated Bipolar/ Two Coils

Product Surveilance Registry Results	
Number of Leads Enrolled in Study	358
Cumulative Months of Follow-Up	19,291
Number of Leads Active in Study	14

Product Surveilance Registry Qualifying Complications	7
Cardiac Perforation	0
Conductor Fracture	1
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	0
Failure To Sense	1
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	1
Medical Judgment	0
Other Complication	0
Oversensing	3
Unspecified	1

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	1
Extracardiac Stimulation	0
Failure To Capture	4
Failure To Sense	0
Impedance Abnormal	2
Insulation Breach	0
Lead Dislodgement	1
Oversensing	2
Unspecified	1
USA Returned Product Analysis	
Conductor Fracture	15
Crimp Weld Bond	1
Insulation Breach	25
Other	4

6942, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	at 108 mo
%	99.1%	99.1%	98.1%	97.5%	96.7%	96.7%	96.7%	96.7%	96.7%
#	305	236	180	140	113	96	75	64	53

DEFIBRILLATION LEAD 6943

Distribution Data	
US Market Release	10/6/1997
CE Approval Date	
Registered US Implants	20,610
Estimated Active US	5,793
Product Characteristics	
Fixation Type	Active Screw In
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	True Bipolar/One Coil

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	1,332
Cumulative Months of Follow-Up	83,939
Number of Leads Active in Study	151

Product Surveillance Registry Qualifying Complications	103
Cardiac Perforation	0
Conductor Fracture	29
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	9
Failure To Sense	7
Impedance Abnormal	8
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	2
Lead Dislodgement	2
Medical Judgment	0
Other Complication	2
Oversensing	41
Unspecified	3

US Acute Lead Observations	
Cardiac Perforation	1
Conductor Fracture	0
Extracardiac Stimulation	0
Failure To Capture	1
Failure To Sense	1
Impedance Abnormal	2
Insulation Breach	1
Lead Dislodgement	0
Oversensing	1
Unspecified	0

USA Returned Product Analysis	
Conductor Fracture	80
Crimp Weld Bond	1
Insulation Breach	31
Other	5

6943, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	11	12	at 156 mo
%	98.6%	97.7%	96.6%	95.6%	93.5%	91.9%	90.6%	89.7%	87.0%	86.2%	82.2%	81.6%	80.7%
#	1,172	984	861	711	597	485	397	326	270	194	143	100	55

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

DEFIBRILLATION LEAD 6944

Distribution Data	
US Market Release	12/13/2000
CE Approval Date	11/5/1999
Registered US Implants	43,462
Estimated Active US	22,097
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	True Bipolar/Two Coils

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	566
Cumulative Months of Follow-Up	21,709
Number of Leads Active in Study	261

Product Surveillance Registry Qualifying Complications	13
Cardiac Perforation	0
Conductor Fracture	7
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	0
Failure To Sense	1
Impedance Abnormal	2
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	2
Unspecified	1

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	2
Extracardiac Stimulation	0
Failure To Capture	14
Failure To Sense	3
Impedance Abnormal	8
Insulation Breach	0
Lead Dislodgement	21
Oversensing	11
Unspecified	6
USA Returned Product Analysis	
Conductor Fracture	143
Crimp Weld Bond	1
Insulation Breach	4
Other	5

6944, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	at 78 mo
%	100.0%	99.7%	99.0%	97.4%	95.0%	95.0%	95.0%
#	467	353	233	143	75	61	55

DEFIBRILLATION LEAD 6945

Distribution Data	
US Market Release	9/26/1997
CE Approval Date	
Registered US Implants	42,741
Estimated Active US	11,761
Product Characteristics	
Fixation Type	Active Screw In
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	Integrated Bipolar/ Two Coils

Product Surveilance Registry Results	
Number of Leads Enrolled in Study	1,186
Cumulative Months of Follow-Up	65,992
Number of Leads Active in Study	94

Product Surveilance Registry Qualifying Complications	43
Cardiac Perforation	0
Conductor Fracture	10
Electrical Abandonment	0
Extracardiac Stimulation	1
Failure To Capture	2
Failure To Sense	4
Impedance Abnormal	7
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	18
Unspecified	1

US Acute Lead Observations	
Cardiac Perforation	1
Conductor Fracture	1
Extracardiac Stimulation	1
Failure To Capture	6
Failure To Sense	2
Impedance Abnormal	1
Insulation Breach	2
Lead Dislodgement	4
Oversensing	7
Unspecified	2

USA Returned Product Analysis	
Conductor Fracture	140
Crimp Weld Bond	1
Insulation Breach	43
Other	6

6945, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	11	12	13	at 162 mo
%	99.4%	98.7%	98.1%	97.5%	96.6%	95.8%	95.1%	93.9%	92.6%	91.6%	90.3%	89.6%	89.6%	89.6%
#	1,017	824	660	528	407	311	274	230	186	155	129	106	73	51

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

DEFIBRILLATION LEAD 6947

Distribution Data	
US Market Release	11/12/2001
CE Approval Date	10/4/2001
Registered US Implants	369,050
Estimated Active US	235,704
Product Characteristics	
Fixation Type	Active Screw In
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	True Bipolar/Two Coils

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	3,608
Cumulative Months of Follow-Up	151,880
Number of Leads Active in Study	1,528

Product Surveillance Registry Qualifying Complications	51
Cardiac Perforation	0
Conductor Fracture	14
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	2
Failure To Sense	2
Impedance Abnormal	8
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	3
Lead Dislodgement	4
Medical Judgment	0
Other Complication	1
Oversensing	15
Unspecified	2

US Acute Lead Observations	
Cardiac Perforation	27
Conductor Fracture	19
Extracardiac Stimulation	2
Failure To Capture	74
Failure To Sense	30
Impedance Abnormal	54
Insulation Breach	4
Lead Dislodgement	108
Oversensing	119
Unspecified	22
USA Returned Product Analysis	
Conductor Fracture	673
Crimp Weld Bond	4
Insulation Breach	62
Other	215

6947, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	at 132 mo
%	99.5%	99.3%	99.0%	98.5%	98.0%	97.5%	96.9%	96.6%	96.1%	95.7%	94.9%
#	2,924	2,347	1,857	1,324	773	476	390	338	276	160	74

DEFIBRILLATION LEAD 6947M

Distribution Data	
US Market Release	2/13/2012
CE Approval Date	3/12/2010
Registered US Implants	57,035
Estimated Active US	54,254

Product Characteristics	
Fixation Type	Active Screw In
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	True Bipolar/Two Coils

Product Surveilance Registry Results	
Number of Leads Enrolled in Study	1,698
Cumulative Months of Follow-Up	25,805
Number of Leads Active in Study	1,341

Product Surveilance Registry Qualifying Complications	3
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	3
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	11
Conductor Fracture	3
Extracardiac Stimulation	6
Failure To Capture	36
Failure To Sense	6
Impedance Abnormal	10
Insulation Breach	0
Lead Dislodgement	75
Oversensing	23
Unspecified	0

USA Returned Product Analysis	
Conductor Fracture	20
Crimp Weld Bond	0
Insulation Breach	2
Other	8

6947M, Survival Curve



Years	1	at 24 mo
%	99.9%	99.8%
#	1,103	273

DEFIBRILLATION LEAD 6948

Distribution Data	
US Market Release	9/2/2004
CE Approval Date	
Registered US Implants	10,379
Estimated Active US	4,218
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	True Bipolar/Two Coils

Product Surveilance Registry Results	
Number of Leads Enrolled in Study	37
Cumulative Months of Follow-Up	1,743
Number of Leads Active in Study	13

Product Surveilance Registry Qualifying Complications	4
Cardiac Perforation	0
Conductor Fracture	3
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	0
Failure To Sense	0
Impedance Abnormal	1
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	2
Extracardiac Stimulation	0
Failure To Capture	6
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach	0
Lead Dislodgement	7
Oversensing	1
Unspecified	3

USA Returned Product Analysis	
Conductor Fracture	175
Crimp Weld Bond	0
Insulation Breach	2
Other	2

6948, Survival Curve



Years	
%	
#	

DEFIBRILLATION LEAD 6949

Distribution Data	
US Market Release	9/2/2004
CE Approval Date	
Registered US Implants	186,784
Estimated Active US	65,386
Product Characteristics	
Fixation Type	Active Screw In
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	True Bipolar/Two Coils

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	923
Cumulative Months of Follow-Up	44,616
Number of Leads Active in Study	237

Product Surveillance Registry Qualifying Complications	95
Cardiac Perforation	0
Conductor Fracture	50
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	3
Failure To Sense	6
Impedance Abnormal	17
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	2
Lead Dislodgement	1
Medical Judgment	0
Other Complication	1
Oversensing	15
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	10
Conductor Fracture	45
Extracardiac Stimulation	0
Failure To Capture	31
Failure To Sense	19
Impedance Abnormal	17
Insulation Breach	6
Lead Dislodgement	22
Oversensing	30
Unspecified	25
USA Returned Product Analysis	
Conductor Fracture	7,077
Crimp Weld Bond	3
Insulation Breach	32
Other	70

6949, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	at 102 mo
%	98.5%	96.8%	93.6%	91.3%	88.8%	85.2%	82.2%	78.5%	78.5%
#	773	638	537	442	354	277	158	67	53

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

DEFIBRILLATION LEAD 6996

Distribution Data	
US Market Release	6/11/2001
CE Approval Date	12/19/1997
Registered US Implants	4,248
Estimated Active US	2,483

Product Characteristics	
Fixation Type	Suture on Anchor Sleeve
Lead Function	Defibrillation
Steroid Indicator	None
Lead Placement	Subcutaneous
Lead Tip Location	Defibrillation
Pace/Sense Polarity	One Coil

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	45
Cumulative Months of Follow-Up	1,420
Number of Leads Active in Study	16

Product Surveillance Registry Qualifying Complications	2
Cardiac Perforation	0
Conductor Fracture	1
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	0
Failure To Sense	0
Impedance Abnormal	1
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	0
Extracardiac Stimulation	0
Failure To Capture	1
Failure To Sense	0
Impedance Abnormal	5
Insulation Breach	0
Lead Dislodgement	1
Oversensing	0
Unspecified	0

USA Returned Product Analysis	
Conductor Fracture	25
Crimp Weld Bond	0
Insulation Breach	0
Other	0

6996, Survival Curve



Years	
%	
#	

PACING LEAD

Distribution Data	
US Market Release	8/3/2005
CE Approval Date	1/31/2003
Registered US Implants	23,886
Estimated Active US	17,729
Product Characteristics	
Fixation Type	Fixed Screw
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium or Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	856
Cumulative Months of Follow-Up	31,736
Number of Leads Active in Study	492

3830

Product Surveillance Registry Qualifying Complications	10
Cardiac Perforation	1
Conductor Fracture	1
Electrical Abandonment	0
Extracardiac Stimulation	1
Failure To Capture	2
Failure To Sense	1
Impedance Abnormal	2
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	2
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

ATRIAL PLACEMENT

US Acute Lead Observations	
Cardiac Perforation	7
Conductor Fracture	1
Extracardiac Stimulation	0
Failure To Capture	22
Failure To Sense	1
Impedance Abnormal	0
Insulation Breach	1
Lead Dislodgement	36
Oversensing	3
Unspecified	2
USA Returned Product Analysis	
Conductor Fracture	10
Crimp Weld Bond	0
Insulation Breach	22
Other	3

3830, ATR, Survival Curve



Years	1	2	3	4	5	6	at 78 mo
%	99.1%	99.0%	99.0%	99.0%	99.0%	99.0%	99.0%
#	719	607	462	199	100	57	51

PACING LEAD

3830

VENTRICULAR PLACEMENT

Distribution Data	
US Market Release	8/3/2005
CE Approval Date	1/31/2003
Registered US Implants	23,886
Estimated Active US	17,729
Product Characteristics	
Fixation Type	Fixed Screw
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium or Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	560
Cumulative Months of Follow-Up	20,713
Number of Leads Active in Study	319

Product Surveillance Registry Qualifying Complications	6
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	1
Failure To Sense	0
Impedance Abnormal	1
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	3
Medical Judgment	0
Other Complication	1
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	7
Conductor Fracture	1
Extracardiac Stimulation	0
Failure To Capture	22
Failure To Sense	1
Impedance Abnormal	0
Insulation Breach	1
Lead Dislodgement	36
Oversensing	3
Unspecified	2
USA Returned Product Analysis	
Conductor Fracture	10
Crimp Weld Bond	0
Insulation Breach	22
Other	3

3830, VEN, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	at 78 mo
%	99.1%	99.1%	99.1%	99.1%	99.1%	97.3%	97.3%
#	449	377	281	129	77	52	50

PACING LEAD

4024

Distribution Data	
US Market Release	10/1/1991
CE Approval Date	
Registered US Implants	218,566
Estimated Active US	37,917
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveilance Registry Results	
Number of Leads Enrolled in Study	1,219
Cumulative Months of Follow-Up	25,294
Number of Leads Active in Study	5

Product Surveilance Registry Qualifying Complications	4
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	3
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	1
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	13
Conductor Fracture	10
Extracardiac Stimulation	2
Failure To Capture	103
Failure To Sense	16
Impedance Abnormal	8
Insulation Breach	1
Lead Dislodgement	49
Oversensing	2
Unspecified	20
USA Returned Product Analysis	
Conductor Fracture	28
Crimp Weld Bond	0
Insulation Breach	203
Other	12

4024, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 114 mo
%	99.8%	99.6%	99.6%	99.6%	99.6%	99.6%	99.6%	99.6%	98.0%	98.0%
#	431	323	252	184	146	118	94	70	60	50

PACING LEAD

Distribution Data	
US Market Release	3/29/1996
CE Approval Date	
Registered US Implants	124,260
Estimated Active US	27,694
Product Characteristics	
Fixation Type	Active Screw In
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium or Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	2,429
Cumulative Months of Follow-Up	124,610
Number of Leads Active in Study	170

4068

Product Surveillance Registry Qualifying Complications	92
Cardiac Perforation	0
Conductor Fracture	4
Electrical Abandonment	0
Extracardiac Stimulation	3
Failure To Capture	23
Failure To Sense	15
Impedance Abnormal	12
Insulation Breach (ESC)	2
Insulation Breach (MIO)	2
Insulation Breach (not further defined)	2
Lead Dislodgement	8
Medical Judgment	0
Other Complication	0
Oversensing	18
Unspecified	3

ATRIAL PLACEMENT

US Acute Lead Observations	
Cardiac Perforation	5
Conductor Fracture	3
Extracardiac Stimulation	1
Failure To Capture	23
Failure To Sense	5
Impedance Abnormal	2
Insulation Breach	1
Lead Dislodgement	31
Oversensing	0
Unspecified	4
USA Returned Product Analysis	
Conductor Fracture	53
Crimp Weld Bond	0
Insulation Breach	207
Other	93

4068, ATR, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	11	12	13	14	at 180 mo
%	98.7%	98.3%	97.8%	97.5%	96.9%	96.6%	95.8%	94.2%	92.9%	91.9%	90.8%	89.4%	87.5%	85.5%	84.7%
#	1,606	1,396	1,197	1,018	873	737	586	486	401	341	281	210	148	99	58

PACING LEAD

4068

VENTRICULAR PLACEMENT

Distribution Data	
US Market Release	3/29/1996
CE Approval Date	
Registered US Implants	124,260
Estimated Active US	27,694
Product Characteristics	
Fixation Type	Active Screw In
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium or Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	1,806
Cumulative Months of Follow-Up	91,664
Number of Leads Active in Study	78

Product Surveillance Registry Qualifying Complications	69
Cardiac Perforation	0
Conductor Fracture	3
Electrical Abandonment	0
Extracardiac Stimulation	2
Failure To Capture	24
Failure To Sense	4
Impedance Abnormal	21
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	1
Lead Dislodgement	0
Medical Judgment	0
Other Complication	2
Oversensing	10
Unspecified	2

US Acute Lead Observations	
Cardiac Perforation	5
Conductor Fracture	3
Extracardiac Stimulation	1
Failure To Capture	23
Failure To Sense	5
Impedance Abnormal	2
Insulation Breach	1
Lead Dislodgement	31
Oversensing	0
Unspecified	4
USA Returned Product Analysis	
Conductor Fracture	53
Crimp Weld Bond	0
Insulation Breach	207
Other	93

4068, VEN, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	11	12	13	at 162 mo
%	99.2%	98.5%	98.5%	97.8%	97.4%	96.8%	95.2%	93.4%	90.2%	89.5%	88.0%	86.4%	86.4%	86.4%
#	1,289	1,110	964	802	666	532	421	330	262	196	129	86	60	52

PACING LEAD

Distribution Data	
US Market Release	6/23/2002
CE Approval Date	2/1/2002
Registered US Implants	100,394
Estimated Active US	61,976
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveilance Registry Results	
Number of Leads Enrolled in Study	214
Cumulative Months of Follow-Up	16,948
Number of Leads Active in Study	116

4074

Product Surveilance Registry Qualifying Complications	2
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	0
Failure To Sense	1
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	1
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

ATRIAL PLACEMENT

US Acute Lead Observations	
Cardiac Perforation	14
Conductor Fracture	1
Extracardiac Stimulation	1
Failure To Capture	42
Failure To Sense	1
Impedance Abnormal	3
Insulation Breach	0
Lead Dislodgement	45
Oversensing	1
Unspecified	0
USA Returned Product Analysis	
Conductor Fracture	5
Crimp Weld Bond	0
Insulation Breach	27
Other	0

4074, ATR, Survival Curve



Years	1	2	3	4	5	6	7	8	at 102 mo
%	99.1%	99.1%	99.1%	99.1%	99.1%	99.1%	99.1%	99.1%	99.1%
#	201	191	184	167	152	138	121	90	69

PACING LEAD

4074

VENTRICULAR PLACEMENT

Distribution Data	
US Market Release	6/23/2002
CE Approval Date	2/1/2002
Registered US Implants	100,394
Estimated Active US	61,976
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveilance Registry Results	
Number of Leads Enrolled in Study	1,081
Cumulative Months of Follow-Up	42,369
Number of Leads Active in Study	578

Product Surveilance Registry Qualifying Complications	7
Cardiac Perforation	0
Conductor Fracture	1
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	2
Failure To Sense	0
Impedance Abnormal	2
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	2
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	14
Conductor Fracture	1
Extracardiac Stimulation	1
Failure To Capture	42
Failure To Sense	1
Impedance Abnormal	3
Insulation Breach	0
Lead Dislodgement	45
Oversensing	1
Unspecified	0
USA Returned Product Analysis	
Conductor Fracture	5
Crimp Weld Bond	0
Insulation Breach	27
Other	0

4074, VEN, Survival Curve



Years	1	2	3	4	5	6	7	8	at 102 mo
%	99.6%	99.4%	99.3%	99.3%	99.3%	99.3%	98.8%	98.8%	98.8%
#	851	630	423	315	262	215	156	93	68

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

PACING LEAD

Distribution Data	
US Market Release	2/25/2004
CE Approval Date	6/14/2004
Registered US Implants	505,442
Estimated Active US	382,473
Product Characteristics	
Fixation Type	Active Screw In
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium or Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	2,502
Cumulative Months of Follow-Up	88,825
Number of Leads Active in Study	1,456

4076

Product Surveillance Registry Qualifying Complications	15
Cardiac Perforation	1
Conductor Fracture	1
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	2
Failure To Sense	3
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	1
Lead Dislodgement	6
Medical Judgment	0
Other Complication	0
Oversensing	1
Unspecified	0

ATRIAL PLACEMENT

US Acute Lead Observations	
Cardiac Perforation	73
Conductor Fracture	4
Extracardiac Stimulation	11
Failure To Capture	92
Failure To Sense	25
Impedance Abnormal	12
Insulation Breach	1
Lead Dislodgement	215
Oversensing	12
Unspecified	12
USA Returned Product Analysis	
Conductor Fracture	57
Crimp Weld Bond	1
Insulation Breach	56
Other	20

4076, ATR, Survival Curve



Years	1	2	3	4	5	6	7	at 90 mo
%	99.7%	99.6%	99.4%	99.3%	99.2%	98.9%	98.5%	98.5%
#	1,822	1,466	1,189	856	441	269	163	92

PACING LEAD

4076

VENTRICULAR PLACEMENT

Distribution Data	
US Market Release	2/25/2004
CE Approval Date	6/14/2004
Registered US Implants	505,442
Estimated Active US	382,473
Product Characteristics	
Fixation Type	Active Screw In
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium or Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	1,401
Cumulative Months of Follow-Up	61,043
Number of Leads Active in Study	632

Product Surveillance Registry Qualifying Complications	7
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	1
Failure To Capture	3
Failure To Sense	0
Impedance Abnormal	2
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	1
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	73
Conductor Fracture	4
Extracardiac Stimulation	11
Failure To Capture	92
Failure To Sense	25
Impedance Abnormal	12
Insulation Breach	1
Lead Dislodgement	215
Oversensing	12
Unspecified	12
USA Returned Product Analysis	
Conductor Fracture	57
Crimp Weld Bond	1
Insulation Breach	56
Other	20

4076, VEN, Survival Curve



Years	1	2	3	4	5	6	7	at 96 mo
%	99.8%	99.8%	99.8%	99.6%	99.3%	99.3%	98.8%	98.8%
#	1,116	955	824	650	379	253	144	61

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

PACING LEAD

4092

Distribution Data	
US Market Release	9/17/1998
CE Approval Date	4/15/1998
Registered US Implants	183,321
Estimated Active US	79,201
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveilance Registry Results	
Number of Leads Enrolled in Study	1,178
Cumulative Months of Follow-Up	66,279
Number of Leads Active in Study	39

Product Surveilance Registry Qualifying Complications	18
Cardiac Perforation	0
Conductor Fracture	3
Electrical Abandonment	0
Extracardiac Stimulation	1
Failure To Capture	9
Failure To Sense	0
Impedance Abnormal	1
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	4
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	3
Conductor Fracture	4
Extracardiac Stimulation	1
Failure To Capture	33
Failure To Sense	0
Impedance Abnormal	2
Insulation Breach	1
Lead Dislodgement	27
Oversensing	1
Unspecified	2
USA Returned Product Analysis	
Conductor Fracture	14
Crimp Weld Bond	0
Insulation Breach	58
Other	2

4092, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	at 132 mo
%	98.9%	98.8%	98.6%	98.3%	98.0%	97.8%	97.8%	97.8%	97.8%	97.8%	97.8%
#	918	812	724	621	507	394	322	259	210	129	61

PACING LEAD

4524

Distribution Data	
US Market Release	10/1/1991
CE Approval Date	
Registered US Implants	100,268
Estimated Active US	21,638
Product Characteristics	
Fixation Type	J-Shape, tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	918
Cumulative Months of Follow-Up	23,323
Number of Leads Active in Study	26

Product Surveillance Registry Qualifying Complications	6
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	3
Failure To Sense	2
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	1
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	2
Conductor Fracture	2
Extracardiac Stimulation	0
Failure To Capture	15
Failure To Sense	4
Impedance Abnormal	1
Insulation Breach	2
Lead Dislodgement	23
Oversensing	0
Unspecified	12
USA Returned Product Analysis	
Conductor Fracture	1
Crimp Weld Bond	0
Insulation Breach	79
Other	3

4524, Survival Curve



Years	1	2	3	4	5	6	7	8	9	10	11	at 138 mo
%	99.3%	98.6%	98.6%	98.1%	98.1%	98.1%	98.1%	98.1%	98.1%	98.1%	98.1%	98.1%
#	364	275	217	163	131	106	86	75	66	55	53	52

PACING LEAD

4558M

Distribution Data	
US Market Release	11/14/1994
CE Approval Date	
Registered US Implants	19,566
Estimated Active US	3,542
Product Characteristics	
Fixation Type	Active Screw In
Lead Function	Pacing/Sensing
Steroid Indicator	None
Lead Placement	Transvenous
Lead Tip Location	Atrium - J
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	540
Cumulative Months of Follow-Up	18,671
Number of Leads Active in Study	3

Product Surveillance Registry Qualifying Complications	12
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	1
Extracardiac Stimulation	0
Failure To Capture	3
Failure To Sense	2
Impedance Abnormal	2
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	2
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	2
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	2
Conductor Fracture	0
Extracardiac Stimulation	1
Failure To Capture	2
Failure To Sense	1
Impedance Abnormal	1
Insulation Breach	0
Lead Dislodgement	2
Oversensing	0
Unspecified	1
USA Returned Product Analysis	
Conductor Fracture	1
Crimp Weld Bond	0
Insulation Breach	24
Other	20

4558M, Survival Curve



Years	1	2	3	4	5	6	7	8	at 108 mo
%	99.1%	99.1%	99.1%	99.1%	99.1%	97.1%	95.9%	95.9%	91.1%
#	278	225	180	140	115	88	80	64	53

PACING LEAD

4568

Distribution Data	
US Market Release	1/2/1997
CE Approval Date	
Registered US Implants	69,208
Estimated Active US	19,145
Product Characteristics	
Fixation Type	J-shape, screw in
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	669
Cumulative Months of Follow-Up	31,663
Number of Leads Active in Study	15

Product Surveillance Registry Qualifying Complications	37
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	19
Failure To Sense	4
Impedance Abnormal	3
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	9
Medical Judgment	1
Other Complication	1
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	3
Conductor Fracture	1
Extracardiac Stimulation	0
Failure To Capture	6
Failure To Sense	1
Impedance Abnormal	2
Insulation Breach	0
Lead Dislodgement	4
Oversensing	1
Unspecified	1
USA Returned Product Analysis	
Conductor Fracture	7
Crimp Weld Bond	0
Insulation Breach	101
Other	52

4568, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	at 120 mo
%	96.6%	96.2%	95.0%	94.0%	93.3%	93.3%	91.4%	91.4%	90.4%	90.4%
#	487	415	326	276	226	171	137	105	83	62

PACING LEAD

4574

Distribution Data	
US Market Release	6/23/2002
CE Approval Date	2/1/2002
Registered US Implants	68,263
Estimated Active US	45,020
Product Characteristics	
Fixation Type	J-shape, tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	728
Cumulative Months of Follow-Up	13,890
Number of Leads Active in Study	515

Product Surveillance Registry Qualifying Complications	4
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	1
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	3
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	1
Extracardiac Stimulation	1
Failure To Capture	22
Failure To Sense	8
Impedance Abnormal	0
Insulation Breach	0
Lead Dislodgement	53
Oversensing	1
Unspecified	4
USA Returned Product Analysis	
Conductor Fracture	10
Crimp Weld Bond	0
Insulation Breach	6
Other	0

4574, Survival Curve



Years	1	2	3	at 42 mo
%	99.2%	99.2%	99.2%	99.2%
#	446	244	94	58

PACING LEAD

4592

Distribution Data	
US Market Release	10/5/1998
CE Approval Date	4/15/1998
Registered US Implants	88,084
Estimated Active US	39,708
Product Characteristics	
Fixation Type	J-shape, tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	324
Cumulative Months of Follow-Up	15,835
Number of Leads Active in Study	56

Product Surveillance Registry Qualifying Complications	7
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	4
Failure To Sense	1
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	2
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	0
Extracardiac Stimulation	0
Failure To Capture	8
Failure To Sense	2
Impedance Abnormal	0
Insulation Breach	1
Lead Dislodgement	31
Oversensing	2
Unspecified	2
USA Returned Product Analysis	
Conductor Fracture	7
Crimp Weld Bond	0
Insulation Breach	22
Other	1

4592, Survival Curve



Years	1	2	3	4	5	6	7	8	9	at 114 mo
%	97.5%	97.5%	97.5%	97.5%	96.7%	96.7%	96.7%	95.5%	95.5%	95.5%
#	199	171	151	138	111	100	81	71	61	51

PACING LEAD

5033

Distribution Data	
US Market Release	2/9/1996
CE Approval Date	
Registered US Implants	2,340
Estimated Active US	450
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	Unipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	1,901
Cumulative Months of Follow-Up	77,308
Number of Leads Active in Study	30

Product Surveillance Registry Qualifying Complications	32
Cardiac Perforation	1
Conductor Fracture	8
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	16
Failure To Sense	0
Impedance Abnormal	4
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	1
Lead Dislodgement	2
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	0
Extracardiac Stimulation	0
Failure To Capture	0
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach	0
Lead Dislodgement	0
Oversensing	0
Unspecified	1
USA Returned Product Analysis	
Conductor Fracture	1
Crimp Weld Bond	0
Insulation Breach	0
Other	3

5033, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	at 192 mo
%	99.5%	99.4%	98.7%	98.5%	98.2%	97.5%	96.9%	96.0%	95.0%	95.0%	94.6%	94.1%	92.9%	91.5%	91.5%	91.5%
#	902	761	672	584	510	436	379	326	276	236	197	169	146	119	101	63

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

PACING LEAD

Distribution Data	
US Market Release	2/9/1996
CE Approval Date	
Registered US Implants	55,426
Estimated Active US	11,492
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveilance Registry Results	
Number of Leads Enrolled in Study	386
Cumulative Months of Follow-Up	46,774
Number of Leads Active in Study	83

5034

Product Surveilance Registry Qualifying Complications	6
Cardiac Perforation	0
Conductor Fracture	1
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	2
Failure To Sense	1
Impedance Abnormal	1
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	0
Medical Judgment	0
Other Complication	1
Oversensing	0
Unspecified	0

ATRIAL PLACEMENT

US Acute Lead Observations	
Cardiac Perforation	2
Conductor Fracture	2
Extracardiac Stimulation	0
Failure To Capture	28
Failure To Sense	3
Impedance Abnormal	0
Insulation Breach	3
Lead Dislodgement	14
Oversensing	0
Unspecified	12
USA Returned Product Analysis	
Conductor Fracture	16
Crimp Weld Bond	0
Insulation Breach	15
Other	7

5034, ATR, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	11	12	13	14	at 174 mo
%	99.5%	99.5%	99.5%	99.5%	99.5%	99.5%	98.8%	98.8%	98.8%	98.8%	98.8%	98.2%	97.4%	97.4%	97.4%
#	383	382	379	376	358	334	297	253	212	187	156	136	114	76	57

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

PACING LEAD

5034

VENTRICULAR PLACEMENT

Distribution Data	
US Market Release	2/9/1996
CE Approval Date	
Registered US Implants	55,426
Estimated Active US	11,492
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	1,213
Cumulative Months of Follow-Up	28,115
Number of Leads Active in Study	8

Product Surveillance Registry Qualifying Complications	11
Cardiac Perforation	0
Conductor Fracture	1
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	7
Failure To Sense	2
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	1
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	2
Conductor Fracture	2
Extracardiac Stimulation	0
Failure To Capture	28
Failure To Sense	3
Impedance Abnormal	0
Insulation Breach	3
Lead Dislodgement	14
Oversensing	0
Unspecified	12
USA Returned Product Analysis	
Conductor Fracture	16
Crimp Weld Bond	0
Insulation Breach	15
Other	7

5034, VEN, Survival Curve



Years	1	2	3	4	5	6	7	at 90 mo
%	99.5%	98.9%	98.4%	98.0%	98.0%	98.0%	96.9%	96.9%
#	517	415	307	221	155	96	61	57

PACING LEAD

Distribution Data	
US Market Release	6/3/1998
CE Approval Date	6/5/1997
Registered US Implants	98,325
Estimated Active US	40,420
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	424
Cumulative Months of Follow-Up	35,785
Number of Leads Active in Study	94

5054

Product Surveillance Registry Qualifying Complications	2
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	1
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	1
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

ATRIAL PLACEMENT

US Acute Lead Observations	
Cardiac Perforation	2
Conductor Fracture	1
Extracardiac Stimulation	0
Failure To Capture	23
Failure To Sense	0
Impedance Abnormal	2
Insulation Breach	1
Lead Dislodgement	27
Oversensing	0
Unspecified	9
USA Returned Product Analysis	
Conductor Fracture	12
Crimp Weld Bond	1
Insulation Breach	31
Other	3

5054, ATR, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	11	at 138 mo
%	99.5%	99.5%	99.5%	99.5%	99.5%	99.5%	99.5%	99.5%	99.5%	99.5%	99.5%	99.5%
#	410	390	357	321	288	251	218	184	148	100	70	50

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

PACING LEAD

5054

VENTRICULAR PLACEMENT

Distribution Data	
US Market Release	6/3/1998
CE Approval Date	6/5/1997
Registered US Implants	98,325
Estimated Active US	40,420
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	982
Cumulative Months of Follow-Up	31,734
Number of Leads Active in Study	57

Product Surveillance Registry Qualifying Complications	9
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	6
Failure To Sense	1
Impedance Abnormal	1
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	1
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	2
Conductor Fracture	1
Extracardiac Stimulation	0
Failure To Capture	23
Failure To Sense	0
Impedance Abnormal	2
Insulation Breach	1
Lead Dislodgement	27
Oversensing	0
Unspecified	9
USA Returned Product Analysis	
Conductor Fracture	12
Crimp Weld Bond	1
Insulation Breach	31
Other	3

5054, VEN, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	at 126 mo
%	99.3%	99.1%	99.1%	98.7%	98.7%	97.3%	97.3%	97.3%	97.3%	97.3%	97.3%
#	474	387	301	260	226	188	163	135	95	67	57

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

PACING LEAD

5068

ATRIAL PLACEMENT

Distribution Data	
US Market Release	1/2/1997
CE Approval Date	
Registered US Implants	102,406
Estimated Active US	27,024
Product Characteristics	
Fixation Type	Active Screw-in
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium or Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	979
Cumulative Months of Follow-Up	26,896
Number of Leads Active in Study	28

Product Surveillance Registry Qualifying Complications	7
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	2
Failure To Sense	0
Impedance Abnormal	1
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	1
Lead Dislodgement	2
Medical Judgment	0
Other Complication	0
Oversensing	1
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	18
Conductor Fracture	4
Extracardiac Stimulation	0
Failure To Capture	31
Failure To Sense	5
Impedance Abnormal	1
Insulation Breach	1
Lead Dislodgement	20
Oversensing	1
Unspecified	7
USA Returned Product Analysis	
Conductor Fracture	42
Crimp Weld Bond	2
Insulation Breach	59
Other	83

5068, ATR, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	at 126 mo
%	99.3%	99.3%	98.9%	98.9%	98.9%	98.9%	98.9%	97.1%	97.1%	97.1%	97.1%
#	354	303	258	226	193	155	128	100	68	58	50

PACING LEAD

5068

VENTRICULAR PLACEMENT

Distribution Data	
US Market Release	1/2/1997
CE Approval Date	
Registered US Implants	102,406
Estimated Active US	27,024
Product Characteristics	
Fixation Type	Active Screw-in
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium or Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveilance Registry Results	
Number of Leads Enrolled in Study	1,371
Cumulative Months of Follow-Up	31,774
Number of Leads Active in Study	44

Product Surveilance Registry Qualifying Complications	9
Cardiac Perforation	0
Conductor Fracture	1
Electrical Abandonment	0
Extracardiac Stimulation	1
Failure To Capture	2
Failure To Sense	0
Impedance Abnormal	1
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	2
Lead Dislodgement	1
Medical Judgment	0
Other Complication	0
Oversensing	1
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	18
Conductor Fracture	4
Extracardiac Stimulation	0
Failure To Capture	31
Failure To Sense	5
Impedance Abnormal	1
Insulation Breach	1
Lead Dislodgement	20
Oversensing	1
Unspecified	7
USA Returned Product Analysis	
Conductor Fracture	42
Crimp Weld Bond	2
Insulation Breach	59
Other	83

5068, VEN, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	at 132 mo
%	99.8%	99.6%	99.2%	98.9%	98.9%	98.9%	98.2%	96.9%	96.9%	96.9%	96.9%
#	449	359	291	246	223	189	151	125	103	83	63

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

PACING LEAD

5072

Distribution Data	
US Market Release	6/5/1998
CE Approval Date	9/25/1997
Registered US Implants	10,054
Estimated Active US	3,807
Product Characteristics	
Fixation Type	Fixed Screw
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium or Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	514
Cumulative Months of Follow-Up	22,872
Number of Leads Active in Study	15

Product Surveillance Registry Qualifying Complications	3
Cardiac Perforation	1
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	1
Failure To Sense	1
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	0
Extracardiac Stimulation	0
Failure To Capture	2
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach	0
Lead Dislodgement	2
Oversensing	0
Unspecified	0

USA Returned Product Analysis	
Conductor Fracture	3
Crimp Weld Bond	0
Insulation Breach	9
Other	0

5072, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	11	at 144 mo
%	99.7%	99.7%	99.2%	99.2%	99.2%	99.2%	99.2%	99.2%	98.1%	98.1%	98.1%	98.1%
#	261	232	216	191	157	136	109	93	83	73	63	52

PACING LEAD

5076

ATRIAL PLACEMENT

Distribution Data	
US Market Release	8/31/2000
CE Approval Date	8/12/1999
Registered US Implants	1,720,845
Estimated Active US	1,089,008
Product Characteristics	
Fixation Type	Active Screw-in
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium or Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	5,039
Cumulative Months of Follow-Up	182,831
Number of Leads Active in Study	2,490

Product Surveillance Registry Qualifying Complications	30
Cardiac Perforation	1
Conductor Fracture	5
Electrical Abandonment	0
Extracardiac Stimulation	2
Failure To Capture	6
Failure To Sense	2
Impedance Abnormal	4
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	1
Lead Dislodgement	6
Medical Judgment	0
Other Complication	2
Oversensing	1
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	268
Conductor Fracture	15
Extracardiac Stimulation	21
Failure To Capture	331
Failure To Sense	54
Impedance Abnormal	20
Insulation Breach	8
Lead Dislodgement	799
Oversensing	47
Unspecified	31
USA Returned Product Analysis	
Conductor Fracture	570
Crimp Weld Bond	0
Insulation Breach	577
Other	195

5076, ATR, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	11	at 144 mo
%	99.7%	99.6%	99.4%	99.1%	98.8%	98.7%	98.7%	98.6%	98.6%	98.3%	98.3%	98.3%
#	3,150	2,249	1,849	1,480	1,177	976	828	638	429	257	136	54

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

PACING LEAD

5076

VENTRICULAR PLACEMENT

Distribution Data	
US Market Release	8/31/2000
CE Approval Date	8/12/1999
Registered US Implants	1,720,845
Estimated Active US	1,089,008
Product Characteristics	
Fixation Type	Active Screw-in
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium or Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveilance Registry Results	
Number of Leads Enrolled in Study	2,133
Cumulative Months of Follow-Up	76,607
Number of Leads Active in Study	694

Product Surveilance Registry Qualifying Complications	23
Cardiac Perforation	1
Conductor Fracture	4
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	9
Failure To Sense	1
Impedance Abnormal	4
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	3
Medical Judgment	0
Other Complication	1
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	268
Conductor Fracture	15
Extracardiac Stimulation	21
Failure To Capture	331
Failure To Sense	54
Impedance Abnormal	20
Insulation Breach	8
Lead Dislodgement	799
Oversensing	47
Unspecified	31
USA Returned Product Analysis	
Conductor Fracture	570
Crimp Weld Bond	0
Insulation Breach	577
Other	195

5076, VEN, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	11	at 138 mo
%	99.4%	99.2%	99.1%	98.8%	98.8%	98.3%	98.1%	97.5%	96.8%	96.8%	95.9%	95.9%
#	1,300	913	749	592	491	415	349	274	198	134	81	63

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

PACING LEAD

Distribution Data	
US Market Release	2/8/2011
CE Approval Date	1/21/2009
Registered US Implants	206,227
Estimated Active US	196,468
Product Characteristics	
Fixation Type	Active Screw In
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium or Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	2,961
Cumulative Months of Follow-Up	59,890
Number of Leads Active in Study	2,230

5086MRI

Product Surveillance Registry Qualifying Complications	5
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	1
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	4
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

ATRIAL PLACEMENT

US Acute Lead Observations	
Cardiac Perforation	208
Conductor Fracture	2
Extracardiac Stimulation	17
Failure To Capture	137
Failure To Sense	27
Impedance Abnormal	9
Insulation Breach	1
Lead Dislodgement	297
Oversensing	29
Unspecified	0
USA Returned Product Analysis	
Conductor Fracture	13
Crimp Weld Bond	0
Insulation Breach	35
Other	10

5086MRI, ATR, Survival Curve



Years	1	2	at 36 mo
%	99.9%	99.8%	99.8%
#	2,226	1,238	122

PACING LEAD

Distribution Data	
US Market Release	2/8/2011
CE Approval Date	1/21/2009
Registered US Implants	206,227
Estimated Active US	196,468
Product Characteristics	
Fixation Type	Active Screw In
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium or Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveilance Registry Results	
Number of Leads Enrolled in Study	2,950
Cumulative Months of Follow-Up	59,779
Number of Leads Active in Study	2,222

5086MRI

Product Surveilance Registry Qualifying Complications	7
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	2
Failure To Sense	1
Impedance Abnormal	1
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	3
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

VENTRICULAR PLACEMENT

US Acute Lead Observations	
Cardiac Perforation	208
Conductor Fracture	2
Extracardiac Stimulation	17
Failure To Capture	137
Failure To Sense	27
Impedance Abnormal	9
Insulation Breach	1
Lead Dislodgement	297
Oversensing	29
Unspecified	0
USA Returned Product Analysis	
Conductor Fracture	13
Crimp Weld Bond	0
Insulation Breach	35
Other	10

5086MRI, VEN, Survival Curve



Years	1	2	at 36 mo
%	99.8%	99.8%	99.4%
#	2,217	1,243	118

PACING LEAD

5092

Distribution Data	
US Market Release	6/3/1998
CE Approval Date	9/25/1997
Registered US Implants	138,380
Estimated Active US	61,159
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	1,195
Cumulative Months of Follow-Up	49,529
Number of Leads Active in Study	101

Product Surveillance Registry Qualifying Complications	10
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	1
Failure To Capture	3
Failure To Sense	0
Impedance Abnormal	1
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	5
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	6
Conductor Fracture	2
Extracardiac Stimulation	3
Failure To Capture	43
Failure To Sense	7
Impedance Abnormal	1
Insulation Breach	3
Lead Dislodgement	62
Oversensing	1
Unspecified	9
USA Returned Product Analysis	
Conductor Fracture	14
Crimp Weld Bond	0
Insulation Breach	43
Other	3

5092, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	11	at 138 mo
%	99.5%	99.3%	99.1%	98.9%	98.9%	98.5%	98.5%	98.5%	98.5%	98.5%	97.5%	97.5%
#	810	643	505	406	321	252	206	157	122	97	70	58

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

PACING LEAD

5534

Distribution Data	
US Market Release	2/9/1996
CE Approval Date	
Registered US Implants	25,846
Estimated Active US	6,322
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium - J
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	267
Cumulative Months of Follow-Up	9,609
Number of Leads Active in Study	3

Product Surveillance Registry Qualifying Complications	6
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	5
Failure To Sense	0
Impedance Abnormal	1
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	0
Extracardiac Stimulation	1
Failure To Capture	3
Failure To Sense	1
Impedance Abnormal	0
Insulation Breach	0
Lead Dislodgement	6
Oversensing	0
Unspecified	4
USA Returned Product Analysis	
Conductor Fracture	7
Crimp Weld Bond	0
Insulation Breach	5
Other	4

5534, Survival Curve



Years	1	2	3	4	at 60 mo
%	97.7%	96.9%	96.9%	95.9%	95.9%
#	148	126	98	79	55

PACING LEAD

5554

Distribution Data	
US Market Release	6/3/1998
CE Approval Date	6/5/1997
Registered US Implants	63,584
Estimated Active US	28,307
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium - J
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	355
Cumulative Months of Follow-Up	8,287
Number of Leads Active in Study	10

Product Surveillance Registry Qualifying Complications	5
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	2
Failure To Sense	0
Impedance Abnormal	1
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	1
Medical Judgment	0
Other Complication	0
Oversensing	1
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	1
Extracardiac Stimulation	0
Failure To Capture	30
Failure To Sense	2
Impedance Abnormal	1
Insulation Breach	0
Lead Dislodgement	36
Oversensing	0
Unspecified	3
USA Returned Product Analysis	
Conductor Fracture	11
Crimp Weld Bond	0
Insulation Breach	26
Other	2

5554, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	at 72 mo
%	100.0%	98.2%	97.2%	96.0%	96.0%	96.0%
#	146	107	82	74	59	50

PACING LEAD

5568

Distribution Data	
US Market Release	1/2/1997
CE Approval Date	8/14/1996
Registered US Implants	95,421
Estimated Active US	50,832
Product Characteristics	
Fixation Type	Active Screw-in
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium - J
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	1,129
Cumulative Months of Follow-Up	35,649
Number of Leads Active in Study	122

Product Surveillance Registry Qualifying Complications	17
Cardiac Perforation	0
Conductor Fracture	1
Electrical Abandonment	0
Extracardiac Stimulation	1
Failure To Capture	6
Failure To Sense	3
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	2
Medical Judgment	0
Other Complication	0
Oversensing	4
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	14
Conductor Fracture	0
Extracardiac Stimulation	2
Failure To Capture	23
Failure To Sense	2
Impedance Abnormal	2
Insulation Breach	1
Lead Dislodgement	40
Oversensing	3
Unspecified	4
USA Returned Product Analysis	
Conductor Fracture	17
Crimp Weld Bond	0
Insulation Breach	42
Other	37

5568, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	11	at 138 mo
%	99.4%	98.7%	98.7%	98.7%	97.9%	97.0%	97.0%	95.7%	95.7%	95.7%	95.7%	94.2%
#	533	431	363	293	233	189	147	124	103	80	62	52

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

PACING LEAD

5592

Distribution Data	
US Market Release	6/3/1998
CE Approval Date	9/25/1997
Registered US Implants	36,220
Estimated Active US	19,077
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium - J
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	696
Cumulative Months of Follow-Up	32,944
Number of Leads Active in Study	116

Product Surveillance Registry Qualifying Complications	5
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	3
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	2
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	1
Conductor Fracture	0
Extracardiac Stimulation	0
Failure To Capture	4
Failure To Sense	2
Impedance Abnormal	0
Insulation Breach	0
Lead Dislodgement	35
Oversensing	1
Unspecified	1
USA Returned Product Analysis	
Conductor Fracture	4
Crimp Weld Bond	0
Insulation Breach	4
Other	0

5592, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	at 126 mo
%	99.6%	99.2%	99.2%	98.9%	98.9%	98.9%	98.9%	98.9%	98.9%	98.9%	98.9%
#	515	426	340	284	228	172	141	115	88	66	53

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

PACING LEAD

5594

Distribution Data	
US Market Release	6/25/2001
CE Approval Date	3/23/2001
Registered US Implants	17,009
Estimated Active US	10,648
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium - J
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	23
Cumulative Months of Follow-Up	1,635
Number of Leads Active in Study	9

Product Surveillance Registry Qualifying Complications	0
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	0
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	0
Extracardiac Stimulation	0
Failure To Capture	1
Failure To Sense	0
Impedance Abnormal	0
Insulation Breach	0
Lead Dislodgement	12
Oversensing	0
Unspecified	2
USA Returned Product Analysis	
Conductor Fracture	9
Crimp Weld Bond	0
Insulation Breach	10
Other	1

5594, Survival Curve



Years	
%	
#	

PACING LEAD

6940

Distribution Data	
US Market Release	10/9/1998
CE Approval Date	
Registered US Implants	25,385
Estimated Active US	6,642
Product Characteristics	
Fixation Type	Active Screw-in
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Atrium - J
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	841
Cumulative Months of Follow-Up	42,929
Number of Leads Active in Study	48

Product Surveillance Registry Qualifying Complications	14
Cardiac Perforation	0
Conductor Fracture	1
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	1
Failure To Sense	3
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	3
Medical Judgment	0
Other Complication	0
Oversensing	6
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	1
Extracardiac Stimulation	0
Failure To Capture	1
Failure To Sense	0
Impedance Abnormal	1
Insulation Breach	0
Lead Dislodgement	6
Oversensing	0
Unspecified	0

USA Returned Product Analysis	
Conductor Fracture	13
Crimp Weld Bond	0
Insulation Breach	20
Other	12

6940, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	11	12	at 150 mo
%	99.7%	99.5%	98.2%	98.0%	98.0%	98.0%	98.0%	98.0%	98.0%	98.0%	94.7%	93.5%	93.5%
#	635	510	421	346	278	218	189	153	126	96	80	69	59

EPI MYOCARDIAL LEAD 4965

Distribution Data	
US Market Release	9/6/1996
CE Approval Date	1/1/1993
Registered US Implants	21,855
Estimated Active US	9,290
Product Characteristics	
Fixation Type	Suture
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Myocardial
Lead Tip Location	Atrium or Right Ventricle
Pace/Sense Polarity	Unipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	228
Cumulative Months of Follow-Up	6,718
Number of Leads Active in Study	11

Product Surveillance Registry Qualifying Complications	13
Cardiac Perforation	0
Conductor Fracture	6
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	3
Failure To Sense	1
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	1
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	2
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	1
Extracardiac Stimulation	0
Failure To Capture	4
Failure To Sense	5
Impedance Abnormal	6
Insulation Breach	0
Lead Dislodgement	0
Oversensing	1
Unspecified	3
USA Returned Product Analysis	
Conductor Fracture	199
Crimp Weld Bond	1
Insulation Breach	41
Other	0

4965, Survival Curve



Years	1	2	3	at 48 mo
%	98.6%	97.6%	96.5%	90.0%
#	125	104	84	61

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

EPI MYOCARDIAL LEAD 4968

Distribution Data	
US Market Release	9/16/1999
CE Approval Date	4/21/1998
Registered US Implants	33,661
Estimated Active US	20,822
Product Characteristics	
Fixation Type	Suture
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Myocardial
Lead Tip Location	Atrium or Right Ventricle
Pace/Sense Polarity	Bipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	864
Cumulative Months of Follow-Up	43,771
Number of Leads Active in Study	297

Product Surveillance Registry Qualifying Complications	61
Cardiac Perforation	0
Conductor Fracture	14
Electrical Abandonment	0
Extracardiac Stimulation	2
Failure To Capture	20
Failure To Sense	3
Impedance Abnormal	4
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	3
Lead Dislodgement	0
Medical Judgment	0
Other Complication	2
Oversensing	13
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	2
Extracardiac Stimulation	1
Failure To Capture	22
Failure To Sense	1
Impedance Abnormal	3
Insulation Breach	1
Lead Dislodgement	4
Oversensing	4
Unspecified	0
USA Returned Product Analysis	
Conductor Fracture	46
Crimp Weld Bond	0
Insulation Breach	28
Other	1

4968, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	7	8	9	10	at 126 mo
%	99.5%	97.5%	96.1%	94.0%	92.6%	90.8%	89.2%	89.2%	86.1%	84.9%	84.9%
#	679	588	501	382	305	234	181	131	82	59	50

Cutoff date for Study data is 31 January 2015
all other data is as of 9 February 2015

EPI MYOCARDIAL LEAD 5071

Distribution Data	
US Market Release	12/3/1992
CE Approval Date	1/1/1993
Registered US Implants	47,810
Estimated Active US	16,066
Product Characteristics	
Fixation Type	Fixed Screw In
Lead Function	Pacing/Sensing
Steroid Indicator	None
Lead Placement	Myocardial
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	Unipolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	365
Cumulative Months of Follow-Up	7,649
Number of Leads Active in Study	92

Product Surveillance Registry Qualifying Complications	18
Cardiac Perforation	0
Conductor Fracture	1
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	14
Failure To Sense	0
Impedance Abnormal	1
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	2
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	1
Conductor Fracture	0
Extracardiac Stimulation	5
Failure To Capture	44
Failure To Sense	2
Impedance Abnormal	2
Insulation Breach	0
Lead Dislodgement	0
Oversensing	0
Unspecified	1
USA Returned Product Analysis	
Conductor Fracture	15
Crimp Weld Bond	0
Insulation Breach	2
Other	0

5071, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	at 48 mo
%	96.5%	93.2%	90.6%	90.6%
#	146	99	71	55

VDD SINGLE PASS LEAD 5032

Distribution Data	
US Market Release	3/22/1996
CE Approval Date	
Registered US Implants	5,218
Estimated Active US	1,093
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	Quadripolar

Product Surveilance Registry Results	
Number of Leads Enrolled in Study	38
Cumulative Months of Follow-Up	287
Number of Leads Active in Study	0

Product Surveilance Registry Qualifying Complications	1
Cardiac Perforation	0
Conductor Fracture	0
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	0
Failure To Sense	1
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	0
Extracardiac Stimulation	0
Failure To Capture	1
Failure To Sense	1
Impedance Abnormal	0
Insulation Breach	0
Lead Dislodgement	1
Oversensing	0
Unspecified	1
USA Returned Product Analysis	
Conductor Fracture	7
Crimp Weld Bond	0
Insulation Breach	6
Other	0

5032, Survival Curve



Years	
%	
#	

VDD SINGLE PASS LEAD 5038

Distribution Data	
US Market Release	9/10/1998
CE Approval Date	4/15/1997
Registered US Implants	9,154
Estimated Active US	3,448
Product Characteristics	
Fixation Type	Tines
Lead Function	Pacing/Sensing
Steroid Indicator	Yes
Lead Placement	Transvenous
Lead Tip Location	Right Ventricle
Pace/Sense Polarity	Quadripolar

Product Surveillance Registry Results	
Number of Leads Enrolled in Study	567
Cumulative Months of Follow-Up	15,624
Number of Leads Active in Study	6

Product Surveillance Registry Qualifying Complications	7
Cardiac Perforation	0
Conductor Fracture	3
Electrical Abandonment	0
Extracardiac Stimulation	0
Failure To Capture	1
Failure To Sense	3
Impedance Abnormal	0
Insulation Breach (ESC)	0
Insulation Breach (MIO)	0
Insulation Breach (not further defined)	0
Lead Dislodgement	0
Medical Judgment	0
Other Complication	0
Oversensing	0
Unspecified	0

US Acute Lead Observations	
Cardiac Perforation	0
Conductor Fracture	0
Extracardiac Stimulation	1
Failure To Capture	1
Failure To Sense	2
Impedance Abnormal	0
Insulation Breach	0
Lead Dislodgement	3
Oversensing	0
Unspecified	0
USA Returned Product Analysis	
Conductor Fracture	4
Crimp Weld Bond	0
Insulation Breach	1
Other	0

5038, Survival Curve



Graph Name

Cumulative Survival Probability Graph Lower 95 Pct Confidence Graph Upper 95 Pct Confidence Graph

Years	1	2	3	4	5	6	at 84 mo
%	99.7%	99.7%	99.7%	98.2%	97.4%	97.4%	94.4%
#	289	219	161	130	106	77	55

ICD and CRT-D Charge Time Performance

Medtronic continues its commitment to providing updated information on charge time performance.

Introduction

Information on charge time performance of Medtronic products is presented in this section of the CRHF Product Performance Report. Medtronic implemented the collection of charge time data on July 1, 1999. The data are collected via our ongoing active clinical study of long-term system performance called the Product Surveillance Registry. The study protocol requests device data be routinely taken and sent to Medtronic at no more than 6-month intervals.

In our analysis performed for this report, only charge times resulting from full energy charges are considered. To ensure consistent reporting across devices, the charge time reported at implant represents the last charge time available from date of implant. When more than one charge time is available in a 6-month interval, a conservative approach has been adopted whereby only the maximum charge time in each 6-month interval is reported. As charge time is directly proportional to the time elapsed since the last capacitor reformation, charges occurring within 15 days of a previous charge are excluded. This precludes the reporting of overly optimistic results.

Data from over 20,000 devices contribute to the charge time data in this report. By tracking and reporting this charge time data, Medtronic is able to ascertain the actual performance of its charging circuitry. The insight gained through this information is applied to Medtronic's ongoing efforts to provide charge times that are short and consistent over the life of the product.

Charge time data for ICD and CRT-D models are presented using boxplots at 6-month intervals. The shaded box on the plots represents the middle half of the data – the Interquartile Range (IQR). The white line in the middle of each box is the median charge time. The top of the box representing the IQR is the third quartile or the 75th percentile (i.e., 75% of all charge times fall below this line), whereas the bottom of the box represents the first quartile or the 25th percentile. Vertical lines are drawn from the quartiles to the farthest value not more than 1.5 times the interquartile range. Any values more extreme than the vertical lines are considered outliers.

7230 Charge Time

Model Number	Brand
7230B	Marquis VR
7230Cx	Marquis VR
7230E	Marquis VR



7231 Charge Time

Model Number	Brand
7231Cx	GEM III VR



7232 Charge Time

Model Number	Brand
7232B	Maximo VR
7232Cx	Maximo VR
7232E	Maximo VR



7274 Charge Time

Model Number	Brand
7274	Marquis DR



7278 Charge Time

Model Number	Brand
7278	Maximo DR



7285, 7295 Charge Time

Model Number	Brand
7285	InSync III Protect
7295	InSync II Protect



7288 Charge Time

Model Number	Brand
7288	Intrinsic



7299 Charge Time

Model Number	Brand
7299	InSync Sentry



7304 Charge Time

Model Number	Brand
7304	InSync Maximo



BLACKWELL, CRT-D Charge Time

Model Number	Brand
DTBA1D1	Viva XT
DTBA1D4	Viva XT
DTBA1Q1	Viva Quad XT
DTBA1QQ	Viva Quad XT
DTBA2D1	Viva XT
DTBA2D4	Viva XT
DTBA2Q1	Viva Quad XT
DTBA2QQ	Viva Quad XT
DTBB1D1	Viva S
DTBB1D4	Viva S
DTBB1Q1	Viva Quad S
DTBB1QQ	Viva Quad S
DTBB2D1	Viva S
DTBB2D4	Viva S
DTBB2QQ	Viva Quad S
DTBC2D1	Brava
DTBC2D4	Brava
DTBC2Q1	Brava Quad
DTBC2QQ	Brava Quad



C154DWK, C164AWK, C174AWK Charge Time

Model Number	Brand
C154DWK	Concerto CRT-D
C164AWK	Concerto CRT-D
C174AWK	Concerto CRT-D



D144DRG, D154ATG, D154DRG Charge Time

Model Number	Brand
D144DRG	Entrust Escudo
D154ATG	Entrust AT
D154DRG	Entrust DR



D144VRC, D154VRC Charge Time

Model Number	Brand
D144VRC	Entrust Escudo
D154VRC	Entrust VR



D154AWG, D164AWG Charge Time

Model Number	Brand
D154AWG	Virtuoso DR
D164AWG	Virtuoso DR



D154VWC, D164VWC Charge Time

Model Number	Brand
D154VWC	Virtuoso VR
D164VWC	Virtuoso VR



D204DRM, D214DRM, D224DRG, D234DRG Charge Time

Model Number	Brand
D204DRM	Secura DR
D214DRM	Secura DR
D224DRG	Secura DR
D234DRG	Secura DR



D204TRM, D214TRM, D224TRK, D234TRK Charge Time

Model Number	Brand
D204TRM	Consulta CRT-D
D214TRM	Consulta CRT-D
D224TRK	Consulta CRT-D
D234TRK	Consulta CRT-D



D204VRM, D214VRM, D224VRC, D234VRC Charge Time

Model Number	Brand
D204VRM	Secura VR
D214VRM	Secura VR
D224VRC	Secura VR
D234VRC	Secura VR



D264DRG, D284DRG, D384DRx, D394DRx Charge Time

Model Number	Brand
D264DRM	Maximo II DR
D284DRG	Maximo II DR
D384DRG	Cardia DR
D394DRG	Egida DR



D264TRM, D284TRK, D384TRx, D394TRx Charge Time

Model Number	Brand
D264TRM	Maximo II CRT-D
D284TRK	Maximo II CRT-D
D384TRG	Cardia CRT-D
D394TRG	Egida CRT-D



D264VRM, D284VRC, D384VRx, D394VRx Charge Time

Model Number	Brand
D264VRM	Maximo II VR
D284VRC	Maximo II VR
D384VRG	Cardia VR
D394VRG	Egida VR



D274DRG, D294DRG Charge Time

Model Number	Brand
D274DRG	Virtuoso II DR
D294DRG	Virtuoso II DR



D274TRK, D294TRK Charge Time

Model Number	Brand
D274TRK	Concerto II CRT-D
D294TRK	Concerto II CRT-D



D274VRC, D294VRC Charge Time

Model Number	Brand
D274VRC	Virtuoso II VR
D294VRC	Virtuoso II VR



D314DRx Charge Time

Model Number	Brand
D314DRG	Protecta XT DR
D314DRM	Protecta XT DR



D314TRx Charge Time

Model Number	Brand
D314TRG	Protecta XT CRT-D
D314TRM	Protecta XT CRT-D



D314VRx Charge Time

Model Number	Brand
D314VRG	Protecta XT VR
D314VRM	Protecta XT VR



D334DRx, D364DRx Charge Time

Model Number	Brand
D334DRG	Protecta DR
D334DRM	Protecta DR
D364DRG	Protecta DR
D364DRM	Protecta DR



D334TRx, D364TRx Charge Time

Model Number	Brand
D334TRG	Protecta CRT-D
D334TRM	Protecta CRT-D
D364TRG	Protecta CRT-D
D364TRM	Protecta CRT-D



D334VRx, D364VRx Charge Time

Model Number	Brand
D334VRG	Protecta VR
D334VRM	Protecta VR
D364VRG	Protecta VR
D364VRM	Protecta VR



D354DRx Charge Time

Model Number	Brand
D354DRG	Protecta XT DR
D354DRM	Protecta XT DR



D354TRx Charge Time

Model Number	Brand
D354TRG	Protecta XT CRT-D
D354TRM	Protecta XT CRT-D



D354VRx Charge Time

Model Number	Brand
D354VRG	Protecta XT VR
D354VRM	Protecta XT VR



Advisories

Potential Loss Of Device Hermeticity

Consulta® CRT-P and Syncra® CRT-P
Original Date of Advisory: June 2013

Product

Consulta® CRT-P and Syncra® CRT-P. Go to http://wwwp.medtronic.com/productperformance/ to determine if a specific device is affected.

Advisory

Medtronic has identified an issue with a connector bracket weld on a subset of Consulta CRT-P models and Syncra CRT-P devices manufactured between April 1 and May 13, 2013. This type of connector bracket weld is unique to Consulta and Syncra CRT-P devices and no other Medtronic device models are affected.

An out-of-specification weld could result in a loss of device hermeticity and compromised device functionality. **There have been no reported or confirmed device failures or patient injuries.** Medtronic estimates the rate of out-of-specification welds to be 1-2% in this subset of devices.

Non-implanted devices from this subset have been recalled to Medtronic for re-inspection with additional controls to ensure that the weld meets specification. In June 2013, Medtronic communicated to impacted physicians that up to 779 devices worldwide (43 in the U.S.) may have been implanted from this subset. The Physician Letter is available at http://www.medtronic.com/for-healthcare-professionals/consulta-syncracrt-p/index.htm

Patient Management Recommendations (As of June 2013)

As a result of on-going investigation and consultation with Medtronic's Independent Physician Quality Panel, Medtronic offers the following patient management recommendations:

- Physicians should advise their patients to seek medical attention immediately if they experience a return of symptoms related to bradycardia or heart failure.
- If considering prophylactic device replacement for pacemaker-dependent patients with a device in the identified subset, physicians should carefully assess individual patient circumstances against the known risk of a device replacement.
- Physicians should continue routine follow up in accordance with standard practice

Status Update

As of January 31, 2015, 536 of the 779 devices have been returned from field inventory. Medtronic estimates the remaining 242 devices (44 in the U.S.) have been implanted. **There have been no reported or confirmed device failures or patient injuries.**

Initial Affected Population	Number of Confirmed Advisory Related Events	Estimated Remaining Active Population	Current Malfunction Rate (confirmed malfunctions over total population)
Up to 779 Worldwide (**44** United States)	**0** Worldwide (**0** United States)	**190** Worldwide (**37** United States)	**0%** Worldwide (**0%** United States)

Advisories

Potential Rapid Battery Depletion

EnTrust® VR/DR/AT ICDs
Original Date of Advisory: March 2012

Product

All EnTrust ICDs.

Advisory

A small percentage of EnTrust ICDs may not meet expected longevity or provide at least three months of device operation between the Elective Replacement Indicator (ERI) and End of Life (EOL) due to a more-rapid-than-expected drop in battery voltage. No patient deaths or serious injuries have been reported as a result of this issue.

The reported events have involved a drop in battery voltage from ~3.0 V to ERI (2.61 V) over a time period ranging from approximately one week to six months. All reported events have occurred at least 30 months after implant.

Medtronic has identified the cause of these occurrences to be an internal battery short that develops as the battery capacity is consumed. The Physician Letter is available at http://www.medtronic.com/product-advisories/entrust/physician/index.htm

Patient Management Recommendations (As of March 2012)

After consultation with Medtronic's Independent Physician Quality Panel, Medtronic offers the following patient management recommendations:

- Physicians should continue routine follow-up sessions at least every three months in accordance with product labeling.

- Physicians should program the audible patient alerts for "Low Battery Voltage ERI" and "Excessive Charge Time EOL" to ON.

- Physicians should replace devices promptly after they reach ERI if the decline in voltage is more rapid than expected.

- Prophylactic replacement of EnTrust ICDs is not recommended.

Status Update

As of January 31, 2015, there have been 91 confirmed events. No patient deaths have been reported due to this issue. No reports have been made of a failure to deliver high voltage therapy.

Initial Affected Population	Number of Confirmed Advisory Related Events	Estimated Remaining Active Population	Current Malfunction Rate (confirmed malfunctions over total population)
69,200 Worldwide (**44,300** United States)	**91** Worldwide (**71** United States)	**15,700** Worldwide (**10,000** United States)	**0.13%** Worldwide (**0.16%** United States)

Advisories

Low Battery Voltage Displayed at Device Interrogation

EnRhythm and EnRhythm MRI Pacemakers
Original Date of Advisory: February 2010

Product

All EnRhythm and EnRhythm MRI pacemakers.

Original Advisory Information (February 2010)

Two specific battery issues with EnRhythm pacemakers were identified. The risks to patients for both issue have been addressed by a Medtronic software update. The Physician Letter is available at http://www.medtronic.com/enrhythm-advisory/physician.html

First Issue

In February 2010, Medtronic had received 62 reports (out of approximately 110,000 devices worldwide) indicating that the battery voltage at device interrogation was lower than the battery voltage that is tracked by the device to provide data for the elective replacement indicator (ERI) notification.

Medtronic's investigation found that none of these reports resulted in loss of therapy. Importantly, the original ERI notification, which uses the nightly battery voltage measurement, was unaffected and accurate. Medtronic identified the root cause as higher than expected battery impedance.

Medtronic's internal testing showed there was no current risk for compromised therapy delivery. If the software update referenced above is not implemented, there will be a potential risk of loss of device functionality in a small percent (less than 0.08% 6 years post-implant) of devices. The software update obviates this risk.

Second Issue

Through internal accelerated testing, Medtronic identified a second issue that projects battery voltage could decrease sooner than expected due to a slightly increased rate of lithium depletion near end of device life. This issue has not been clinically observed and is not expected to occur until approximately 9 years post-implant. If the software update referenced above is not implemented, there may be a potential risk for loss of therapy at or near ERI in a small number of devices. The software eliminates this issue by changing ERI criteria.

Software Update (As of October 2010)

The battery issues described above and subsequent software update are summarized in the table below. When a device receives the software update, if battery impedance is greater than the new ERI threshold ERI will be triggered shortly thereafter. Therefore, clinicians may observe an ERI/EOL indicator at the next patient follow-up. When ERI is triggered by battery impedance, additional battery capacity remains and can support device function at ERI parameters for at least one year. Medtronic is not aware of any reports of loss of therapy due to this issue.

As a reminder, when ERI is triggered, EnRhythm devices revert to VVI pacing at 65 ppm at the programmed output settings. EOL is declared 90 days after ERI or at a battery voltage of 2.69V, whichever comes sooner.

Advisories

Battery Issue	Software Update
Battery voltage could decrease sooner that expected due to a slightly increased rate of lithium depletion	Changed ERI battery voltage threshold from 2.59V to 2.81V to ensure 90 days of therapy from ERI to EOL
Higher than expected battery impedance	Added a secondary ERI trigger based on battery impedance. This new criteria will identify devices with increased battery impedance before device performance is impacted. If triggered, displayed battery voltage is reset to 2.81 V to ensure alignment with ERI battery voltage threshold

Updated Performance Information (as of August 2011)

We now have access to battery impedance and ERI performance on more than 5000 EnRhythm devices that have received the EnRhythm software update. Our modeling based on these data shows that approximately 6-10% of devices will reach ERI within 5 years post-implant. Consistent with our previous communications, we continue to expect average device longevity to be reduced by approximately 10 –15%, with the expected average longevity remaining at 8.5 to 10.5 years, depending on device settings.[1]

Updated Patient Management Recommendations (as of August 2011)

After consultation with Medtronic's Independent Physician Quality Panel, we recommend:

- Performing a device follow-up within 90 days after the software download to identify devices that triggered ERI shortly after the software update. Subsequent follow up can be performed per standard practice. During programmer interrogation of a device at ERI, there is a slight possibility a transient drop in pacing amplitude could occur. If this is noted, either remove the programmer head or temporarily program to a higher output voltage.
- If an unanticipated ERI/EOL is declared, it is likely due to battery impedance. In such cases, additional battery capacity remains and can support device function at ERI parameters for at least one year. However, when ERI or EOL (typically 90 days after ERI) declaration is seen, schedule device replacement.

Status Update

First Issue

Included in the August 2011 Performance Update was information about the projected percentage of devices that would encounter an early ERI due to unexpected high battery impedance. As of January 31, 2015, percentage of devices that encountered ERI due to battery impedance has not exceeded the rate of 6-10% within 5 years of post-implant as communicated with our August 2011 Performance Update. Only devices using the updated software can trigger ERI due to impedance.

Initial Affected Population	Number of Confirmed ERIs due to impedance	Number of Confirmed ERIs due to impedance within 5 years post-implant	Estimated ERI rate due to impedance within 5 years post-implant[2]	Confirmed events of loss of therapy due to battery impedance	Estimated Remaining Active Population
All EnRhythm pacemakers (**146,500** Worldwide)	**13,690** Worldwide	**5,103**	**5.5%**	**0**	**65,400** Worldwide

Advisories

Second Issue

Initial Affected Population	Number of Events of Loss of Therapy Due to Increased Rate of Lithium Depletion	Estimated Remaining Active Population
All EnRhythm pacemakers (**146,500** Worldwide)	**0** Worldwide	**65,400** Worldwide

---

[1]*The 8.5 year estimate represents a high use scenario (DDD, 100% pacing in atrium and ventricle with 3.0 V output in both chambers). The 10.5 year estimate represents a typical use scenario for a sinus node dysfunction patient with the MVP function ON (AAI(R) <=> DDD(R), 50% pacing in atrium and 5% pacing in ventricle with 3.0 V output in both chambers). Projections are based on modeling and not actual field returns, due to limited availability of implant experience beyond 6 years. Field performance will continue to be monitored and modeling updated to reflect actual data.*

[2]*Accounts for underreporting of impedance ERIs based on the fraction of replaced devices in the U.S. registration system that are subsequently returned.*

Advisories

Potential Separation of Interconnect Wires (2009)

Kappa 600/700/900 and Sigma 100/200/300 Pacemakers
Original Date of Advisory: May 2009

Product

A specific subset of Kappa and Sigma series pacemakers may fail due to separation of interconnect wires from the hybrid circuit. You may use the "Search for Information by Serial Number" tool at http://wwwp.medtronic.com/productperformance/ to determine if a specific device is affected. The Physician Letter is available at http://www.medtronic.com/kappasigma/physician.html

Advisory Population

Specific subsets of Kappa and Sigma series pacemakers may fail at a higher than expected rate due to separation of wires that connect the electronic circuit to other pacemaker components (e.g., battery, connector). This may present clinically as loss of rate response, premature battery depletion, loss of telemetry, or no output.

Some patients, whose devices experience a wire separation resulting in a loss of pacing output, will experience a return of bradycardia symptoms (e.g., fainting or lightheadedness). In rare cases involving pacemaker dependent patients, loss of pacing output may result in death or serious injury.

Since 1997, there have been over 1.7 million Kappa and Sigma devices implanted worldwide. . At the time of the original advisory communication, an estimated 15,200 Kappa and 6,100 Sigma devices affected by the advisory remained implanted and active. These devices were manufactured primarily between November 2000 and November 2002. Most of these devices have been implanted in patients for five years or longer and may be nearing normal elective replacement time.

There is no provocative testing that can predict which specific devices may fail, and no device programming can mitigate this issue if it occurs.

Patient Management Recommendations

We realize that each patient requires unique clinical consideration and we support your judgment in caring for your patients. After consultation with Medtronic's Independent Physician Quality Panel, Medtronic offers the following recommendations for patients:

- Physicians should advise their patients to seek medical attention immediately if they experience symptoms (e.g., fainting or lightheadedness).
- Physicians should consider device replacement for patients who are both pacemaker dependent and who have been implanted with a device in the affected subsets. Medtronic will offer a supplemental device warranty if the device is not already at elective replacement time.
- Physicians should continue routine follow-up in accordance with standard practice for those patients who are not pacemaker dependent.

Status Update

Advisory Population

Patient management recommendations remain unchanged. As of January 31, 2015, Medtronic has observed 459 Kappa devices and 309 Sigma devices with this failure mechanism from the Kappa and new Sigma device subsets. This represents 0.79% (Kappa) and 2% (Sigma) of the original affected implant population.

Advisories

Four hundred twenty-two (422) of the Kappa devices (0.72%) and 241 of the Sigma devices (1.60%) were returned with information indicating a problem with the patient's pacing system prior to explant. The remaining 37 Kappa devices (0.06%) and 68 Sigma devices (0.45%) were returned with no information indicating a potential malfunction while implanted or with insufficient information to determine the state of the device at explant. Lacking definite information indicating proper operation until explant, these remaining devices are conservatively categorized as having experienced interconnect wire separation while implanted.

As of May 2009, our modeling predicts failure rates due to this issue of 1.1% (Kappa) and 4.8% (Sigma) over the remaining lifetime of those pacemakers still in service at that time.

Out of the initial advisory population of 58,300 Kappa devices and 14,900 Sigma devices worldwide, approximately 300 Sigma devices remain implanted worldwide. Of these, less than 100 Sigma devices are in the United States.

Continued Vigilance

Included in the advisory communication was information about an additional subset of Kappa devices where we have observed a much lower rate of occurrence of this issue. We estimate that none of these devices remain active.

Initial Affected Population	Number of Confirmed Advisory Related Events	Estimated Remaining Active Population	Current Malfunction Rate (confirmed malfunctions over total population)	Predicted Malfunction Rate Over the Remaining Life of the Devices Still Implanted
Kappa Pacemakers				
58,300 Implanted Worldwide (est.) (**17,600** United States)	**410** Worldwide (**211** United States) with information indicating a clinical presentation. An additional **36** worldwide (**24** US) without information indicating a clinical presentation or with insufficent information to determine the state of the device at explant.	No active population remains	**0.70%** Worldwide (**1.19%** United States)	**N/A**
Sigma Pacemakers				
14,900 Implanted Worldwide (est.) (**3,700** United States)	**2**41Worldwide (**52** United States) with information indicating a clinical presentation. An additional **68** worldwide (**17** US) without information indicating a clinical presentation or with insufficent information to determine the state of the device at explant.	**300** Worldwide (<1**00** United States)	**2**% Worldwide (**1.6**% United States)	**4.8%**

Advisories

Potential Conductor Wire Fracture

6930, 6931, 6948, 6949 Sprint Fidelis Defibrillation Leads
Original Date of Advisory: October 2007

Product

All Model 6930, 6931, 6948, and 6949 implantable defibrillation leads.

Advisory

There are two primary locations where chronic conductor fractures have occurred on Sprint Fidelis leads: 1) the distal portion of the lead, affecting the anode (ring electrode) and 2) near the anchoring sleeve tie-down, predominantly affecting the cathode (helix tip electrode), and occasionally the high voltage conductor. These two locations account for approximately 90% of the chronic fractures identified in Returned Product Analysis (RPA). The remaining 10% of chronic fractures occurred in the DF-1 connector leg and the proximal portion of the RV coil. High voltage conductor fractures could result in the inability to deliver defibrillation therapy. Anode or cathode conductor fractures (at either location) may present clinically as increased impedance, oversensing, increased interval counts, multiple inappropriate shocks, and/or loss of pacing output.

Patient Management Recommendations (Updated April 2011)

The Lead Integrity Alert (LIA) provides three days advance notice prior to inappropriate therapy to 76% of patients with lead fractures[1]. As a result, we strongly recommend that all Sprint Fidelis patients who have the ability to upgrade to Lead Integrity Alert do so promptly. Also ensure that high voltage lead impedance alerts (maximum of 100 ohms) are programmed. When a lead fracture is suspected or confirmed, immediate patient attention is strongly recommended. Physicians should inform their patients to seek medical attention without delay if they experience unexpected shocks.

- **If a Fidelis lead fracture of any type has occurred,we recommend implanting a new high voltage lead with or without extraction of the Fidelis lead.**
- In patients with normal device function and no manifestation of lead fracture, no action is recommended. The risk of prophylactic intervention appears to be greater than serious injury resulting from lead fracture even for pacemaker dependent patients, except in select individual patient circumstances as determined by the physician.
- In the event of a device change-out or upgrade procedure, with no manifestation of lead fracture, consider the patient age and lead model data above, as well as patient life expectancy, co-morbidities, ease of extraction related to implant time, patient preference, etc., for the following options:
    - Leave a properly performing lead intact.
    - Implant a new ICD lead without extraction of the existing lead.
    - Carefully consider all factors before prophylactic placement of a pace-sense lead. Data shows an increased risk of high voltage conductor fracture if a pace-sense conductor fracture has previously occurred. This data is available at www.medtronic.com/fidelis
    - Individual patient circumstances may warrant extracting and implanting a new ICD lead. If warranted, Medtronic's Independent Physician Quality Panel recommends the lead extraction procedure be performed by a physician with extensive lead extraction experience.[2]

Advisories

Status Update

As of January 31, 2015, of the initial implant population of 205,600 in the United States, approximately 72,700 remain implanted. According to Product Surveillance Registry results, lead survival is estimated to be 78.5% (+4.6/-4.3%) at 102 months. As the implanted population ages and the sample size increases for each time interval, the accuracy of the estimated survival probability will increase as shown by tighter confidence intervals.

Keeping Physicians Informed

The most recent Sprint Fidelis lead performance information, including survival curves, physician letters, and subpopulation data, can be found at www.medtronic.com/fidelis and will be updated annually. Medtronic's website also has a selected list of peer-reviewed publications related to Fidelis lead performance and extraction. Medtronic is committed to answering your questions and keeping you informed. If you have any questions or concerns, please contact your Medtronic Representative or Medtronic Technical Services at 1-800-723-4636 (US).

Initial Affected Population	Number of Confirmed Advisory Related Events	Estimated Remaining Active Population	Additional information about the Sprint Fidelis lead is available at www.medtronic.com/fidelis.
279,500 Worldwide(**205,600** United States)	**6,763** Worldwide**(4,821** United States)	**96,300** Worldwide(**72,700** United States)	

Footnotes:

1: Swerdlow C, Gunderson, B, et al."Downloadable Algorithm to Reduce Inappropriate Shocks Caused by Fractures of Implantable Cardioverter-Defibrillator Leads", Circulation, November 2008, 118: 2122-2129.

2: "Transvenous Lead Extraction: Heart Rhythm Society Expert Consensus on Facilities, Training, Indications, and Patient Management", Heart Rhythm, Vol 6, No 7, July 2009.

Advisories

Potential Separation of Interconnect Wires (2005)

Sigma Implantable Pulse Generators
Original Date of Advisory: November 2005

Product

A specific subset of Sigma series pacemakers may fail due to separation of interconnect wires from the hybrid circuit. You may use the "Search for Information by Serial Number" tool at http://wwwp.medtronic.com/productperformance/ to determine if a specific device is affected.

Advisory

This subset of Sigma series pacemakers that may fail due to separation of interconnect wires from the hybrid circuit may present clinically as loss of rate response, premature battery depletion, intermittent or total loss of telemetry, or no output.

Separation of redundant interconnect wires has been observed on hybrid terminal blocks. Device failure occurs only where both interconnect wires separate from a hybrid terminal block. In October 2005, testing and analysis identified the root cause of these failures and the affected population. Hybrid circuits used in this subset of devices were cleaned during manufacturing with a particular cleaning solvent that could potentially reduce the strength of the interconnect wire bond over time.

No provocative testing can predict which devices may fail.

Patient Management Recommendations

Recommendation for the management of patients who have pacemakers affected by this advisory were changed in May 2009. Current recommendations are:

We realize that each patient requires unique clinical consideration and we support your judgment in caring for your patients. After consultation with Medtronic's Independent Physician Quality Panel, Medtronic offers the following recommendations for patients in the 2005 Sigma advisory:

- Physicians should advise their patients to seek medical attention immediately if they experience symptoms (e.g., fainting or lightheadedness).
- Physicians should consider device replacement for patients who are both pacemaker dependent and who have been implanted with a device in the affected subsets. Medtronic will offer a supplemental device warranty if the device is not already at elective replacement time.
- Physicians should continue routine follow-up in accordance with standard practice for those patients who are not pacemaker dependent.

Status Update

Patient management recommendations remain unchanged. As of January 31, 2015, 839 devices out of approximately 40,000 devices worldwide have been confirmed as having experienced interconnect wire separation.

Four hundred seventy-four(474) of the Sigma devices (1.1%) were returned with information indicating a problem with the patient's pacing system prior to explant. The remaining 365 Sigma devices (0.90%) were returned with no information indicating a potential malfunction while implanted or with insufficient information to determine the state of the device at explant. Lacking definite information indicating proper operation until explant, these remaining devices are conservatively categorized as having experienced interconnect wire separation while implanted.

Advisories

Our original modeling predicted a failure rate from 0.17% to 0.30% over the remaining lifetime of these pacemakers. However, as of May 2009 updated modeling now predicts a failure rate of 3.9% over the remaining device life of those devices still in service at that time.

Out of the initial advisory population of 40,000 worldwide, approximately 4,000 remain implanted. Approximately 900 of these are in the United States.

Initial Affected Population	Number of Confirmed Advisory Related Events	Estimated Remaining Active Population	Current Malfunction Rate (confirmed malfunctions over total population)	Predicted Malfunction Rate Over the Remaining Life of the Devices Still Implanted
40,000 Implanted Worldwide (est.) (**9,900** United States)	**474** Worldwide (**96** United States) with information indicating a clinical presentation. An additional **365** Worldwide (**66** US) without information indicating a clinical presentation or with insufficient information to determine the state of the device at explant.	**4,000** Worldwide (**900** United States)	**101%** Worldwide (**1.0%** United States)	**3.9%**

Performance Notes

Dual Chamber Pacemakers with Measurement Lock-up ERI
Kappa 600, 700, 800, 900, EnPulse, Adapta, Versa, Sensia, Relia, and Vitatron Models E50A1, E60A1, and G70A1

Purpose of this Information

This Performance Note describes a rare measurement lock-up issue that impacts the Medtronic dual chamber pacemakers listed above. If this measurement lock-up occurs, the device will trigger a false Elective Replacement Indicator (ERI). A reset is available to clear this condition and there is no need to explant the device. This issue does not impact battery longevity.

Background

If this rare measurement lock-up occurs in the pacemaker, it causes the device to read a value of zero for battery voltage. After four measurements of zero, the device will trigger ERI and revert to a VVI pacing mode at 65 bpm. There is no loss of ventricular pacing and the output voltage will remain the same.

Programmer Software Reset Method (Adapta, Versa, Sensia, Relia, Vitatron Series E and G)

Programmer software is available which can differentiate a regular ERI and an ERI caused by the measurement lock-up issue. Upon interrogation of a device with the measurement lock-up ERI, the programmer software recognizes the issue and guides the clinician to clear the ERI (Example 1). Following an ERI reset, the device parameters should be reviewed and reprogrammed to clinician specifications.

Example 1 – Programmer Software Detects Measurement Lock-up ERI



Reset Method for Kappa and EnPulse

A service tool continues to be available through Medtronic Technical Services to clear the measurement lock-up issue for Kappa and EnPulse devices.

The issue can be identified using the programmer or via CareLink transmission; the battery voltage measurements and remaining longevity will appear as blank values (Example 2). If this measurement lock-up occurs, contact Medtronic Brady Technical Services at 1-800-505-4636 for assistance.

Example 2 – Programmer Screens for Measurement Lock-up ERI (Kappa and EnPulse)



Clinical Management of VCM near Elective Replacement

Background

Medtronic Technical Services has received reports of devices going to ERI or end of life (EOL) sooner than expected after a normal follow-up in which the device longevity was projected to be approximately 18 months. It has been noted that these cases typically involve Kappa 700 devices where Ventricular Capture Management set the ventricular lead to high output (5 V, 1 ms), which occurs by device design when a high threshold is measured. It is important for physicians and allied professionals to understand VCM behavior as it relates to longevity so that they can, in turn, understand how this affects management of the device and follow-up visits as VCM equipped IPGs near the end of their expected longevity.

Device Longevity and VCM Behavior

Ventricular Capture Management is a feature that uses evoked response sensing to determine the stimulation threshold needed to capture the ventricular chamber. Proper detection of the evoked response is crucial to the VCM algorithm determining an accurate capture threshold. There are rare conditions, however, during which the VCM algorithm will not be able to measure the evoked response accurately.[1] When this occurs, for safety reasons the VCM algorithm will reprogram the output to 5 V, 1 ms until the subsequent VCM measurement.

If the device has considerable remaining longevity, these occasional excursions to high output do not substantially affect remaining longevity. However, if the device has less than approximately 18 months remaining longevity, there is the possibility that the high output condition caused by the 5 V, 1 ms output will drain the battery and trigger ERI.

When ERI is declared by the device, VCM is disabled and the outputs are left at 5 V, 1 ms until the device is reprogrammed at an in-office follow-up. This increased current drain of a high output condition will speed depletion of the device, possibly resulting in the device getting to the EOL (battery voltage ≤ 2.15 V).

Please note that the following parameter changes occur when the device goes to ERI:

Table: IPG Therapy Parameter Changes at ERI

Parameter	Value
Pacing Mode	VVI
Lower Rate	65 bpm
Single Chamber Hysteresis	OFF
Sleep Function	OFF
Ventricular Capture Management	OFF
Atrial Sensing Assurance	OFF
Ventricular Sensing Assurance	OFF

Kappa 700 is Medtronic's first-generation VCM algorithm, which has a relatively higher incidence of evoked response undersensing compared to subsequent algorithms, resulting in more frequent high output conditions. Therefore, Kappa 700 products are the primary focus of this note. It should be noted that IPGs equipped with the second-generation VCM algorithm (Kappa 900, EnPulse, Adapta/Versa/Sensia, and Relia) have not been observed with evoked response undersensing in the general population, though the items listed in "Follow-Up Considerations" may also be used on these devices.

Follow-Up Considerations

- Estimated longevity in the event the device goes to high output can be determined by the following steps. This allows the clinician to determine follow-up frequency if he or she is concerned the device may go to ERI due to high output.
  - Program the ventricular channel to 5 V, 1 ms
  - Navigate to Data/Battery and Lead Measurements
  - When the message stating "Warning – Old Data" is displayed, select "Yes" to measure battery voltage and lead impedance at the new ventricular outputs
  - An updated remaining longevity estimate will be calculated on the elevated outputs. Note the "Minimum Remaining Longevity." Clinical decisions can be based on this value.
  - Program the Amplitude and Pulse Widths back to their original values before leaving the session
- If the capture trends and lead impedance trends are stable, VCM can be programmed to "Monitor Only" for the remaining device life. This should be considered only if remaining longevity is 18 months or less.
- Follow-up frequency can be increased for those patients who do not have stable capture or lead impedance trends. This can be done via a CareLink Home Monitor, or in-office.

[1] Medtronic, Inc. (2001). Medtronic Kappa 700/600 Series Pacemaker Reference Guide (Chapter 4, p. 27). Can be retrieved from http://manuals.medtronic.com.

Performance Notes

General Follow-Up and Replacement of ICD Leads

Implanted leads operate in the challenging biochemical environment of the human body and the body's response to foreign objects. Implanted leads are also subject to mechanical stresses associated with heart motion, body motion, and patient anatomy.

In this environment, pacemaker and defibrillation leads cannot be expected to last forever. Unlike implantable cardioverter defibrillators (ICDs), a lead's longevity cannot be predicted nor are there simple indicators that a lead is approaching the end of its service life. The determination that a lead may be approaching end of service life requires follow-up of the chronically implanted lead and thorough evaluation of lead integrity at ICD replacement.

Follow-Up of Chronically Implanted Leads

The frequency of follow-up for ICD patients will depend on a number of factors including the patient's medical condition, ICD system implant time, hospital/clinic follow-up practice, and Medicare guidelines. In all cases, it is important to assess the functionality of the ICD system and the integrity. For newly implanted leads, it is beneficial to establish a baseline of chronic performance parameters once the lead has stabilized, generally within 6 to 12 months after implant. These performance parameters should include pacing and sensing thresholds and impedance. During routine patient follow-up, these procedures can be used to evaluate lead integrity.

- Measure pacing and sensing threshold and compare to the chronic baseline. Significant increases or decreases may be indicative of lead failure, dislodgement, perforation, exit block, etc.
- Measure pacing impedance where possible and compare to the chronic baseline. Decreases of 30% or more or pacing impedances below 200-250 ohms may be indicative of insulation failure. Sudden and significant increases in pacing impedance may be indicative of conductor fracture.
- High voltage lead circuit impedance should be between 10-75 ohms at system implant. Chronic measurements below 10 and above 200 ohms may be indicative of high voltage lead circuit failure.
- Carefully review ECGs or the nonsustained detection log on Medtronic ICDs for indications of pacing and/or sensing abnormalities such as oversensing, undersensing, and loss of capture
- Elicit and investigate any patient complaints/symptoms that may be suggestive of potential lead failure

Where routine follow-up indicates, additional tools should be used to further evaluate performance. Tools include radiographic data, ICD electrograms, ICD Patient Alert and performance information from the Product Surveillance Registry (PSR).

The final decision on the functional integrity and continued use of an implanted lead must be a matter of medical judgment based on these factors as well as specific patient conditions.

General Criteria for Lead Replacement

The evaluation of a chronically implanted lead is an important part of the decision to continue to use the lead with a new ICD. However, these results alone do not necessarily predict the future integrity of that lead. With the expected longevity of today's ICDs varying between approximately 5 and 10 years, a physician replacing a device should consider a number of factors, including those listed below.

Factors that should be considered in a decision to replace or continue to use include:

- Pacing and sensing thresholds should be evaluated for the potential to maintain acceptable levels
- Pacing impedance should be measured. Bear in mind that pacing impedance below 250 ohms results in excessive battery current drain, which may seriously compromise ICD longevity, regardless of lead integrity.
- The physical appearance of the lead should be examined for insulation cracks, breaches, or other indications of lead wear or degradation
- Medtronic System Longevity Study data should be referenced. Actuarial survival of the lead and the observed lead failure mechanisms are specific factors to consider. Use of a new lead should be considered if failure mechanisms suggest an increased time dependency as suggested in the shape of performance curve for the specific lead model.
- Current publications may provide additional information on the clinical management of leads.[1-3] Ultimately, the decision to replace an implanted lead involves medical judgment.

[1] Hauser RG, Cannom D, Hayes DL, et al. Long-term structural failure of coaxial polyurethane implantable cardioverter defibrillator leads. *PACE*. June 2002;25(6):879-882.

[2] Ellenbogen KA, Wood MA, Shepard RK, et al. Detection and management of an implantable cardioverter defibrillator lead failure: incidence and clinical implications. *J Am Coll Cardiol*. January 1, 2003;41(1):73-80.

[3] Hauser RG, Kallinen LM, Almquist AK, Gornick CC, Katsiyiannis WT. Early failure of a small-diameter high-voltage implantable cardioverter-defibrillator lead. *Heart Rhythm*. July 2007;4(7):892-896.

Clinical Management of High-Voltage Lead System Oversensing

Appropriate sensing by an ICD system refers to the sensing of cardiac events that may or may not require therapy delivery. ICD systems must sense relatively large QRS complexes while avoiding sensing of smaller T waves, yet continue to sense often small variable amplitude ventricular fibrillation. Thus, ICD systems attempt to dynamically adjust sensing of electrical events and discriminate between them based on detection algorithms and programmed settings.

Inappropriate sensing can occur when an ICD system classifies events of non-cardiac origin as QRS/VF events, or senses and counts T and far-field P waves as ventricular depolarizations. This is often referred to as "oversensing," and may result in delivery of inappropriate high-voltage therapies. This is due, in part, to the desire to err on the side of delivering lifesaving high voltage therapy rather than withholding it. Thus, an ICD system that is experiencing oversensing issues will continue to deliver therapeutic shocks as required, but may also subject the patient to unnecessary shocks.

Oversensing can be difficult to manage, in that the precipitating cause of the oversensing can be problematic to isolate. Oversensing can be caused by many factors, including myopotentials/far-field sensing, electromagnetic interference, T wave sensing, connector issues, incomplete or complete conductor fractures, and insulation breaches. While the individual physician must exercise medical judgment in determination of appropriate clinical management of ICD systems, the chart below may assist in the process of causal factor differentiation and possible intervention.

Phenomenon	Causal Factors	Characteristics	Management/Comments
Myopotentials/ Far-field sensing	Diaphragmatic muscle potentials in breathing, wide tip-to-ring (coil on integrated bipolar leads) spacing	Nonphysiological sensed event on EGM, which may confuse detection potentially resulting in false positive shocks	Check R waves for deterioration. Reprogram sensitivity. Try repositioning lead. Consider change-out to true bipolar lead, or if true bipolar lead in use, one with closer tip-to-ring spacing than current lead.
EMI (Electro-Magnetic Interference)	Arc welders, electrical generators, store walk-through security scanners, poorly insulated electrical equipment	Multiple and consecutive short intervals (< 140 ms) independent of underlying sinus beats. Associated with proximity to the EMI source.	Avoid EMI areas. True bipolar leads less susceptible.
T-wave sensing	Drugs, ischemic tissue, exercise, Long QT syndrome, electrolyte imbalance	Sense markers seen on EGM related to T wave. False positive detection.	Check for R wave deterioration and characteristics. If R wave > 3.0 mV, reprogram sensitivity. If R wave < 3.0 mV, reposition/replace lead. Address causal factor (e.g., drugs [if appropriate/medically viable]).
Connector problems	Loose setscrew, cross-threaded setscrew, incomplete lead insertion into header	This is an acute phenomenon seen within 6 months of implant (usually sooner)	Requires invasive check of connections. May be reproducible with pocket manipulation.
Incomplete conductor fracture	One or more filars of a multifilar conductor fracturing while leaving enough filars intact to provide a conduction circuit	Characterized by chaotic oversensing related to motion of the fracture site	Check EGMs and x-rays. Manipulate lead at suspected fracture site if possible as a provocative test. If confirmed, replace lead.
Lead insulation breach	Cuts, tears, metal ion oxidization, abrasion, cold flow, environmental stress cracking	Characterized by cyclical and/or erratic, intermittent, spontaneous oversensing; often post-pace or post-shock can cause false positives	Replace lead. If acute, usually secondary to implant damage/replacement damage. If late, material characteristic.
Oversensing during interrogation with programming head (not wireless telemetry) with complete lead fracture	Interrogation with a programming head in combination with complete lead fracture that creates an open circuit can induce noise on the sensing circuitry inside the ICD can	Nonphysiologic sensed event on EGM. If detection is enabled during interrogation, oversensing may result in inappropriate therapy.	Quickly remove the programming head. CANCEL the interrupted interrogation and manually load the software for the specific device model. Reposition the programmer head over the device and immediately select SUSPEND. Device will resume detection when programming head is removed, or when RESUME is selected. Replace lead.

Technical Services is available at all times to advise clinicians in the troubleshooting and management of Medtronic products. For assistance in the United States, please call 1 (800) 723-4636. In other countries, please contact your local Medtronic representative.

Performance Notes

Tests and Observations for Clinical Assessment of Chronic Pacing Leads

Test/Observation	Possible Insulation Failure	Possible Conductor Failure	Possible Other System Failure	Effect on Test/ Observation
Pacing Impedance (Telemetered or Measured Invasively)	Sudden and Significant Decrease	Sudden and Significant Increase	Dislodgement. . . . . Decrease Perforation. . . . . Increase or Decrease Electrolyte Imbalance. . . . . Increase or Decrease Improper IPG/Lead Connection. . . Increase or Decrease	
Pacing Thresholds (Telemetered/Programmed or Measured Invasively)	Sudden and Significant Increase, Especially in Bipolar System	Sudden and Significant Increase	Dislodgement. . . . . Increase Exit Block. . . . . Increase Infarct at Electrode Site. . . . . Increase Perforation. . . . . Increase Improper IPG/Lead Connection. . . Increase	
Electrograms (Telemetered or Measured Invasively)	Sudden and Significant Decrease in Amplitudes and/or Slew Rates for P and/or R Waves	Sudden and Significant Decrease or Disappearance of Amplitudes and/or Slew Rates for P and/or R Waves	Dislodgement. . . . . Decrease Perforation . . . . . Decrease Infarct at Electrode Site. . . . . Decrease Electrolyte Imbalance. . . . . Decrease Improper IPG/Lead Connection. . . Decrease	
Waveform Analysis (Oscillographs of Pacer Artifact from ECG Electrodes)	Sudden Increase in Ratios of Leading-Edge Voltages to Trailing-Edge Voltages (i.e., over 25% increase)	Intermittent or No Pacer Artifacts (Even in Asynchronous Mode)	Improper IPG/Lead Connection	Intermittent or No Pacer Artifacts (Even in Asynchronous Mode)
Radiographs (Post-Implant, Recent, Current)	Not Discernible	Visual Observation of Conductor/Connector/ Electrode Fracture (Sometimes Discernible)	Dislodgement or Perforation. Improper IPG/Lead Connection.	Sometimes Discernible
Visual Inspection (Invasive)	Insulation Breach and/or Degradation, or Ligature Cut-Through	Not Easily Discernible	Connector Defect or Connector Pulled Apart. Improper IPG/ Lead Connection.	Sometimes Discernible
Pectoral Muscle Stimulation	Sudden Onset, Especially in Bipolar System		Connector Defect in Bipolar or Unipolar. Hypersensitivity to Unipolar Pulse Generator Can. Anti-Stim Coating or Protection Deficient.	
Phrenic Nerve/ Diaphragmatic Stimulation	Sudden Onset in Bipolar or Unipolar Systems		Perforation or Displacement of Atrial Lead (Phrenic Nerve)	
Pacemaker ECG Stimulus Artifact Size and Morphology Change (May Not Be Possible with Digital ECG)	Sudden Onset and Significant Change, Especially in Bipolar System (Increase in Size)	Sudden Changes, Usually a Decrease in Size	Perforation or Dislodgement. Connector Defect. Improper IPG/ Lead Connection.	Sometimes Discernible
Oversensing (Intermittent or Continuous)	Sudden Onset, Especially in Bipolar Systems		Physical Contact between the Electrode(s) on the Lead and that of Another Lead. Inappropriate IPG Parameter Setting. Improper IPG/Lead Connection.	Sometimes Discernible
Undersensing (Intermittent or Continuous)	Sudden Onset in Either Unipolar or Bipolar Systems	Sudden Onset in Either Unipolar or Bipolar Systems	Dislodgement or Perforation. Infarct at Electrode Site. Electrolyte Imbalance. Inappropriate IPG Parameter Setting. Improper IPG/Lead Connection.	Sometimes Discernible
Loss of Capture	See "Pacing Thresholds" Above	See "Pacing Thresholds" Above	See "Pacing Thresholds" Above	

Mailer Kits Available for Returning Product

Medtronic urges all physicians to return explanted products and to notify Medtronic when a product is no longer in use, regardless of reason for explant or removal from use. The procedures for returning products vary by geographic location.

Mailer kits with prepaid US postage are available for use within the United States to send CRT, ICD, IPG, and leads to Medtronic's CRHF Returned Product Analysis Lab. These mailers are sized to accommodate the devices and leads from a single patient or clinical event and are designed to meet US postal regulations for mailing biohazard materials.

If the product being returned is located outside the United States, please contact your local Medtronic representative for instructions.

Medtronic also requests the return of devices from non-clinical sources, such as funeral homes, and will assume responsibility for storage and disposal of the product once received.

Mailer kits can be obtained by contacting the Returned Product Lab.

CRHF Returned Product Analysis Laboratory
Phone: 1 (800) 328-2518, ext. 44800
Email: crdm.returnedproduct@medtronic.com

www.medtronic.com

World Headquarters
Medtronic, Inc.
710 Medtronic Parkway
Minneapolis, MN
55432-5604 USA
Tel: (763) 514-4000
Fax: (763) 514-4879

Medtronic USA, Inc.
Toll-free: 1 (800) 328-2518
(24-hour technical support for physicians and medical professionals)

Europe
Medtronic International Trading
Sàrl Route du Molliau 31
CH-1131 Tolochenaz Switzerland
Tel: (41 21) 802 7000
Fax: (41 21) 802 7900

Canada
Medtronic of Canada Ltd.
6733 Kitimat Road Mississauga,
Ontario L5N 1W3 Canada
Tel: (905) 826-6020
Fax: (905) 826-6620
Toll-free: 1 (800) 268-5346

Asia Pacific
Medtronic International, Ltd.
16/F Manulife Plaza
The Lee Gardens, 33 Hysan
Avenue Causeway Bay
Hong Kong
Tel: (813)-6430-7026
Fax: (852) 2891 6830
enquiryap@medtronic.com

Latin America
Medtronic USA, Inc.
Doral Corporate Center II
3750 NW 87th Avenue Suite 700
Miami, FL 33178 USA
Tel: (305) 500-9328
Fax: (786) 709-4244

Medtronic